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PhD by Publication – Barry Jubraj 
Medicines optimisation: A pharmacist’s contribution to delivery and education 
Abstract 
This thesis describes the author’s publication history from 2001 to 2019, and relates this 
to their key career milestones from registration as a pharmacist in 1991.  From a career 
output of over 80 items published in a variety of media, eleven key publications form the 
basis of four publication themes, which the author has related to the concept of 
medicines optimisation.   An exemplar case is used to illustrate these publication themes, 
arranged into four chapters: a) improving the patient experience and supporting 
medication adherence b) providing safe care: medication review, polypharmacy and 
deprescribing c) making medicines optimisation part of routine practice through clinical 
education, and d) supporting safe practice through professional and personal 
development of healthcare staff. 
Following Chapter 1 (introduction), the second chapter discusses the author’s 
contribution to the medication adherence agenda which closely relates to their outputs 
encouraging the development of pharmacists’ consultation skills, particularly with 
patients who have a learning disability.  The third chapter discusses the author’s 
published outputs in the areas of medication review, polypharmacy and deprescribing, 
the success of which they outline as contingent on the improved communication skills 
and person-centred approach described in Chapter 2. 
Chapters four and five discuss the author’s wide-ranging contribution as a clinical 
educator with a focus on developing others, which the author contends is an essential 
underpinning of the mission to deliver the benefits of medicines optimisation. The 
exemplar case from the introduction is briefly revisited to illustrate that the author’s 
publications directly relate to the challenges of the patient’s medication regime which in 
turn relate to three of the four Royal Pharmaceutical Society principles of medicines 
optimisation. 
The conclusion of this thesis includes a summary of the methodologies used in the key 
publications, and summarises the author’s belief that their career activity, leading to their 
publications, broadly align to the concept of medicines optimisation.  Moreover, a 
recommendation can be made that education of all stakeholders should be explicitly 
mentioned in any future refinements of its definition. 
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Medicines optimisation:  A pharmacist’s contribution to delivery and education 
Chapter 1: Introduction  
1.1 Prologue 
This thesis summarises a collection of published outputs from a 30 year pharmacy career, 
during which the author also trained as a teacher and counsellor.  Through the process of 
recording the career and life journey for this thesis, the author has been humbled by the 
many opportunities received, the patient partnerships built, and the students and 
qualified staff supported throughout their journey.  The author has made it their mission 
to interact and consult with everyone in a caring, empathic way, to develop students, 
juniors and colleagues to do the same, and to help patients get the most out of their 
medicines by maximising the benefits and minimising the risk of harm.   
The author has also reflected deeply on their own development throughout key elements 
of their career journey.  Firstly, this thesis has served as a ‘mirror’ to reflect back to the 
author what they have contributed to and achieved for the profession, the influence 
received and given, and the way that they have developed professionally.  The resulting 
publications in this thesis are directly linked to the career journey outlined in Figure 5. 
Professionally, the author has become a practitioner with expertise in a number of 
different areas that are reflected in the diversity of the thesis chapters.   It has been an 
encouragement that these areas of expertise broadly cohere with the concept of 
‘medicines optimisation’, the importance of which will be explained in Chapter 1.2. 
The publications in this thesis also reflect the author’s personal journey.  Training as a 
teacher and counsellor, as well as a pharmacist, has led others say that the author has 
accumulated a lot of wisdom and has a compassionate, caring approach towards those 
that they encounter.  The mention in Figure 5 of the author becoming a parent to a 
disabled child is an important part of their journey because of the published outputs that 
have directly resulted from this experience.   
The author’s achievements are outlined in their curriculum vitae (Appendix 1) and 
publication list (Appendix 2), with author verifications recorded in Appendix 3.  These 
achievements have culminated in the award of three fellowships.  These include 
Fellowship of the Faculty of the Royal Pharmaceutical Society.  This required the author to 
submit evidence of attainment against six competency clusters in the pharmacy 
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professional development framework for advanced practice, the ‘Advanced Pharmacy 
Framework’ (1). The author achieved the highest staging of each cluster, namely ‘mastery’ 
(see Appendix 4 for a summary). 
 
1.2 Medicines Optimisation: why is it important? 
Medicines optimisation is the latest iteration of how pharmacists (and other 
professionals) can improve the prescribing, dispensing and administration of medicines 
(2).  The key challenges outlined by NICE and illustrated by the exemplar case in Chapter 
1.9 have been drivers for health systems across the world to increase the effectiveness 
and quality of medicines use as well as reducing risk and expenditure.  Alongside this, 
there has been an increasing drive to ensure that patients are involved in clinical 
decisions that are made about them, meaning that patients need to be at the centre of 
their own care (3).  From these principles has emerged the concept of ‘medicines 
optimisation’ in England. 
 
1.3 Definitions of ‘medicines optimisation’ 
Several definitions of ‘medicines optimisation’ have been offered, which mainly describe 
the concept and are not universally agreed, although the sentiments appear to be similar: 
1. Medicines optimisation is an approach that seeks to maximise the beneficial 
clinical outcomes for patients from medicines with an emphasis on safety, 
governance, professional collaboration and patient engagement (4)  
2. Medicines optimisation is defined as a person-centred approach to safe and 
effective medicines use, to ensure that people obtain the best possible outcomes 
from their medicines (5)  
3. A definition of medicines optimisation, quoted in the influential King’s Fund 
publication about polypharmacy and medicines optimisation (6), is that it 
“requires evidence-informed decision making about medicines, involving effective 
patient engagement and professional collaboration to provide an individualised, 
person-centred approach to medicines use, within the available resources”   
4. Medicines optimisation looks at the value which medicines deliver, making sure 
they are clinically effective and cost-effective. It is about ensuring people get the 
right choice of medicines, at the right time, and are engaged in the process by 
their clinical team (7). 
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The first definition has been used in Figure 4, which is taken from the author’s PhD prima 
facie statement (Appendix 5).  This was the definition that the author was most familiar 
with at that time.    
  
1.4 ‘Medicines Optimisation’: a concept now central to health policy, particularly in 
England 
The Royal Pharmaceutical Society’s (RPS) good practice guidance on medicines 
optimisation describes it as emerging from a recognition that medicines use is too often 
sub-optimal and requires a ‘step change’ in the way that patients are supported to get the 
best out of their medicines (8). The guidance goes on to describe goals to improve the use 
of medicines, which have been concisely described by NHS England as follows (7): 
 Improve their outcomes 
 Take their medicines correctly 
 Avoid taking unnecessary medicines 
 Reduce wastage of medicines 
 Improve medicines safety 
 
The RPS guidance also describes four principles of medicines optimisation that have been 
widely supported and cited (see Figure 1 in the original thesis – removed from this 
submission copy of the thesis and replaced with text versions of the principles as follows): 
1. Principle 1: Aim to understand the patient’s experience 
2. Principle 2: Evidence based choice of medicines 
3. Principle 3: Ensure medicines use is as safe as possible 
4. Make medicines optimisation part of routine practice 
 
The author’s longstanding engagement with the principles of medicines optimisation has 
included peer discussions with colleagues regarding their concerns about the RPS’s 
explanation of principle 4.  This states that: “Health professionals routinely discuss with 
each other and with patients and/or their carers how to get the best outcomes from 
medicines throughout the patient’s care”.  The RPS guidance lists outcomes that principle 
4 is intended to influence, including patients receiving consistent messages about 
medicines through improved liaison between the healthcare team, reducing waste and 
the NHS achieving greater value for medicines expenditure.  The author has long 
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contended that few, if any of these outcomes meaningfully reflect the title of this 
principle.  Whilst not disagreeing with the list of outcomes, the author has written and 
spoken about education being a vital component in making medicines optimisation part 
of routine practice, beginning with undergraduates and continuing as part of lifelong 
learning.  This is explored in more detail in Chapter 3, with respect to medication review. 
1.5 An evidence-base for medicines optimisation 
In order to explore the evidence to support medicines optimisation, it is important to 
articulate what it is.  In Chapters 1.3 and 1.4 medicines optimisation is described as 
follows: 
 A process (3) 
 An approach (2) 
 Something which ‘looks at’ (6) 
The Royal Pharmaceutical Society’s Principles of Medicines Optimisation (8) illustrated in 
Figure 1 seek to concretise such descriptions.  There is no primary literature that supports 
the overall ‘process’ or ‘approach’ of medicines optimisation and no attempts in the 
literature to achieve this have been found, probably because it is a ‘process’ or an 
‘approach’ or a ‘concept’.  Instead, the evidence for medicines optimisation is more 
indirect; and is most likely to be found in primary literature that demonstrates, for 
example, the need to understand the patient experience (principle 1), improve outcomes 
in evidence-based use of medicines (principle 2) and medication safety (principle 3).  The 
author believes that these combine to provide evidence supporting the variety of 
definitions of medicines optimisation such as those outlined in Chapter 1.3.  The relevant 
primary literature outlined above was evaluated by the author throughout this thesis, 
particularly in Chapters 2 and 3.  Moreover, the focus of their publications was strategic 
and targeted at providing the profession with the skills needed to optimise medicines use 
in the population as a whole. 
1.6 The broader context of medicines optimisation 
Published literature compares ‘Medicines Optimisation’ with previously-developed 
concepts such as ‘pharmaceutical care’ and ‘medicines management’ (3).  In 1990, Hepler 
and Strand published the term ‘Pharmaceutical care’ and described the responsibility that 
pharmacists should assume for developing a therapeutic relationship with the patient (9).  
In 1993, the author wrote a short dissertation on this for a postgraduate degree, focusing 
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on comparing the interpretation of the concept in the United States and the United 
Kingdom (10).  The author’s literature search at the time revealed an emphasis on the 
need to improve patient care and for pharmacists to take greater responsibility for that 
care.  Hepler and Strand were clear about pharmacists’ ‘social responsibility’ to reduce 
preventable drug-related morbidity and mortality, and the need to practice a patient-
centred approach. This aligns with the second RPS principle of medicines optimisation 
concerning safe medicines use (8).  ‘Taking responsibility’ as outlined by Hepler and 
Strand also links to the medicines optimisation imperatives of “effective patient 
engagement” (6).  The author believes that the link between pharmaceutical care and 
medicines optimisation as defined in England is clear. 
Medicines management was described as a “system of processes and behaviours that 
determines how medicines are used by patients and healthcare services” (3).   A more 
comprehensive definition was offered by the Audit Commission in 2001 (11):  
‘Medicines management in hospitals encompasses the entire way that medicines are 
selected, procured, delivered, prescribed, administered and reviewed to optimise the 
contribution that medicines make to producing informed and desired outcomes of patient 
care.’  
This definition contained an early mention of the word ‘optimise’ and the report goes on 
to describe the need to reduce medication errors, to link medicines management with 
clinical governance, and to ensure that pharmacy is a patient-centred service with 
pharmacists as a key member of the clinical team.  This represented an important shift 
from pharmacy being a technical profession to assuming greater clinical responsibility, 
with a specific mandate to contribute to the reduction of medicines-related risk and the 
delivery of improved health outcomes.  Medicines management became fully enshrined 
in official government documents (12). 
The definitions of medicines optimisation outlined in Chapter 1.3 contain aspects that can 
be clearly seen in the original concepts of pharmaceutical care (USA) and medicines 
management (UK), including: 
 Clinical governance 
 Patient (person) centeredness 
 Medication safety 
 Pharmacists building relationships with patients 
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There is no literature that directly links together the concepts of medicines management, 
pharmaceutical care and medicines optimisation, although in 2001 the Royal 
Pharmaceutical Society described medicines management as ‘a strategy that has many 
components’, one of which is pharmaceutical care, which ‘effectively…is medicines 
management for individuals at a clinical level…. it is all that clinical pharmacy practice 
represents’ (13).  The author believes that the concept of ‘medicines optimisation’ is a 
culmination of medicines management and pharmaceutical care, particularly in England. 
 
1.7 Medicines Optimisation: Scotland, Wales and Northern Ireland  
A survey of policy documents in these UK countries demonstrates that the priorities of 
patient safety, person-centred care and optimal use of medicines are very similar to the 
concept of medicines optimisation in England.  Two key policy documents in Scotland: 
“Prescription for Excellence - the future of pharmaceutical care: vision and plan” (14), 
followed by “Achieving Excellence in Pharmaceutical Care: A Strategy for Scotland” (15), 
demonstrate a preference for the use of the term ‘pharmaceutical care’, with language 
similar to that of Hepler and Strand (9) and ambitions similar to those of medicines 
optimisation as outlined in England.  There are contextual differences, for example 
recognising that 20% of the Scottish population live in rural communities.  However the 
desired outcomes are the same. 
In Wales, ‘medicines optimisation’ is not a formal term used by the Welsh Government or 
NHS Wales and is not referred to in written policy.  The term ‘optimise’ in terms of 
optimising therapeutic outcomes was mentioned in a recent 10 year vision for pharmacy 
in Wales (16). It was not a document produced by the Welsh assembly but has been 
adopted and agreed by them.  The terms used formally in Wales are ‘medicines 
management’ (17) and ‘prudent prescribing’ (18).  Some of the principles associated with 
these terms are similar to those of medicines optimisation, including medication safety 
and working in partnership with patients.  
The term ‘medicines optimisation’ is widely used in Northern Ireland and is supported by 
the Department of Health ‘medicines optimisation quality framework’ (19).  This identifies 
the shift to medicines optimisation beginning with the implementation, for example, of 
NICE guideline NG5 on medicines optimisation (5).   The term ‘medicines optimisation’ is 
viewed as broader than medicines management and includes a regional medicines 
Page 15
  
optimisation model, quality standards and a regional innovation plan.  The deliverables 
outlined by the framework are similar to medicines optimisation. They include better 
outcomes, medicines safety and the involvement of patients in decisions about their care. 
 
1.8 Medicines Optimisation in overseas countries 
In 2006, the International Pharmaceutical Federation (FIP), stated that ‘Increasingly, the 
pharmacist’s task is to ensure that a patient’s drug therapy is appropriately indicated, the 
most effective available, the safest possible, and convenient for the patient’ (20); 
imperatives that align with the RPS four principles of medicines optimisation.  The report 
goes on to promote the philosophy of ‘pharmaceutical care’ as defined by Hepler & 
Strand (9). 
In North America, at least one ‘Center for Medication Optimization’ exists in the United 
States (21) describing medication optimization as a ‘patient-centred, collaborative 
approach to managing medication therapy that is applied consistently and holistically 
across care settings to improve patient care and reduce overall healthcare costs’.  This is 
important to stakeholders including government, health insurers, clinicians and patients, 
because if medication is optimised, costs are reduced, particularly if complications are 
avoided.  Canada does not have an equivalent term but recognises the term 
‘pharmaceutical care’ and seeks to promote ‘appropriate prescribing’ (22). 
Australian clinicians and researchers have been at the forefront of the deprescribing 
movement (see Chapter 3) and an important report from 2018 describes the goal of 
quality use of medicines to optimise ageing in older Australians (23).  The Australian 
National Medicines Policy is being updated in order to improve, for example, its patient-
centred focus, medication safety, and the focus on outcomes (24), all of which align with 
the imperatives of the RPS four principles of medicines optimisation.  The NICE definition 
of medicines optimisation is recognised and used by the Pharmaceutical Society of New 
Zealand (25); and their National Pharmacy Action Plan  2016-20 has drawn on initiatives 
from around the world, including developing pharmacist prescribers, pharmacists in GP 
surgeries and minor ailment schemes as seen in the United Kingdom (26).  ‘Medicines 
Management’ as used in this report encompasses services such as medicines optimisation 
and medicines adherence, the former of which covers patient concerns about safety and 
efficacy of their medicines and complex medication regimes.  Like Australia, there is a 
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focus on outcomes, particularly for their ageing population and those with long-term 
conditions. 
Finally, as an example of a low-resource setting, Namibia is a country developing its 
pharmacy workforce having launched their first pharmacy school in 2011 (27).  A focus on 
medicines optimisation (based on the NHS term), has been emerging through 
undergraduate, pre-registration and postgraduate pharmacy training (28), with an 
ambition to develop pharmacists’ ability and increase the numbers needed to deliver on 
this agenda. 
In summary, across the world, the principles of person-centred care, reduction of risk and 
tackling polypharmacy, particularly in older people, are common goals.  Health systems in 
the UK and other countries share the same ambitions; and the use of the word ‘optimise’ 
is common.  Differences in language exist, for example in the use of terms such as 
‘pharmaceutical care’ and ‘medicines management’.  However a number of countries 
acknowledge the UK use of the term ‘medicines optimisation’ and have developed their 
own local terminology, strategy and desired outcomes to meet their own health system 
needs. 
 
1.9 Medicines Optimisation: a typical medication regime encountered by the author 
During their professional career, the author regularly encountered patients experiencing 
medicines-related problems, many of which are listed A-F at the end of this section and 
feature throughout this thesis.  Many such patients were seen in the author’s local elderly 
care rehabilitation unit (see Chapter 3.1).  The author’s work with one such patient was 
shortlisted as a finalist for a National Patient Safety Award in 2014 (see Chapter 3.3.3).  
Figures 2 and 3 below are copies of the author’s slides using an exemplar case in teaching 
and discussion with undergraduates and postgraduates.  Points 1-4 at the top of each 
slide contain questions posed to students as part of an educational workshop.  Figure 2 
contains the example medication list before a collaborative review by the author and 
their medical colleagues, and Figure 3 outlines typical changes made as a result of the 
author and geriatrician reviewing the medicines in partnership with their patients.  The 
changes made to the medication were chosen to represent common interventions made 
by the author during their medication reviews. 
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Figure 2: Medication list before review 
 
 
Figure 3: Medication list following review by the author, geriatrician and patient 
 
 
Figure 3 identifies the medicines stopped in the exemplar case, ranging from alendronate 
which has complicated administration instructions (29) that may be challenging for older 
patients, to antiemetics that may have been mistakenly continued following an acute 
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hospital stay for surgery.  In the author’s clinical setting, they would typically verify the 
medication history, discuss how the patient felt about managing their medicines, 
contribute this on the ward round with members of the multi-disciplinary team, and 
explain the process of decision-making to students and junior doctors who were in 
attendance, in order to maximise the educational value of the consultation.  
 
The exemplar case illustrates many of the key medicines-related challenges summarised 
by the 2015 National Institute for Health and Care Excellence (NICE) guideline: ‘The safe 
and effective use of medicines to enable the best possible outcomes’ (5).  These 
challenges are listed below (A-F). For each medicines-related challenge, it can be seen  
which medicines in the exemplar case relate to which NICE challenge.  The reader is 
signposted to the relevant chapter of this PhD thesis where details will be given of the 
author’s contribution to the literature in these areas: 
 
A. Medicines not being taken by patients as described (‘non-adherence’).  For 
example, sertraline not being taken if the patient was not aware that they were 
taking an antidepressant or did not think that they needed it.  See Chapter 2 of 
this thesis  
B. An increasing number of people within an ageing population living with at least 
one long-term condition.  For example, hypothyroidism, ischaemic heart disease 
and chronic constipation. See Chapter 3 
C. An increasing number of patients taking multiple medicines (‘polypharmacy’). The 
exemplar patient was taking sixteen medicines.  See Chapter 3  
D. The need for greater patient involvement in decisions about their care in different 
ways, and putting the patient first at all times.  An example in this case would be 
the risks and benefits of statins in later years, discussed within the context of 
what is important to the patient.  See Chapter 2  
E. Deficiencies in the safety of medicines, for example leading to avoidable 
admission to hospital for medicines-related reasons. The complicated 
alendronate administration instructions referenced under Figure 2 may lead to a 
serious risk of oesophageal ulceration.  See Chapter 3 
F. The need to consider education and training needs of staff.  The author 
consistently took opportunities to explain decisions and their rationale to 
students and juniors who were present. See Chapters 4 and 5  
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The last point (F) was only mentioned tangentially in the NICE guidance, which the author 
believed should have been more prominent.  The workshop questions for undergraduate 
and postgraduate students at the top of Figures 2 and 3 are an example of the author’s 
mission to define and engage with the educational imperatives associated with 
medicines-related challenges.  The goal has been to equip students and registered 
clinicians to deliver appropriate clinical outcomes related to safe and effective medicines 
use.    
Finally, the World Health Organisation (WHO) has prioritised transitions of care as an area 
of medicines-related risk (see details in Chapter 3.1).  The exemplar case was used by the 
author in their teaching and speaking to illustrate that medicines may continue to be 
prescribed in new clinical settings even though they are no longer needed (the 
antiemetics).  This is something that the author was consistently and often uniquely able 
to identify and resolve. 
 
1.10  Aims of this thesis 
In this thesis, the author will aim to: 
1. Demonstrate that their body of published work: 
a. Coheres with and, in some cases, predates the definitions and goals of 
medicines optimisation found in Chapter 1.4 and 1.5 
b. Broadly aligns to the Royal Pharmaceutical Society principles of medicines 
optimisation 1 and 3 (shown in Figure 1) 
2. Has positively impacted clinical and educational practice that relates to principles 
of medicines optimisation 
3. Develop the scope of medicines optimisation principle 4 to demonstrate that 
making “medicines optimisation part of routine practice” should include 
appropriate education and training approaches, which the author has championed 
through their publications 
4. Reflect on whether a more unifying definition of medicines optimisation can be 
recommended (see Appendix 5 where the author stated this as an intention) 
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1.11 Method, literature used and rationale for key publications used in this thesis 
This thesis describes the author’s career journey that led to publications in the areas 
covered by each of the four main chapters of the thesis.  Figures 4 and 5 below will be 
used to illustrate the career journey.  Chapter 6, including Table 4, contains a summary 
description and critical evaluation of the methods used in the author’s key publications.  
There was one personal element that has been included, which was the arrival of the 
author’s severely disabled son in 2006.  Parenting a disabled child has profoundly 
influenced the author’s approach to their own clinical and educational practice because 
of the medicines-related challenges that the author has experienced as a parent and 
carer. 
Figure 4 outlines the author’s key publication themes that have led to each thesis 
chapter. It has been adapted from an original version contained in the author’s prima 
facie statement that was submitted as an application requirement for this thesis (see 
Appendix 5). It begins the process of illustrating the coherence of the author’s 
publications with the goals of medicines optimisation (see Chapter 1.4), and the inter-
relationships between the publication themes. Figure 5 is a timeline that relates the key 
publications in this thesis to the author’s career and personal journey, highlighting the 
activities at the time of these publications.  These publications have their own reference 
list that reflects the methodology used for each.  The author has reviewed the 
contemporary literature to compare with their publications and confirm the relevance 
and impact of their own work. 
 
1.12  Summary 
In this introduction, the author has described the term, concept and importance of 
‘medicines optimisation’.  The author will build on the intentions stated within their PhD 
prima facie statement (Appendix 5), and outline throughout the thesis how the author’s 
thinking has evolved with respect to those intentions.  In Chapters 2-5 of this thesis the 
author will outline their body of work, focusing on eleven key publications (see 
Appendices 6-16) that reflect and represent the author’s other published work (see 
publication list in Appendix 2).  Reference will be made to the author’s exemplar case 
throughout.  Finally, in Chapter 6, the author will revisit the stated aims of this thesis, 
return to the exemplar case, consider the future and summarise with a case vignette 
written about the author. 
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Medicines Optimisation (MO) definition: 
Medicines optimisation is an approach that 
seeks to maximise the beneficial clinical 
outcomes for patients from medicines with 
an emphasis on safety, governance, 
professional collaboration and patient 
engagement 
Medication review, polypharmacy and 
deprescribing publications 
Publications demonstrate the following MO 
outcomes: 
 Patient satisfaction/engagement 
 Patient safety 
 Professional collaboration 
Health beliefs, medication adherence, 
consultation skills, patient empowerment and 
clinical empathy publications 
Publications demonstrate the following MO 
outcomes: 
 Patient satisfaction 
 Patient engagement 
 Beneficial therapeutic effects of medicines 
Developing and empowering the workforce 
publications 
Publications demonstrate the following MO 
outcomes: 
 Professional development 
 Equipping for professional collaboration 
 Making MO part of routine practice 
Clinical education and training publications 
Publications demonstrate the following MO 
outcomes: 
 Competence/assessment of competence 
to deliver MO 
 Contribute to clinical governance 
 
Main focus of PhD chapter 3 Main focus of PhD chapter 2 
Main focus of PhD chapter 5 
Main focus of PhD chapter 4 
Example link from publications in 
CV:  
Medication review can help tackle 
polypharmacy which is one reason 
for non-adherence 
Example link from publications in CV:  
 Training in consultation skills is 
imperative in order to understand the 
patient experience and make joint 
decisions with them 
Example link from publications in CV: 
The ‘Bottom up approach to education 
around medication review and 
deprescribing’ seeks to embed medication 
review into the culture of clinical practice 
Example link from publications in 
CV:  
 These publications cover the 
development of knowledge, skills 
and also behaviours/attitudes 
Figure 4: Key publication themes (taken from prima facie statement):  
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Figure 5: Career and personal timeline with key publications  
 
  Number Key publication title 
 
Date 
1 Haemodialysis patients’ beliefs 
about treatment: implications 
for adherence to medication 
and fluid-diet restrictions 
2001 
(research 
completed 
in 1994) 
8 Developing a culture of self-
directed learning in pharmacy 
2009 
10 Reflecting on Teaching and 
Learning in Healthcare 
2012 
11 Development and piloting of a 
competency framework for 
pharmacy educational and 
practice supervisors 
2012 
9 Use of a multisource feedback 
tool to develop pharmacists in a 
postgraduate training 
programme 
2013 
4 Intermediate Care [An optimal 
setting for review of 
inappropriate medication in 
elderly patients] 
2014 
5 A pilot survey of junior doctors’ 
attitudes and awareness 
around medication review: time 
to change our educational 
approach? 
2015 
3 Pharmacy consultations with 
patients with learning 
disabilities 
2016 
2 Why we should understand the 
patient experience? Clinical 
empathy and Medicines 
Optimisation 
2016 
7 The Acute Care Assessment 
Tool – Pharmacy ACAT 
2016 
6 A themed journal issue on 
deprescribing 
2017 
Clinical, education, 
CPD roles at the 
Chelsea & 
Westminster Hospital 
 
Seconded to 
JPB  
(chapter 4) 
Disabled son  
(chapter 2) 
Seconded to 
NIHR CLAHRC 
(chapter 3) 
Clinical senior 
lecturer, King’s 
College London 
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PhD by Publication – Barry Jubraj 
Chapter 2: Medicines Optimisation: Improving the patient experience and 
supporting medication adherence 
 
What this chapter is about 
In Chapter 2 the author will describe their work in the areas of adherence to medication 
and how pharmacists should relate to patients, including those with a learning disability.  
The author’s experience in consulting with patients included identifying non-adherence. 
The exemplar case in Chapter 1, where non-adherence to an antidepressant was 
identified leading to a decision to stop that medicine, is typical of the author’s 
encouragement of patients to take an active role in making decisions about their 
medicines.  The author will outline how personal experience led to national influence in 
how pharmacists can support patients with a learning disability.    
 
2.1 Introduction 
Throughout the author’s clinical and academic career, improving the patient experience 
has become an increasingly prominent driver within the health service agenda in the UK. 
The Kennedy report published in 2002 in response to what became known as the Bristol 
heart surgery scandal recommended that health professionals should treat patients as 
partners, with equal but different expertise (30). Some of the professional development 
implications of this are discussed in Chapter 4 of this thesis. Moreover, the Health 
Foundation also describes ethical and practical drivers for the change towards what is 
known as ‘person-centred care’, including the need to treat patients with respect, 
compassion and dignity; and the potential for this approach to improve clinical outcomes 
and adherence to treatment plans (31).  The WHO  recognised that health was impacted 
by a variety of factors including social, economic and environmental, meaning that caring 
for the whole person is necessary (32). 
The author’s peer mentor, Professor Nina Barnett, stated that ‘Pharmacists are in a 
unique position to add value to medicines-related consultations using a person-centred 
approach to evidence-based medicine’ (33). Pharmacists have been encouraged to move 
from a ‘product-centred’ to a ‘patient-centred’ approach to consulting with patients (34), 
which recognises that patients have a right to be involved in decisions about medicines 
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(35). The author has experienced over their career that many pharmacists do not 
demonstrate a person-centred approach.  Many appear to struggle to make clinical 
decisions or suggestions that improve quality or lead to even greater benefit, instead 
focusing on identifying problems or mistakes.  The view that pharmacists should change 
their decision-making from predominantly non-maleficence to a greater focus on 
beneficence (36) was therefore to be welcomed.  Moreover, patient and public 
perceptions around how involved they are in decisions about their care have not changed 
significantly over recent years (37); and therefore more work needs to be done, for 
example around medication adherence (see Chapter 2.2.1) and shared decision-making.  
The latter is about health professionals and patients working together to put people at 
the centre of decisions about their own treatment and care (38). The expectations of 
government, policy-makers and professional leaders are that pharmacists will embrace 
the concept of person-centred care and deliver a quality of care that is congruent with 
the Royal Pharmaceutical Society’s four principles of medicines optimisation (8), the first 
of which is to ‘understand the patient experience’.  By doing this effectively, pharmacists 
have a key role in helping patients to get the most out of their medicines.  Examples 
include improving adherence to prescribed treatment, and overcoming barriers to 
medicines-taking, including where communication difficulties exist. One such difficulty is 
a learning disability, which is discussed in Chapter 2.4. 
 
2.2 Key publication 1: Haemodialysis patients’ beliefs about treatment: implications for 
adherence to medication and fluid-diet restrictions (39) (see Appendix 6) 
 
2.2.1 Background 
Adherence to a medication regimen has been defined as “the extent to which patients 
take their medications as prescribed by their healthcare providers.” (40)  Over the last 40 
years, non-adherence to treatment recommendations in general, and medication non-
adherence in particular has been increasingly recognised. For example, in 1996 a key 
study in The Lancet  (41) acknowledged that low adherence to treatment 
recommendations limits the benefits of medical care.   
An internationally renowned health psychologist, Professor John Weinman (JW), and a 
pharmacist, now Professor of Behavioural Medicine, Robert Horne (RH), have together 
contributed extensively to the medication non-adherence literature. They have published 
evidence confirming that patients have beliefs and concerns about illness and treatment.  
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They have contributed to the understanding of the concepts of ‘intentional’ and 
‘unintentional’ non-adherence, which has been defined as follows (42): 
Unintentional – when patients intentions to take the medication as advised are thwarted 
by barriers that are essentially beyond their control, such as forgetfulness, poor 
comprehension language barriers, or physical inability to manage the medication (e.g. 
difficulties opening containers or using administration devices). 
Intentional – a conscious decision by the patient to take the medication in a way which 
differs from instructions, or not to take it all. This often takes the form of patients 
reducing the frequency of dosing or the number of medications down to a level that they 
(and not their doctor) feel is appropriate, or premature discontinuation of therapy. 
Their work has also explored how patients’ beliefs and concerns about medication lead to 
active decisions about whether or not to adhere to treatment.  With other experts, they 
have also challenged the use of an older term ‘non-compliance’, arguing that this term 
suggests that not following treatment recommendations is the patient’s fault, for 
example through ignorance or forgetfulness (43).  National guidance now exists to 
support clinicians in tackling non-adherence (35), and the concept is routinely taught in 
many healthcare training curricula. The pharmaceutical industry also funds programmes 
to support patients who are prescribed their treatments.  In spite of these initiatives, a 
recent report by the Organisation for Economic Co-operation and Development (OECD) 
states that “Despite mounting evidence, amassed for more than four decades, poor 
adherence to medications still affects approximately half of the population that receives 
prescriptions” (44).  
 
2.2.2 The author’s MSc adherence research  
In 1993, two years after qualifying as a pharmacist, the author undertook an MSc 
programme in clinical pharmacy, 50% of which contained a research element.  The 
research study explored adherence to treatment recommendations in haemodialysis 
patients, under the co- supervision of JW and RH. The author’s research took place at 
their base hospital in London, on a haemodialysis unit, and involved recruiting eighty 
haemodialysis patients to complete a questionnaire exploring beliefs about their illness 
and treatment.  The questions were taken from three sources: the ‘Illness Perception 
Questionnaire’ (45), the ‘Medicines Representations Questionnaire’ (46); and self-report 
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questions about adherence and health.  The chosen questions were compiled into a 
specific questionnaire for the purposes of the study.  The majority of questions consisted 
of a series of statements with a five point Likert scale (47) to allow responses ranging, for 
example, from ‘never’ to ‘often’ and ‘strongly agree’ to ‘strongly disagree’.  Statistical 
analysis was undertaken of the 47 returned questionnaires.  A key finding was that 
patients’ own beliefs about their treatment were related to adherence to medication and 
fluid-diet restrictions in a coherent way.  An example of this was that negative views 
about medicines, such as fear of side effects, predicted for self-reported non-adherence.  
One of the main contributions of this study was to quantify the prevalence of certain 
beliefs (including about illness and treatment) and to identify which beliefs were related 
to intentional non-adherence.  The study also demonstrated that adherence issues are 
not restricted to medicines, but can also affect diet and fluid restrictions which can be 
burdensome for patients with kidney disease. 
 
2.2.3 The subsequent publication and impact of the research 
Data from this research contributed directly to the development of Horne & Weinman’s 
‘Beliefs About Medicines’ Questionnaire (BMQ) (48), a flexible instrument that can be 
adapted to assess beliefs about all medicines for a particular condition or for individual 
components of a regimen. The author’s work in haemodialysis patients was 
acknowledged in this publication, as well as in the supervisors’ own key paper on patient 
beliefs and adherence (49).  Both of the supervisors’ papers are cited in the author’s key 
publication 1, since it was published some years after the original research was 
undertaken and after the supervisors’ own work was published.  Over forty citations have 
been found and it continues to be read via the author’s Researchgate® profile.  Professor 
Weinman recently told the author that this publication in his view is a ‘minor publication 
classic’. This positive feedback was highly valued because the author’s research 
contributed to what is one of JW’s most cited publications to date (48).   
Post MSc., the author’s professional journey in the field of medication adherence 
continued both directly in patient care as well as through teaching undergraduates and 
junior pharmacists. In 2003, the author began undergraduate training as a counsellor, 
which led to personal reflections on the appropriate overlap between counselling clients 
and patient consultations, including adherence-related conversations.  This led to the 
author publishing a discussion article exploring how pharmacists could learn from the 
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skills that counsellors develop (50).  The author applied learning around rapport, empathy 
and good listening skills to the clinical consultation, and made an early reference to the 
haemodialysis research outlined above.  The author has continued to use this article in 
teaching, particularly for postgraduate foundation pharmacists who are beginning to 
apply these skills in their practice.  The author’s training as a counsellor has profoundly 
impacted their approach to patient care and being a tutor (Chapter 5.4.3), mentor and 
supervisor (see Chapter 5.5 which describes the author’s activity in mentoring and 
supervision).  The importance and value of empathy are core to the author’s beliefs about 
professional as well as personal relationships. 
In 2015, the author was appointed as Clinical Senior Lecturer in Medicines Optimisation at 
King’s College London, where Professor Weinman was based.  The author’s background in 
adherence research and wide-ranging practice experience in tackling adherence-related 
patient problems, led to a request to contribute to a King’s College Massive Open Online 
Course (MOOC) on adherence (51). A MOOC is an online course aimed at large-scale 
participation and free access via the internet. MOOCs are similar to university courses, 
but typically do not offer academic credit.  The author contributed real-life examples of 
consulting with patients and suggesting practical strategies to improve adherence.  Since 
the launch, approximately 25,000 learners from a multi-professional and international 
audience have registered for the MOOC.  The potential for influencing attitudes and 
approaches to non-adherence was therefore significant.  The author’s practical and 
down-to-earth contribution, such as inviting patients with dexterity problems to manage 
their medicines on a tray on their lap to avoid dropping tablets on the floor, was hopefully 
helpful to many. 
The author has recently assumed the role of Associate Director for the Medicines Use and 
Safety Network of NHS England’s Specialist Pharmacy Service (SPS) (52) and has initiated 
a collaboration to explore links between non-adherence and medication safety.  The 
author’s initiative resulted from attending the launch of the King’s College London Centre 
for Adherence Research and Education (CARE) (53) in the autumn of 2018.  A peer 
discussion with Professor Barnett around the patient safety agenda led to a realisation 
that medication non-adherence can be a safety issue.  The author therefore ran an SPS 
workshop in March 2019 to explore the link and to get feedback from participants.  
Overwhelmingly, pharmacist participants reported that they had not previously 
considered adherence in safety terms (54). The clinical director for the south London 
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Health Innovation Network (55) attended the workshop event and has invited future 
collaboration to explore the links further.  This proposed link supports recent research 
published around the same time, stating that “Harm from non-adherence to medications 
may explain the relationship between polypharmacy and mortality” (56). 
 
2.3 Key publication 2: Why we should understand the patient experience? Clinical 
empathy and Medicines Optimisation (57) (see Appendix 7) 
 
2.3.1 Background 
The relationships between patient experience in medical consultations and their 
outcomes have been explored over many decades.  For example, in 1982, Ley surveyed 
the literature and concluded that patients’ compliance with medical advice (see Chapter 
2.2.1 for comparison with the term ‘adherence’), correlates with patients’ satisfaction 
with the consultation, communication and care received (58).  A general practice study 
from 2004 demonstrated a positive relationship between doctor-patient concordance 
(defined as agreement between the two about, for example, the reasons for the 
consultation and patient involvement with decisions) and medication adherence (59).  
Wolf et al. reported that studies demonstrated that ‘patients expect to have a 
comfortable and warm interaction with a physician’ as well as clinical competence; and 
they suggest a scale to measure the satisfaction of patients in their consultations (60).  
The term ‘clinical empathy’ has been used in the medical literature and seeks to apply the 
importance of empathy to clinical practice, for example stating that “empathy facilitates 
trust and disclosure and can be directly therapeutic” (61).   
As pharmacists have developed their role to undertake clinical consultations with 
patients, little has been written about the quality of their interactions.  In 2012, the Chief 
Pharmaceutical Officer for England said that pharmacists “should reflect on how much in 
their practice they are engaging with patients and the public” (62).  As described in 
Chapter 1, the Royal Pharmaceutical Society published four principles of medicines 
optimisation in 2013 (8), the first of which is to ‘understand the patient experience’.  At 
around the same time the NHS, including pharmacy stakeholders, were examining the 
report from the scandal surrounding the standards of care at Mid-Staffordshire hospital in 
England (63), which stated unequivocally that services needed to be provided by caring 
and compassionate staff.   
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In response to these developments, the Centre for Pharmacy Postgraduate Education 
(CPPE) developed a consultation skills learning package for pharmacy (64) that was 
published in England in 2014 (65) and sent to all 65,000 pharmacists and pharmacy 
technicians registered in England. The author was invited to be part of the working group 
and a reviewer of the package, and contributed a video clip for the associated online 
version (66).  The clip emphasised the importance of effective consultation skills as well as 
the need to educate juniors about this (see Chapter 4.4). The author and one of the lead 
writers of the package, Professor Nina Barnett (NB), were also invited by CPPE to film a 
consultation example (67) and associated debrief (68) to model good consultation skills 
for inclusion.   
The author’s experience as a counsellor and having become both a carer and patient in 
the 2000s, profoundly reinforced their belief that ‘understanding the patient experience’ 
requires the building of a rapport with individual patients, however short the 
consultation.  The author’s 2007 article (see Chapter 2.2.3) outlining what pharmacists 
might learn from mainstream counselling, stated that “consultation and guidance are best 
delivered through a healthy and manageable professional relationship”.  The author 
approached NB to discuss the lack of literature around the need for pharmacists to 
develop empathy as a key element of their consultation skills, particularly with respect to 
adherence. This led to a publication for the Pharmaceutical Journal (34) that encouraged 
pharmacists to move from a product-centric approach to a more patient-centric 
approach, which is consistent with other published opinions (69).  The author and NB 
then decided to explore the application of ‘clinical empathy’ to pharmacy consultations.  
 
2.3.2 Article development 
The author and NB approached colleagues from the publications outlined above to 
collaborate.  A lead writer of the CPPE consultation skills package, Lesley Grimes (LG), 
agreed to contribute, as did Sneha Varia, who co-wrote the above Pharmaceutical Journal 
article with us.  The author had worked with two clinical psychologists at University 
College and King’s College in London, both with expertise in medicines use, who agreed to 
join the writing team.  The author took the lead in planning and editing this publication, 
which was structured around the published literature related to empathy, clinical 
consultations and current pharmacy practice.  The pharmacist co-authors applied these 
concepts to current practice in clinical consultation.  The article included examples of key 
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consultation questions and recommendations for pharmacy practice and undergraduate 
education. 
 
2.3.3 Impact and associated outputs 
The clinical empathy article has eight citations, where the concept has been applied to 
clinical situations such as smoking cessation, diabetes, obesity and learning disability (LD).  
In Chapter 2.4.1, the author describes the need for patients with LD to be given time 
(including process time) and a patient/compassionate approach during consultations.  LG 
invited NB and the author to publish a blog in the Pharmaceutical Journal entitled 
“Making our patients feel cared for” (70) which picked up on the theme of compassion 
and caring.  A recent citation in the Pharmaceutical Journal recommended that a focus on 
empathy and compassion should be included in undergraduate teaching (71).  This has 
been a feature of the author’s teaching of undergraduate and postgraduates since their 
teacher-practitioner role began in 1998.   
The author also embedded the concept of clinical empathy in their undergraduate 
education role, in particular linking it to an annual workshop for second year pharmacy 
students at King’s College London about the four principles of medicines optimisation.  
The author then drew heavily on the concept of clinical empathy to guide the placement 
co-ordinator with the development of a novel ‘socialisation internship’ for undergraduate 
pharmacy students at King’s College London (72), adapted from the first model of its kind 
in the UK (73).  This involved undergraduates volunteering and reflecting on their 
experiences in settings ranging from care homes, to coaching underprivileged teenagers, 
as well as exploring their own ability to empathise in a real-life setting.  Analysis of 
written feedback from students for a 2018 final year pharmacy student project 
demonstrated that many students reported intentions to be ‘more empathic’ and ‘more 
understanding’ in their practice (74). The importance of this feedback was the potential 
impact of these students on individual patients and their colleagues as they become role 
models, although there appears to be little evidence that clinical placements in of 
themselves have a lasting impact on attitudes to patients.  The author plans to co-
produce a publication of the findings of this analysis in 2019. The socialisation internship 
was verbally commended during an interim MPharm accreditation visit to King’s College 
London by the General Pharmaceutical Council (GPhC), the regulator who accredits 
pharmacy degrees in Great Britain.  The internship was also mentioned in the written 
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report (75).  This is important because the GPhC are currently emphasising placements in 
their accreditation visits to schools of pharmacy, and will often cite examples of good 
practice from one school to another. 
The author’s consultation skills videos for the CPPE consultation skills package have been 
used in consultation skills training across England and have been linked to a national 
declaration of competence developed by CPPE for community pharmacists to 
demonstrate readiness to provide professional services (76). XXXX has said the following 
about the video clips: 
“We know that these videos are well used and we have used them to support our learning 
delivery in our clinical pharmacy in general practice learning pathway and will use them in 
our Medicines Optimisation in Care Homes pathway as well. Including these in a range of 
learning programmes across the country…. People often comment to us that these videos 
are highly relevant and speak directly to the services that people offer and the way in 
which they routinely work”.  
 (XXXX, personal communication.  Reproduced with permission) 
 
In 2019, the author was invited to join a national working group, hosted by CPPE, to work 
with NHS England/Improvement to develop training on shared decision-making. 
The author also published an online journal article about consultation skills and personal 
experience as a carer (77), in which the consultation skills video links were embedded.  
The author has been told by some readers that this was a helpful way to combine 
messages from two types of media into one publication.  These activities have led directly 
to a number of invitations to speak at strategic learning events, conferences and webinars 
about clinical empathy and being a carer (see Appendix 2 full publication list: sections 
entitled ‘Conference abstracts/posters; and learning event/webinar presentations’, and 
‘Other media’)  
 
2.4 Key publication 3: Pharmacy consultations with patients with learning disabilities (see 
Appendix 8) (78); (and associated publications, including those related to ‘My Medication 
Passport’) 
 
2.4.1 Background 
The author’s work around clinical empathy and consultation led to further opportunities 
because of their role as a carer.  The author’s disabled son, Alexander (name and initials –
AJ - disclosed with both parents’ permission), has Down’s syndrome (DS), complex 
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medical needs and an associated severe learning disability (LD).  The author was aware of 
national guidance encouraging consideration of impairments such as LD when 
undertaking a clinical consultation (35).  They had also experienced both good and poor 
consultations with AJ, including relatively few good consultations with pharmacists.  In 
2014 the author was seconded by their hospital to work with the National Institute of 
Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care 
for north-west London (CLAHRC NWL) (79) (hereafter abbreviated to CLAHRC NWL).  
CLAHRC NWL established a medicines optimisation work stream in 2009 and outputs 
included a co-created patient-held tool for recording medication records with patients.  
The tool is called ‘My Medication Passport’ (MMP) (80) and was developed by and for 
older adults.  However, the author decided to pilot the MMP in their son AJ to explore its 
utility.  The author found that the tool ‘took the pressure off’ recalling medicines-related 
information at consultations, such as the complete medication list and how medicines are 
practically administered at home.  As a pharmacist, the author was mindful that for a 
reliable drug history, ideally two sources of information should be consulted (81).  The 
senior CLAHRC NWL team connected the author with a professor of paediatrics 
associated with CLAHRC NWL and the Royal College of Paediatrics & Child Health, who 
was keen to publish this experience.  This led to a case study about AJ being published in 
BMJ Case Reports (82), which to date has been cited six times. One citation was in a 
published literature review in 2017 that identified and evaluated studies that have 
investigated the implementation, sustainability and/or evaluation of patient-held 
information about medicines.  The author’s work was also one of only eleven publications 
identified (83) (see Chapter 2.4.3 where that work is described).  CLAHRC NWL also wrote 
a blog with MMP testimonials including ‘Alexander’s story,’ which outlines details of the 
case report (84).  Moreover, Alexander’s story was expanded as a case vignette (85) 
which is discussed in chapter 6 of this thesis. 
This work inspired the author to contact the Down’s Syndrome Association (DSA) to 
explore opportunities to work together; because the author believed that others with 
Down’s Syndrome and/or a learning disability are likely to struggle with the same 
challenges that the author had encountered.  The DSA invited the author to host a focus 
group afternoon with adults with DS entitled ‘Visiting the Pharmacist’ (86). Participants 
stated that they would like to have their own conversations with pharmacists, had 
questions that they wished to ask, and knew little about how pharmacists could help 
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them with their medicines.  Throughout the afternoon, the author was personally 
impacted and convinced that these individuals needed process time in consultations and 
to be treated with compassion and empathy.  This had been raised by an information 
officer at the DSA in conversation prior to the focus group.  Participants were shown a 
copy of MMP and generally liked the tool, stating that it could provide a useful record 
when going to medical appointments.  Following the focus group, the author approached 
the Pharmaceutical Journal with a request to write a learning article about appropriate 
communication for all pharmacists (78).  This is key publication 3. 
 
2.4.2 Article development 
The author invited Lesley Grimes, LG (see Chapter 2.3.2) from CPPE to contribute her 
expertise in pharmacy consultations to the article.  A meeting between the author and 
DSA staff elucidated their experience around the challenges that people with LD may face 
when communicating with others in all walks of life, for example financial or other health-
related conversations.  DSA staff were keen to co-produce the article and raise the profile 
of the DSA, which the author was keen to support.  The DSA provide valuable background 
on the health challenges that those with LD may face via their website (87).  The author 
then used the focus group findings (see above) and the discussions with DSA staff to 
make appropriate reference in the article to the CPPE consultation skills package (65) with 
the help of LG.  Key clinical consultation challenges that patients with LD may face were 
included.  The author concluded by outlining communication approaches for pharmacists 
to incorporate into their practice, for example allowing process time. 
 
2.4.3 Impacts and associated outputs, including MMP publications 
This publication regarding consultations with people with LD has been cited in other work 
and agrees with their key messages.  Firstly, those with LD are not getting enough 
information about their medicines from doctors or pharmacists (88).  Moreover, patients 
may not realise that they can ask pharmacists questions, who may in turn have a 
tendency to address parents and carers rather than the patient with LD.  This issue in the 
author’s publication was subsequently cited (89) and the point made that long 
consultations are not necessarily needed and pharmacists do not need to worry about 
getting the consultation ‘wrong’. 
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XXXX has told the author that this publication was included in the CPPE learning disability 
training package because “it is a well written paper that was directly relevant to our 
learners….and encourages people to explore…and start to plan a change to their 
practice…written from a changing practice perspective”. (XXX, personal communication.  
Reproduced with permission) 
Following the focus group and in discussion with the DSA, ‘My Medication Passport’ was 
recommended as a consultation tool by the DSA, and the author wrote an article for the 
DSA journal introducing MMP for those with DS and their carers to consider using in 
medicines-related consultations (90).  The findings from the focus group also led to the 
DSA co-producing, publishing and promoting an online leaflet by the same name ‘Going to 
the Chemist’ (91). The co-production approach to ‘Going to the Chemist’, whereby service 
users are equal partners in development, is an important feature and supports the views 
of others when producing information to support patients (88). The author was invited to 
review the leaflet and then wrote an article about it in the DSA Journal (92). Since the 
launch, ‘Going to the Chemist’ has had 138 downloads as well as online views.  The DSA 
have told the author that they anticipate the leaflet will continue to be helpful to readers. 
It should also provide benefits particularly when they visit pharmacists who have read the 
author’s article on consultation with patients with LD in the Pharmaceutical Journal. 
The Royal Pharmaceutical Society (RPS) invited the author to participate in a national 
group producing a summary guidance card for pharmacists caring for patients with LD 
(93).  This card was sent with the Pharmaceutical Journal to every pharmacist that is a 
member of the RPS, and it is part of a ‘Medicines Optimisation Hub’ hosted by them, 
which also refers to the author’s learning disability publication (94). The author was also 
invited by CPPE to contribute to a new national learning package on LD, which cited the 
Pharmaceutical Journal article, the author’s work with the DSA, and led to a national 
webinar (95) on the topic of pharmacy and LD.  The author also co-wrote the foreword to 
the CPPE learning package, contributed to a national campaign to raise awareness of LD; 
including participating in a national Facebook event (96) and contributing a video with 
their son (97).  Moreover, all of their LD publications were accepted onto CPPE’s national 
repository of resources for LD (98).  Positive feedback was received on the author’s 
contribution to the learning package from the director of CPPE (See Table 1, Chapter 2.5). 
Subsequently, the author supervised an undergraduate project evaluating views on the 
CPPE learning package which was presented at the Clinical Pharmacy Congress in 2018 
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(99).  A key finding was that pharmacists faced communication challenges with patients 
with LD. The author was also interviewed for a summary online article about how 
pharmacists can advise and support patients with LD (100). This article also reported an 
encouraging development known as the ‘Making Time’ project (101), where pharmacists 
seek to give the time to patients with LD that they need.  This also reflects the DSA 
Information Officer and author’s experience of interacting with individuals with LD.  
‘Making time’ is the type of initiative that the author would like to see promoted as an 
example of the RPS’s medicines optimisation principle 1 (8).   
The author also participated locally by representing their hospital pharmacy on a Trust-
wide LD steering group and contributed their caring experience for someone with LD.  
The author contributed to the design and evaluation of a medicines information leaflet 
for patients with LD and their carers, which has been presented at conference and 
submitted to the CPPE repository of LD resources (102) [Please note, author was 
mistakenly omitted from the authorship list]. 
As introduced in Chapter 2.4.1, the author’s BMJ case report about the use of My 
Medication Passport led to an invitation in 2017 to act as an expert panel group member 
for ‘PhiMED’ (‘Patient-held information about medicines) (103), a large mixed-methods 
descriptive scheme of research with a number of work-packages, to explore the use and 
perception of patient-held information, given their experience with MMP.  Since then, the 
author has contributed to group work on interpreting study findings, advising on aspects 
of study recruitment, and participating in the research itself.  PhiMED ended in March 
2019 and it has been confirmed that the author will participate as a collaborator in 
subsequent publications, once the key findings are confirmed.  The author is responsible 
for NHS England’s Specialist Pharmacy Services’ national monthly webinars that attract 
over 100 listeners and many more subsequent downloads via the SPS website.  The 
author arranged a webinar in 2019 to disseminate the PhiMED findings. Key finding are 
that in general, patient experience with PhiMED was positive; but no one example met 
the needs of all users (104).  This supports with the author’s BMJ case study findings (82).  
A key PhiMED study output was a video to encourage patients and carers to consider 
carrying a record of their medicines, which the author believes will be another 
contribution to the medication safety agenda (105). 
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2.5 Summary 
The themes of medication adherence, patient experience and pharmacist consultations 
have been central to the author’s clinical and educational practice, with regular 
publication and speaking, particularly over the past ten years.  This has coincided and is 
similar to the drivers behind the development of person-centred care that have been 
outlined at the start of this chapter, and latterly the publication of the four principles of 
medicines optimisation by the RPS.  One of the author’s publications contains an 
interview conducted with the writer of the RPS’s Medicines Optimisation guidance, 
Catherine Picton (CP), discussing the four key principles of medicines optimisation (106).  
The author asked CP about her view on the most important principle.  Principle 1, 
‘understanding the patient experience’, was stated as arguably the most important, partly 
because of pharmacy’s traditional weakness in this area.  The author believes that this 
supports the key messages in their own publications, academic teaching to 
undergraduates/postgraduates, and at conferences and meetings.  All of these aim to 
encourage the pharmacy profession to change.  It is important to note that the author’s 
work in the areas of medication review, polypharmacy and deprescribing (Chapter 3 of 
this thesis) have drawn significantly on the author’s expertise and experience in clinical 
consultation outlined in this chapter.  A key example is that consultations with patients 
about polypharmacy and stopping medicines require elucidating patients’ views and 
concerns about their medicines in ways that are patient-centred and empathic.  This 
agrees with literature stating that the ‘patient voice’ needs to be heard in these 
conversations (107).   
In terms of learning disability and MMP, the author has also supervised undergraduate 
research reviewing uptake of MMP by pharmacists across England.  The Pharmaceutical 
Journal has in principle agreed to publish the findings, which outline how MMP has been 
used in situations such as LD and with older people in medicines-related consultations 
(108).  This is important because of the wide coverage of pharmacists that this journal 
potentially reaches.  Another recent proof-of-concept student project was the first to trial 
the use of MMP in special schools (109).  A special school in Britain is an educational 
establishment that caters for the needs of children of school age with a physical or mental 
impairment; and the author’s son currently attends one of the special schools used in the 
MMP study.  Although small numbers were involved, the findings highlighted medicines 
reconciliation challenges and a lack of familiarity of school staff with the way in which 
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parents and carers administer medicines to their children at home.  The British 
Association for Community Child Health have asked to see details of the project with a 
view to publishing the findings, which the author will aim to do in 2019.   
The author has also reviewed recent national coverage of a key LD report exploring 
mortality in those with LD (110). The national profile around care for those with LD is 
increasing but the report mentions nothing about the significant risks that medicines can 
present in this cohort.  The Pharmaceutical Journal has agreed in principle to publish an 
informed response to this report written by the author and their colleague who co-wrote 
the foreword for the CPPE national learning package on LD.  This colleague has also 
invited the author to co-write a book chapter in 2019 covering medication and learning 
disability.   
The author has a unique combination of experience in being both a carer for someone 
with Down’s Syndrome-associated LD and also a pharmacist.  They have sought to make a 
substantial contribution to initiatives to help the profession improve their standard of 
care for these patients and their families.  Table 1 includes examples of feedback on the 
author’s contribution to the medicines agenda with respect to LD. 
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Table 1: Feedback examples on the author’s contribution to the learning disability 
agenda with respect to medicines 
Organisation 
 
Project Feedback 
Centre for 
Pharmacy 
Postgraduate 
Education 
(CPPE) 
Learning 
disabilities training 
package 
“You brought two essential elements to this learning 
programme for us. Firstly, you brought your status. You 
are a well-known and highly respected professional who is 
part of a high level network and is recognised for 
excellence in consultation skills. Secondly you brought the 
honesty of your lived experiences. This second part was 
the one that really made a difference for me personally. 
When I watched your video in which you talked about 
trying to find the right ways to help Alexander take his 
medicines, it really stopped me in my tracks and made me 
ask myself how many times I may have failed to help one 
of my customers simply because I never stopped to check 
that they were ok.” (XXXX, personal communication.  
Reproduced with permission) 
 
Specialist 
pharmacist in 
mental health 
Forthcoming book 
chapter on 
medicines in 
learning disability 
I have approached you as Alexander's Dad and all the 
expertise you have as a parent rather than in your 
capacity as a healthcare professional in order that that 
the 'voice' of people with learning disabilities is heard . 
The fact that you just happen to be so skilled in writing 
and a successful academic pharmacist is for me a 
wonderful added bonus. I have not asked anyone else as I 
thought that you would be the ideal person (XXXX, 
personal communication.  Reproduced with permission) 
 
Down’s 
Syndrome 
Association 
(DSA) 
Medicines leaflet 
for patients with 
LD admitted to 
hospital and 
articles for the DSA 
journal 
The leaflet is excellent. I think an article for the Down’s 
Syndrome Journal about the work you have done, the 
process and outcomes is a very good idea - we could use 
the information in a variety of ways and so can the world 
of pharmacy. Please let me know if or when I can show 
the leaflet to others (Down’s Syndrome Association)  
 
 
Finally, the author has identified a potential gap in an initiative by Down’s Syndrome 
International to develop international health guidelines for people with Down’s Syndrome 
(111)(112). There appears to be little mention of the challenges that may face such 
patients with medicines administration and adherence and the author recommends 
including this as part of guideline development.  The author contacted Down’s Syndrome 
International with examples of their own work in this area, and has now been invited to 
review and contribute to the international guideline with respect to medicines.  The 
international co-ordinator commented on the author’s “extremely valuable work and 
insights”. 
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PhD by Publication – Barry Jubraj 
Chapter 3: Medicines Optimisation: Providing safe care: Medication review, 
polypharmacy and deprescribing 
 
What this chapter is about 
Chapter 2 outlined the author’s work related to medication adherence and how 
pharmacists should interact with patients given their developing roles.  Chapter 2.3.1 
indicated that successful consultations with patients (which may, according to health 
professionals, be partly defined by improved adherence to medication) will depend on 
the quality of the interaction between them.  In this chapter, the challenge of 
polypharmacy (defined below) is explored and is linked with Chapter 2 as research 
indicates that medication adherence can be negatively impacted by polypharmacy (113) 
(114).   As such the author contends that the work described in this chapter can only be 
successful if the principles in Chapter 2 are practised, including clinicians recognising the 
need to explore the potential or existence of ‘intentional’ and ‘unintentional’ non-
adherence (Chapter 2.2.1).  The author made every effort to make patients feel 
comfortable in disclosing if they were not taking all of their medicines as prescribed, 
partly due to the burden of polypharmacy.  The author will describe their work chiefly 
undertaken during their secondment to, and honorary post with, a National Institute for 
Health Research body, CLAHRC NWL (see Chapter 2.4.1).  Examples of this work were 
shortlisted for a national award, won a local award, led to a strategic educational 
approach; and the opportunity to co-edit an international journal themed issue on 
deprescribing. 
 
3.1. Background 
An ageing population in Western societies has led to many older people living with more 
than one long-term health condition, which is known as ‘multimorbidity’. Such patients 
are more likely to be prescribed a number of medicines, which is described as 
‘polypharmacy’ and has been defined as the use of multiple medications or the use of a 
medication that is not indicated (115).  The number of medicines taken by an individual 
patient that constitutes polypharmacy is not universally agreed, but the author and 
others in the field commonly agree with a figure of six medicines (116). Polypharmacy has 
been categorised as either ‘appropriate’, or ‘problematic’. ‘Appropriate’ polypharmacy 
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recognises that the prescribing of ‘many’ medicines can be entirely appropriate in 
patients with several chronic conditions (117), and care is needed to ensure that such 
patients receive the treatment that they need.  ‘Problematic polypharmacy’ is by contrast 
described as “the prescribing of multiple medicines inappropriately, or where the 
intended benefit of the medicine is not realised”. (118).  In the UK, the National Institute 
for Health and Care Excellence (NICE) acknowledges that multimorbidity is common and 
is often associated with polypharmacy (118).  Internationally, polypharmacy was 
prioritised by the World Health Organisation (WHO) in 2017 by including it as one of three 
priorities to be addressed as part of its ‘Medication without Harm’ challenge (119).  
Another priority was ‘transitions of care’ (briefly discussed in Chapter 1.9). 
In order to identify patients contending with potential problematic polypharmacy 
alongside other medicines-related challenges, the concept of ‘medication review’ has 
become established in both the literature and clinical practice.  This has been described 
as “a structured, critical examination of a patient’s medicines with the objective of 
reaching an agreement with the patient about treatment, optimising the impact of 
medicines, minimising the number of medication related problems and reducing waste” 
(120).  Literature and guidance, developed since 2002, involve defining ‘levels’ of 
medication review (121) according to how in-depth a review is; and identifying outcomes. 
The author’s work with NIHR CLAHRC colleagues also yielded locally-accepted definitions 
of levels of medication review (116).  Outcomes include understanding the patient 
experience, facilitating improved adherence, or stopping medicines.  Stopping medicines 
has become known as ‘deprescribing’, with a variety of definitions in the literature (122).  
A recent definition published by the English Deprescribing Network (123) is as follows: 
Deprescribing is a collaborative process, with the patient and/or their carer, to ensure the 
safe and effective withdrawal of medicines that are no longer appropriate, beneficial or 
wanted, guided by a person-centred approach and shared decision-making.  
This definition matches the patient (or person)-centred imperatives outlined in Chapter 2, 
in terms of the need for collaboration and person-centred care.  The author presents 
different definitions of deprescribing in their teaching of both undergraduates and 
postgraduates (see Chapter 3.4.2) to encourage students to critique them by evaluating 
whether the patient is mentioned or not.  The author has found this to be an effective 
way of engaging students to critically consider and discuss what person-centred care 
actually means. 
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The history and development of medication review has been described (124), and for 
older patients, medication review is an acknowledged essential element of the 
‘Comprehensive Geriatric Assessment’ (125).  Between 2008-2015, the author developed 
significant clinical experience in undertaking medication reviews in their role as a senior 
pharmacist for older persons’ rehabilitation at the Chelsea & Westminster Hospital.  This 
included identifying problematic polypharmacy and prompting appropriate deprescribing, 
for example in patients similar to the exemplar case in Chapter 1. 
 
3.2. Introduction to author involvement 
Prior to 2008, the author drew on their research and publication experience in 
medication adherence and patient consultation (outlined in Chapter 2), to review and 
rationalise medication regimes for patients.  This was undertaken in their role as a 
generalist ward pharmacist and subsequently as a specialist pharmacist for elderly 
medicine. The author’s frequent observation was that complex medication regimes 
contributed to the non-adherence that patients reported during many consultations.  In 
2008, the author assumed responsibility for the Chelsea & Westminster (C&W) Hospital’s 
pharmacy service to the elderly care rehabilitation unit mentioned above. Patients were 
admitted from a variety of settings, including acute care and referrals from GPs. The 
author’s experience outlined above was deployed in consultations with this cohort of 
patients. 
In 2009, C&W became host to the National Institute for Health Research (NIHR) 
Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Northwest 
London (see Chapter 2.4.1). CLAHRCs were established in England in the 2000s to foster 
collaboration between academia and health services to undertake applied research and 
translate this into clinical practice in a timely and effective manner.  A ‘medicines 
optimisation’ work stream was established by CLAHRC NWL to improve prescribing for 
the elderly, which included tackling the challenge of problematic polypharmacy.  
Following the roll-out of a number of projects, including ‘My Medication Passport’ (see 
Chapter 2.4.1) and the development of a medication review tool known as STOPIT (see 
Appendix 17), the author volunteered to test this tool in the rehabilitation unit.  This 
project led directly to the author’s secondment to CLAHRC NWL from the Chelsea & 
Westminster Hospital that began in 2014 and continued until 2019. 
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3.3 Key publication 4: Intermediate Care [An optimal setting for review of inappropriate 
medication in elderly patients] (126) (see Appendix 9) 
 
3.3.1 Background 
Approaches to tackling medicines-related risk such as polypharmacy have included the 
development of methods and instruments to assist in the assessment of medication 
appropriateness (127).  As part of this, a number of lists of potentially inappropriate 
medicines were published.  An early example was ‘Beers Criteria’, which are guidelines 
developed by an American geriatrician in 1991 to try and improve the safety of 
prescribing medications in older people (128).  A more recent European contribution was 
the ‘STOPP’ criteria (129) which may better reflect UK acute hospital prescribing patterns.  
The author supported a CLAHRC NWL team who used the STOPP criteria to develop their 
own local ‘potentially inappropriate prescriptions’ (PIP) list (130).  
 
3.3.2 The elderly care rehabilitation STOPIT study  
The author wanted to test whether the STOPIT tool demonstrated utility in an elderly care 
rehabilitation setting.  Given that rehabilitation patients are often ‘stepped down’ from 
acute care settings including the adjacent hospital, or referred directly from general 
practitioners (GPs), the author hypothesised that these patients’ medication regimes 
were likely to have been reviewed and not require significant further review.  With 
support from CLAHRC NWL, the author led a five month proof-of-concept study, during 
which the STOPIT tool was used as part of the medication review process, undertaken 
during the weekly ward round involving the consultant geriatrician, registrar, foundation 
doctors, the pharmacist (the author) and a nurse.  Five months was chosen in order to 
maximise the number of patients in the study.  This was challenging because a typical 
patient stay for rehabilitation was six weeks or longer, meaning that the turnover of 
patients was comparatively low.  The multi-disciplinary team reviewed each patient up to 
twice a week, using the STOPIT tool to decide whether a medication review was 
necessary, and utilised the author’s adherence conversations with patients to guide the 
review and record the recommendations.   
 
The results showed that 15/36 (42%) of patients had at least one medication stopped 
during their stay on the rehabilitation unit.  The findings surprised the team and CLAHRC 
NWL because the hypothesis that these patients will have been adequately reviewed 
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before admission was not supported.  This raised questions about the role of medication 
review for acutely unwell patients, and was one consideration that contributed to the 
development of the subsequent ‘ReMAC’ project (see Chapter 3.3.4). 
 
3.3.3 Subsequent publications and impact of the research 
Following publication, one patient’s case from this proof-of-concept study was shortlisted 
as a finalist in the ‘Preventing Avoidable Harm category’ for the National Patient Safety 
and Care Awards 2014.  During the presentation, the judges told the author and 
consultant geriatrician of their interest in the finding that rehabilitation patients 
benefitted from a medication review following an acute hospital stay, as was the case 
with most of the patients in the study.  They discussed not being aware of other work that 
focused on medication reviews in the rehabilitation setting.  Two hospitals in England 
asked to replicate the use of the STOPIT tool. During one enquiry the author’s work was 
commented on as ‘practical’ and the STOPIT tool being more applicable than the ‘more 
academic’ STOPP/START tool that is widely cited (129). 
The study team was then invited by to write an e-book of case studies based on CLAHRC 
NWL’s medicines optimisation outputs, which included and cited the above study.  The 
author co-led the development of the e-book which was published in 2015 (131).  The 
publisher wanted practical case examples that the author and colleagues had 
encountered and clinically managed, along with learning points and principles for practice 
that could be utilised by readers.  The author contributed three cases to the following list: 
 
1. An elderly patient wanting to take fewer medicines (National Patient Safety and 
Care Awards finalist) 
2. A patient with dementia taking potentially inappropriate medication 
3. Stopping all but one medicine in a patient with anxiety and memory problems 
4. Medication review in an outpatient clinic 
 
Subsequently, the author led the team in considering other settings where the STOPIT 
tool had not been tested at the local hospital. The outpatient setting was chosen because 
of a lack of literature in this area.  For this proof of concept study, senior medical staff 
collected data about medication reviews prospectively and consecutively for their older 
outpatients seen in clinic over a four month period.  STOPIT data was recorded, including 
details of each patient’s current medication, how the list was confirmed, and what was 
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stopped or altered during the consultation. Eighty-seven medication reviews were 
undertaken in 77 patients.  In 24/101 (24%) of these reviews, a change was made to the 
538 medicines recorded, and 7% of medicines were stopped.  Importantly, the doctors 
reported that the tool was helpful in a busy outpatient setting without slowing down their 
activity. The author led the publication of this study (132).   
 
In network discussions with doctors and pharmacists about these projects, the author 
became increasingly aware of some barriers to stopping medicines, including fears about 
potential clinical consequences, patient reluctance to stopping a medicine, financial 
incentives to dispense, or a belief that stopping a medicine initiated by someone else 
should not be their responsibility.  This is similar to other findings about barriers in the 
literature (133) (134).  The author experienced amongst pharmacist colleagues a more 
general reluctance to suggest stopping medicines, particularly guideline-recommended 
therapies, which has also been explored in the literature (135).  The author attributes this 
to a lack of confidence and observations that pharmacy students and juniors are very 
reluctant to deviate from guidelines and sometimes lack the ability to ‘think outside the 
box’ appropriately.  This led the author to publish a commentary article and blogs 
encouraging ‘being brave’ in suggesting stopping medicines where appropriate (136) 
(137).  The author reasoned to the CLAHRC team that education of undergraduates and 
novice practitioners may be one way to change the culture, and the blog referenced 
above was co-written with a junior pharmacist and pharmacy student.  This was 
important to the author’s mission to equip pharmacists as part of the Modernising 
Pharmacy Careers programme described in Chapter 4.1.  CLAHRC encouraged the author 
to explore this hypothesis and the author’s work is described in Chapter 3.4. This work 
has led directly to the author influencing strategic changes in pharmacist postgraduate 
education, including the first national pharmacy postgraduate foundation programme 
which is described in Chapter 4.1. 
 
The author has received a number of invitations to present their work around medication 
review and deprescribing, including for NHS England’s Specialist Pharmacy Service (138).  
The WHO ‘Medication without harm challenge’ mentioned in Chapter 3.1 has led to NHS 
England establishing a ‘Medicines Safety Programme’ (139).  An element of this is 
establishing a repository of good practice examples, hosted by the NHS Specialist 
Pharmacy Service (140). The author and CLAHRC NWL colleague Dr Vanessa Marvin, 
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recently submitted the STOPIT example for review and inclusion, and this has now been 
accepted (141).  The submission specifically stated that the original and widely-cited 
STOPP/START criteria (129) is very long and the aim of STOPIT (Appendix 17) was to be 
more concise and user friendly by using major headings of medicines to review, such as 
those causing falls or bleeding.  The tool has also been abbreviated into a handy card that 
fits into security badge lanyards. Inclusion in the repository is an important national 
affirmation of the quality of this work that has the potential to impact users nationally 
and beyond.   
 
3.3.4 Review of Medication in Acute Care – the ReMAC project 
Research has shown that acutely unwell patients may be admitted to hospital because of 
their medicines.  It has been estimated that at least 5% of all hospital admissions are 
linked to medicines with almost half being preventable (142) (143). Work has been 
undertaken to mitigate this, including identifying the most likely medicines to cause 
admission (144), and developing tools to identify patients at risk, such as PREVENT (145) 
(146).  
 
A significant CLAHRC NWL project at the Chelsea & Westminster Hospital entitled ‘Review 
of Medication in Acute Care (‘ReMAC’) began in 2015, with the aim of embedding patient-
centred medication reviews into routine practice in acute care across north-west London 
(147) (148).  This was a quality improvement project using a ‘breakthrough collaborative 
approach’.  This can be described as a multi-organisational effort, using expert knowledge 
from different disciplines, to design and promote adoption of a quality improvement 
package.  It encourages participation and generates energy and enthusiasm to effect 
change (149).  The author’s findings from the earlier rehabilitation study (see Chapter 
3.3.2), that medication reviews may not have occurred during recent hospital stays, 
reinforced the need for this work to the CLAHRC medicines optimisation team.  Whilst the 
author was not a core member of the ReMAC project described next, they contributed to 
the CLAHRC development of definitions of medication review in acute care and 
supervised the medical student project element of ReMAC that is outlined below. 
The key ReMAC interventions included multidisciplinary medication reviews with patients 
in acute care, making deprescribing decisions where appropriate, and clearly 
documenting changes prior to discharge, in order to improve communication with general 
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practitioners and community pharmacists.  An early analysis of the hospital’s 
performance included 200 discharges of patients aged 70 or over within a three month 
period.  Twenty-eight per cent of patients had a medication review whilst they were 
inpatients, and within this group and 47% had a medicine deprescribed (148).  
 
A further development of ReMAC was the author co-supervising a medical student to 
collect data about medication reviews undertaken at the Chelsea & Westminster 
Hospital, and deprescribing information for 126 patients admitted because of a fall. The 
results showed that 112/679 (16.5%) of the medicines recorded on admission could have 
increased the risk of falls; and 30/112 (26.7%) of these falls-risk medicines were reduced 
or stopped through medication review.  Moreover, in all cases where medication review 
led to the deprescribing of falls-risk medicines for a patient, a pharmacist was involved in 
the decision. The resulting publication is currently one of the author’s most read and cited 
papers with nearly 140 reads on Researchgate® (116) and 23 citations to date.  This study 
was important because few published interventions had occurred in the hospital setting 
(150), and citations of this work reinforce the value of pharmacist involvement in 
suggesting possible medications to deprescribe in general (151) and particularly falls-risk-
inducing drugs (152).  This work also supports other literature in recognising that older 
people are more prone to falls and there is a need for clinicians to know more about 
medicines that may induce falls, such as anticholinergic medications (153).  In summary, 
this work has the potential for wide-ranging impact as those who read and cite it are 
likely to be like-minded professionals seeking to improve the management of falls-related 
medication reviews in acute hospital settings. 
 
3.4 Key publication 5: A pilot survey of junior doctors’ attitudes and awareness around 
medication review: time to change our educational approach? (154) (see Appendix 10) 
 
3.4.1 Background 
The author’s secondment to CLAHRC NWL and substantive academic role provided 
project supervision opportunities for final year pharmacy undergraduates in the area of 
medication review, polypharmacy and deprescribing.  The author reflected on their 
previous STOPIT work (see Chapters 3.3.2 and 3.3.3) in the context of the wider literature, 
and concluded that polypharmacy was a common problem which was not yet tackled 
consistently as part of routine clinical practice (133).  An initial literature search by the 
author’s first pharmacy student revealed that most of the research and publications 
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appeared to be aimed at senior doctors and pharmacists, with little aimed at clinical 
students or novices.  This was a key moment in the author’s thinking and reinforced their 
emerging view about educating juniors (see Chapter 3.3.3).  This was particularly relevant 
since the author’s other role at the time involved revising elements of the postgraduate 
foundation training programme for junior hospital pharmacists in London and across 
south-east England (see Chapter 4.3).   Others have suggested that existing medical 
training was not adequate to equip medical students to prescribe appropriately for 
patients on multiple medications (155), reinforcing the author’s view that culture change 
was needed to include educating these and other critical stakeholders such as 
pharmacists, and preparing them to support the mission to tackle problematic 
polypharmacy as they become competent to do so.  Through an action-effect quality 
improvement method (156), CLAHRC NWL agreed with the author that research was 
needed into the role of junior doctors in medication review.  The author therefore 
proposed, developed and supervised a project undertaken by a year 4 pharmacy 
undergraduate to survey junior doctors on their awareness of medication review and 
review tools.  The aim was to use the findings to suggest educational approaches to 
improve the skills, confidence and awareness of junior doctors to contribute 
appropriately to the medication review process. 
 
3.4.2 Article methodology and results 
The author led a CLAHRC NWL project team in developing a questionnaire that explored 
self-reported awareness and views around medication review and deprescribing amongst 
all junior doctors in one London teaching hospital, the Chelsea & Westminster Hospital 
NHS Foundation Trust. A focus group consisting of senior doctors, other pharmacists, the 
pharmacy student and the author identified topics around which to ask questions.  Topics 
included how junior doctors felt about reviewing medicines, who they believed should 
review medicines and make subsequent decisions; and awareness of medication review 
tools.  After piloting, the questionnaire was sent to all 42 junior doctors within the 
hospital, with a 48% response rate.  Among the findings of this preliminary study, 16/20 
had never heard of medication review tools, and whilst the same proportion (16/20) 
stated that they were comfortable prescribing within their speciality, they were also 
uncomfortable in stopping medicines without consulting a senior doctor.  This supports 
other findings, for example hospital doctors’ prescribing decisions were influenced by 
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relationships with other team members, including senior doctors (157). Chapter 3.3.3 
mentions other barriers to deprescribing.  Whilst it is appropriate that junior doctors 
consult before stopping medicines because of a lack of experience, confidence and 
expertise, the findings of this work reinforced to the author the need to question how to 
prepare and develop undergraduates and novice clinicians to appropriately prompt a 
medication review from their early days of practice.  The author postulated that this 
would make them more likely to routinely consider undertaking medication reviews when 
they are more senior and experienced clinicians.  The author therefore developed a 
unique ‘bottom up approach to education around medication review and deprescribing’, 
which CLAHRC NWL adopted and supported a launch by the author at a CLAHRC NWL 
event in 2015 (158).  This approach involved educational initiatives to raise awareness 
and suggesting the inclusion of relevant learning outcomes and teaching about 
medication review, polypharmacy and deprescribing for undergraduate and junior 
clinician curricula.  Legitimate concerns have been raised about the use of the term 
‘bottom up’, which may suggest that junior clinicians are ‘at the bottom’ of a real or 
imagined hierarchy.  The author does not seek for the term to be applied pejoratively, but 
rather practically, given the earlier observation that literature appeared to be aimed at 
senior clinicians.  The use of this phrase is not without precedent: and has been used in at 
least one other published educational intervention aimed at patients, rather than 
clinicians (159).  Moreover, the necessity of education of undergraduate clinicians about 
medication review and deprescribing has been mentioned elsewhere in the literature at 
around the same time as the author’s work (134) (160).  
 
3.4.3 Impacts and associated outputs 
Following the publication of this study, and the author preparing to change jobs, the 
author’s colleagues developed training in the use of the STOPIT tool for junior doctors 
and pharmacists at the Chelsea & Westminster Hospital.  They shared their resources to 
enable other hospitals in North West London to routinely train their junior doctors and 
pharmacists to use the STOPIT tool.  This publication has so far achieved 28 citations 
(some of which are self-citations within related work), which the author is encouraged by 
given that this was a pilot study in one hospital.  Citations commonly draw attention to 
the reluctance of juniors to stop medicines that have been started by others, which is 
understandable and, as stated above, often appropriate.  The study was also cited by 
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drawing attention to junior doctors not believing it to be their responsibility to undertake 
medication review or deprescribing activities (161).  The survey questions from this and 
similar studies have been used internationally, for example in Singapore (162).  
As part of the ‘bottom up’ strategy, the author began to approach educational institutions 
to promote teaching around medication review and deprescribing, including each of the 
three university schools of pharmacy in London, the London postgraduate pharmacy 
Foundation School, a school of nursing and two medical schools.  The author was asked 
for undergraduate teaching ideas and learning outcomes by a number of institutions, 
including Southampton Medical School and the Older Adults nursing fellowship at King’s 
College London.  Medway School of Pharmacy invited the author to rewrite their 
postgraduate module on deprescribing in 2017 and this work is under review by the 
university.  King’s College London runs the largest inter-professional learning programme 
in Europe and the author was asked in 2019 to contribute deprescribing teaching material 
for a novel workshop on medication review.   CLAHRC NWL runs learning events three 
times a year and the author is regularly invited to reinforce the key points of the ‘bottom 
up’ initiative through presentation, such is CLAHRC’s conviction that momentum should 
be maintained.  The results of this engagement strategy were published in an article that 
formed part of key publication 6 (see Chapter 3.5) (163).    
The author then took the initiative to make a case for including a competency around 
deprescribing within a new single competency framework for prescribers, which was led 
by the Royal Pharmaceutical Society (164).  The author was one of two individuals who 
provided a deprescribing-related literature review used in the development of the 
framework, in which ‘deprescribing’ was specifically mentioned (165). The author was 
subsequently invited to establish regular teaching about deprescribing at King’s College 
London’s non-medical prescribing programme and a number of other postgraduate and 
undergraduate programmes (see the end of Chapter 4.3). An example of feedback from 
students was that the teaching was highly influential and will impact their outlook on 
deprescribing in the future. 
The junior doctor study and subsequent ‘bottom up’ approach led to invitations from 
Health Education England (HEE) and NHS England (NHSE) to advise on their initiatives to 
educate clinicians about medication review, polypharmacy and deprescribing.  In 2017, 
the author was asked to review a forthcoming HEE-commissioned e-learning programme 
on deprescribing for health professionals (166).  In 2018, NHSE invited the author to join a 
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working group to develop a national approach to developing learning outcomes around 
medication review and deprescribing. The author suggested scoping existing teaching 
material amongst pharmacy schools and has been invited to submit the results of this 
work for publication in a forthcoming themed journal issue on deprescribing.  This has 
been submitted for publication (167), and the findings suggest that polypharmacy and 
deprescribing are not always explicitly and universally embedded in curricula, although 
helpful mention has been found in teaching about the care of older people.  Therefore, 
the author’s current work is relevant and likely to influence country-wide 
recommendations that influence the teaching of undergraduate and novice clinicians in 
the future. 
Finally, in December 2018, the Secretary of State for Health and Social Care requested a 
review into overprescribing in the NHS (168). Lines of enquiry will include addressing 
problematic polypharmacy, equipping GPs to challenge hospital prescribing, and 
empowering patients to ask more about their medicines.  The author approached the 
review team to outline the educational imperatives for this work, and was invited to 
submit a summary of their work for consideration.  Following this, the author was invited 
to join a team of facilitators for a national event in May 2019, where a large number of 
national stakeholders and experts reviewed the challenge of overprescribing with a view 
to making recommendations to the Secretary of State.  The scope of this event and the 
presence of key decision-makers means that the outputs are likely (at the time of writing) 
to have far-reaching impact on future policy in the area of polypharmacy and 
deprescribing.  Feedback from participants to the author at the event suggested that 
some outputs are likely to align with the author’s work that has aimed to equip future 
clinicians in their ability and motivation to review medicines; and influence culture 
change so that problematic polypharmacy is less likely to occur.  When polypharmacy 
does occur, the author’s vision is that a new generation of clinicians will, as juniors, 
prompt the team to review medicines; and feel confident in making appropriate decisions 
as seniors with or without medication review tools. 
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3.5 Key publication 6:  A themed journal issue on deprescribing (169)(170) (see table of 
contents in Appendix 11) 
3.5.1 Background 
The author’s work in the area of medication review and deprescribing coincided with the 
polypharmacy and adherence work undertaken by Professor Nina Barnett (NB) (171) 
(172).  Together the author and NB reflected on the opportunity to contribute to culture 
change that empowers pharmacists to make an increasing contribution to the medication 
review process, and to critically evaluate their role in the area of deprescribing.  The 
author and NB therefore approached the European Journal of Hospital Pharmacy (EJHP) 
in 2015, to suggest a dedicated themed journal issue on the topic of deprescribing.  The 
proposal was accepted, and through our co-editorship it was published in January 2017. 
 
3.5.2 Themed issue content selection and process 
With support from the EJHP editor-in-chief and their team, the author and NB identified 
topics for publication and potential authors.  This was done through peer discussion and 
reflecting on the literature as well as pooling insights from conversations with 
stakeholders around areas of concern and gaps in knowledge.  The aim was to support 
the publication of deprescribing issues hitherto under-represented in the literature, for 
example nursing perspectives on deprescribing.  Barriers to deprescribing include fears on 
the legal position around deprescribing (173) so the author sought a pharmacist who 
subsequently trained as a lawyer to investigate this.  Other examples of commissioned 
work included case studies and the opportunity for deprescribing research groups across 
the world to contribute their work.  The guest editors were keen to gain as wide an 
international perspective as possible, covering different care settings, ranging from acute 
hospital settings to nursing homes.  The editors also wished to introduce readers to as 
many existing medication review and deprescribing tools/approaches as possible. The 
themed issue contents page (Appendix 11) lists what was included.  
In terms of identifying authors, active and esteemed individuals and research groups 
were based, for example, in Ireland, Australia, Israel, Canada and the UK.  The author and 
NB successfully secured at least one contribution from each of these leading groups for 
the themed issue, all of whom encouraged the development of the issue.  A Professor of 
Primary Care at Imperial College, who partners with NIHR CLAHRC NWL, stated that “The 
themed issue is particularly noteworthy due to the international contributorship, including 
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key thinkers on this topic from Australia, Ireland, Israel, and UK” (174).  The author took 
the lead on article commissioning and manuscript revision, whilst NB led on the initial 
review of submitted manuscripts.  
 
3.5.3 Outcomes and Impacts  
The journal editor reported strong interest in the themed issue, which led to the author 
and NB being invited by the journal to record a podcast to publicise it further (175).   
Letters and other messages to the editor were positive and the themed issue achieved an 
Altmetric Attention Score in November 2017 of 15. This was a High Attention Score 
compared to outputs of the same age at that time, cohering with the journal’s editor-in-
chief advising the author that the issues of polypharmacy, medication review and 
deprescribing were important.   
The themed issue is also on the reading list for the non-medical prescribing programme 
for postgraduate pharmacists and nurses at King’s College London.  In addition, it was 
publicised as a news item amongst King’s Health Partners shortly after publication (176), 
bringing this issue to the attention of one of only six academic health science centres in 
England. 
 
3.5.4 Subsequent work resulting from the themed issue 
The themed issue has led to a number of invitations to collaborate and contribute further 
work.  See Table 2.
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Table 2: Summary of work resulting from the author’s themed journal issue on deprescribing 
Invitation from 
 
Output Key findings Publication status 
Professor Doron 
Garfinkel, contributor to 
our themed issue, via NB 
 
A follow up project and publication 
adapting the junior doctor survey 
(Chapter 2.4) to compare 
awareness of medication review 
and deprescribing between 
medical and pharmacy students 
 
Mixed understanding of the term 
‘medication review’ and perceptions of 
roles that differ from practice.  More 
taught information received on starting 
rather than stopping medicines 
Accepted for publication in 
progress for Professor 
Garfinkel’s themed journal 
issue on deprescribing (177) 
anticipated 2020 
Author’s own suggestion 
in collaboration with 
lecturer in nursing, King’s 
College London 
 
Repeating the above survey 
adapted for nursing students at 
King’s College London and 
suggesting educational 
interventions 
Relative lack of awareness of the 
concepts and the need to develop 
teaching on these topics 
Nursing journal identified and 
write up planned for 2019 
Age UK via colleague who 
co-wrote our junior 
doctor survey publication 
 
Summarised the work of NIHR 
CLAHRC NWL on medication review 
and deprescribing in older adults in 
hospital 
 
A UK hospital has undertaken work 
around reviewing medicines in a variety 
of clinical situations involving older 
people including surgery, initiating 
medicines and on discharge  
Peer reviewed article for 
journal ‘Public Policy and 
Aging Report’ Published in 
2018 (178) 
NIHR CLAHRC NWL A national conference for CLAHRCs 
in England to present medicines-
related work 
Themed issue presented as a keynote 
via peer presentation with NB 
Conference notes published in 
2017: (179)(179) 
Collaborator in junior 
doctor survey publication 
 
Development of consensus 
statements to guide actions and 
escalations following medication 
review of newly-admitted unwell 
older adults 
Acutely unwell older adults admitted to 
hospital may face delay in decision-
making around possible causative 
medicines.  Agreement between 
doctors and pharmacists may help 
guide decisions 
Peer reviewed article 
published in 2018 (180). 
Follow up PJ article published 
in 2019 (181). 
WHO repository submission 
published in 2019 (182)  
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The outputs outlined in Table 2 demonstrate how the author’s themed journal issue has 
led to other outputs in the area of medication review and deprescribing; and contributing 
to other work that attempts to tackle research gaps or coheres with other literature.  The 
author has also reflected positively on the interest that can result from relatively small-
scale pilot and student projects.  For example, the author’s surveys of medical, pharmacy 
and nursing students were conducted by final year pharmacy students and led to 
discussions with peers across the country and positive feedback about how there appears 
to be little in the literature exploring these topics.   
The consensus statement publication was cited as an example of how pharmacists can 
identify medications for deprescribing (183). This complimentary review described the 
work in detail, stating that “This type of research is challenging, time-consuming, but 
extremely valuable for grey, subtle, nuanced areas of clinical practice”.  This was certainly 
the case for the lead writer of this publication and the author, given that achieving 
consensus required a significant commitment of time from the doctors and pharmacists 
involved (the author was a member of the expert panel). Recent work suggests the 
method of communication and the medium through which [medication review] 
recommendations are made may have a significant impact on whether or not they are 
implemented (184).  
 
3.6 Summary 
The author’s writing, speaking and research into medication review, polypharmacy and 
deprescribing has raised awareness nationally and internationally of the associated 
educational imperatives, including the need to develop learning outcomes, teaching and 
other resources for students, novice clinicians and prescribers.  This work agreed with the 
views of others, as outlined in this chapter.  The author’s work in this area also linked with 
the imperative to understand the patient experience that is discussed in Chapter 2 of this 
thesis.   For example, Reeve et al emphasise the importance of patient involvement in 
deprescribing, stating that patient-centred care is associated with improved outcomes 
such as medication adherence (161). This was supported by Anderson et al who 
concurred with the findings from Reeve et al, and affirmed the need for a ‘patient-
centred deprescribing process’ (134).   Moreover, Vasilevskis et al also stated that few 
polypharmacy interventions consider patient-centred factors, such as convenience and 
cost (150). When asked about convenience around medicines taking, the author was 
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often told that the number of tablets to take was highly inconvenient.  The number of 
tablets prescribed in the author’s exemplar case is discussed further in Chapter 6. 
Previously under-explored settings for medication review, such as rehabilitation and 
outpatients, as well as views from nursing have been investigated.  The author is also 
extensively networked with national and international practitioners and researchers 
concerned with the global challenge of polypharmacy.  This included reviewing funding 
applications for research into deprescribing, maintaining an honorary post with CLAHRC 
NWL until 2019 as part of its medicines optimisation work stream, and contributing 
expertise and experience to the Specialist Pharmacy Service (SPS) work stream on 
polypharmacy.  The above-mentioned consensus statement work was accepted for 
inclusion in the World Health Organisation repository of good practice for medicines 
safety as part of a new National Medicines Safety Programme, as described in Chapter 
3.5.4 and Table 2.   Finally, the author’s collaboration with colleagues outlined in Chapter 
2.2.3 linking adherence with medication safety has the potential to strengthen and 
further develop the health system’s understanding about the interaction between 
adherence, polypharmacy, deprescribing and safety. 
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PhD by Publication – Barry Jubraj 
Chapter 4: Medicines Optimisation: Making it part of routine practice 
through clinical education 
 
What chapters 4 and 5 are about 
In Chapters 4 and 5, the author will outline their local, regional and national contribution 
to clinical education and professional development within pharmacy.  The author 
completed their Postgraduate Certificate in Education for Adults (PGCEA) in 1998 which 
provided the confidence and foundation to influence pharmacy education both regionally 
and nationally.  This contribution was recognised through nominations and awards for 
teaching and mentoring (see curriculum vitae, Appendix 1); and most notably the national 
2013 Royal Pharmaceutical Society’s ‘Excellence in Education’ award (185) (see 
testimonial and other student feedback in Appendix 18).  A common thread in the 
feedback the author has received is ‘going the extra mile’ for students.  This is why, in 
Chapter 1, the author outlined how they would always seek to explain clinical decisions to 
the junior doctors and medical students who were present.  The author always sought to 
find the educational value and opportunity in all of their activities, resulting in, for 
example the King’s College London ‘Socialisation Internship’ (Chapter 2.3.3); and ‘the 
bottom up approach to education around medication review and deprescribing’ (Chapter 
3.4.2).  Moreover, in 2012 the author was appointed by the UCL School of Pharmacy as an 
honorary associate professor in recognition of their teaching, learning, supervision and 
research activity.  This was linked to the author’s educational role with the Joint 
Programmes Board (see below), and undergraduate/postgraduate roles at University 
College London.   
 
4.1 Introduction   
For all health professions, learning and development post-qualification is essential for 
keeping up-to-date and practising safely.  The author has written that pharmacy is no 
different from the other clinical professions and pharmacists commonly undertake post-
registration certificates, diplomas and higher degrees, particularly in the hospital sector 
(186).  The purpose of these qualifications has been to expand knowledge and skills to 
allow pharmacists to deal with more complex cases throughout their career, as well as 
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providing opportunities to apply for higher grade roles.  Traditionally, postgraduate 
pharmacy programmes were mainly classroom-based. 
In the 1990s and 2000s, performance and competence issues such as the Bristol heart 
surgery scandal (30) (also see Chapter 2.1) gained media attention and led to 
introspection within the health professions around accountability and fitness to practice.  
Professor Ian Kennedy’s resulting report (187) emphasised the need to maintain 
competence, performance appraisal and continuing professional development (CPD) as 
part of a commitment to improving the quality of healthcare.  Importantly, it stated that 
“CPD must be part of a process of lifelong learning for all healthcare professionals”.  
Moreover, the patient experience and involvement of patients in providing feedback on 
and planning services was emphasised.  The author believed that this was a key milestone 
for the development of person-centred care and shared decision-making, which is briefly 
described in Chapter 2.1.  The importance of lifelong learning was previously emphasised 
in the Secretary of State for Health’s 1998 consultation document ‘A first class service: 
Quality in the new NHS’ (188).  
A subsequent development within medicine was the ‘Modernising Medical Careers’ 
programme (189).  This began with the introduction of a Foundation Programme, which, 
for the first time, required newly-qualified doctors to demonstrate their abilities and 
competence against set standards (190).  Pharmacy published its own ‘Modernising 
Pharmacy Careers’ (MPC) programme (191), which  emphasised the need for pharmacists 
to practice as ‘clinical professionals,’ ready to, for example, consult with patients 
(discussed in Chapter 2); and care for patients with more than one long-term condition 
that may involve the prescribing of a number of medicines (discussed in Chapter 3).  
Explicitly, MPC stated that “Medicines optimisation from registration will be a key new 
skill which relies on enhanced communication, influencing and motivating skills to 
support medicines adherence and wellbeing”.  The author’s work was cited in the MPC 
document (see Chapter 5.4 which outlines their work in a regional group entitled 
‘Developing Educational and Practice Supervisors’ - DEPS). 
Leaders in pharmacy education from London believed that competency-based training 
was a right response to Kennedy (192),  using the newly-developed ‘General Level 
Framework’ (GLF) post registration; and active demonstration of fitness to practice, 
particularly as part of a career development strategy (193) (194).  Out of this emerged the 
Joint Programmes Board (JPB) for south-east England (195), a partnership between 
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university schools of pharmacy and NHS hospitals, who launched the first post-
registration foundation programme for hospital pharmacists in the UK in the mid-2000s.  
The programme was given academic credits to postgraduate diploma level, and made use 
of the principles of work-based learning (WBL) and workplace-based assessment (WPBA) 
that mapped to the GLF. These concepts are outlined in the next section, 4.2.  Existing 
WPBA tools from medicine were adapted for use in the programme. 
 
4.2 The context of WPBA in pharmacy 
The assessment of medical trainees in the twentieth century was mainly based on written 
assessments of knowledge, with a gradual shift towards assessing skills and competence 
over the last 20-30 years (196).  This was in recognition that factual knowledge alone 
cannot be an adequate demonstration of good clinical practice (197).  Medical education 
recognises and values practitioner development along the paradigm of Miller’s Pyramid 
which describes awareness levels ranging from ‘heard of’ and ‘knows about’ to ‘shows 
how’ and ‘does’ (198).  This was used by the General Pharmaceutical Council in ‘standard 
10’ of its 2011 standards for the initial education and training of pharmacists (199); and 
the JPB drew heavily on these principles and medical literature to make the case for 
competency-based assessment in the workplace for pharmacy (193). However, 
competency-based assessment was controversial, with concerns that competencies were 
socially constructed, difficult to measure (196), and may lead to a reduction in 
educational content (200). One way of assessing individual clinicians against competency 
statements is the use of a WPBA, and this became a routine assessment paradigm in UK 
medical education over the last 20 years, on the understanding that WPBA should be 
formative rather than summative (201) .  The author’s experience of managing WPBA in a 
pharmacy programme since 2008 echoes a finding within medicine that they “are not 
being reified as the formative assessments originally intended” (202).  As in medicine, the 
author has encountered negative views including that WPBA are “an unnecessary set of 
hoops to jump through;” “difficult to achieve because of workload pressures”; and 
“cumbersome to use”.   Moreover, educational concerns around criteria such as validity, 
reliability and acceptability apply to WPBA use in pharmacy, just as in medicine (203); and 
the author also encountered persistent confusion around the difference between 
formative and summative assessment. Although WPBA still exists in Health Education 
England-funded foundation training for pharmacists (204), it remains to be seen whether 
it will be retained in the longer term.  From years of experience using WPBA tools, the 
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author contends that with a comprehensive explanation, including the difference 
between formative and summative assessment, as well as training in the assessment 
tools and management of expectations, WPBA can be a powerful aid to professional 
development.  WPBA can have a beneficial impact by allowing real-life assessment of 
trainees’ ability to practice the key elements of medicines optimisation, including those 
outlined in this thesis, such as understanding the patient experience.  The author has 
coined the phrase that “competency frameworks should be aspirational and not 
impositional”, as a response to juniors and their tutors who felt that competencies were 
burdensome and ‘tick box’.  The author’s view has been that a competency framework 
can identify successes and accomplishments, as well as what should be tackled next by 
identifying competences that have not already been covered.  This view was shared with 
a JPB professor who agreed and encouraged the author to write it up and publish. 
 
4.3 Summary of the author’s role in foundation training 
In 2008, the author was recruited via secondment part-time from the Chelsea & 
Westminster Hospital to the Joint Programmes Board, as the Lead for Work-based 
Learning Support, focusing on tutor training.  This followed an invitation to join the JPB 
implementation steering group in 2005, having led the implementation of the foundation 
training programme in the author’s own hospital, which was completed in 2006.  As 
described at the end of Chapter 4.2, the senior JPB team had identified that hospitals 
were encountering challenges with the culture change from traditional postgraduate 
university-based models, to making use of the principles of WBL, WPBA and competency-
based training at work.  It became clear that hospital pharmacy departments needed 
adequate tutor training and the establishment of educational infrastructures to support 
this new approach, so the author was tasked with ‘winning hearts and minds’ of trainees, 
supervisors and hospital pharmacy managers as discussed earlier.  Many pharmacy staff 
were suspicious of competency-based training and WBL/WPBA, which reflects similar 
concerns raised in the medical literature, such as this approach being ‘reductionist’ or a 
‘tick-box’ exercise (205) (200).  The author rose to the challenge of overcoming these 
barriers, starting with leading one of four major discussion groups (206); and beginning to 
write/ co-write a number of publications in the areas of WPBA (201) and self-directed 
learning (see Chapter 4.5) and the need for educational infrastructures (207).  The author 
was asked to speak about educational infrastructure at a national conference (208), 
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which was important because for the first time, hospital pharmacy departments needed 
to consider what needed to be in place to support WBL and WPBA, in terms of tutors, 
resources of time, and appropriate practice experience for trainees. 
The author led work to delineate workplace supervisory roles and responsibilities in order 
to bring clarity to the educational infrastructures that hospitals were trying to establish 
and maintain (209).  The author also designed tutor training, visited hospitals across 
south-east England, taught learning sets, and was responsible for upskilling the pharmacy 
workforce to meet the requirements of pharmacy foundation training across south-east 
England.  The author alone trained in excess of 500 supervisors and educational 
programme directors, many of whom are still in post to date.  The author also 
incorporated some basic training on education into trainee learning sets to introduce 
them to a future role as educators in general and supervisors in particular.  The author 
was keen to develop current trainees who were supervised by senior staff new to a 
revised method of supervision, into those who were comfortable with a new type of role 
in the workplace.  The author’s work had the potential to significantly impact the 
development of pharmacy workplace supervision, with a Professor of Education at UCL 
and the Joint Programmes Board describing the author as “the leading authority in 
workplace pharmacy education in the country”.  Moreover, a member of the English 
Pharmacy Board of the Royal Pharmaceutical Society who co-wrote the educational 
infrastructure paper (207) told the author that “the paper where we introduced the term 
‘educational infrastructure’ is a seminal piece for pharmacy and was used within hospitals 
(a part of the Lord Carter Hospital Pharmacy Transformation Plan) and by HEE (even 
though they may not explicitly use our definition) in the work that they do around 
educational quality”. 
In the second half of the author’s secondment from 2012, a major focus was managing 
the revision of the second (higher) stage of foundation training.  The author engaged 
stakeholders in a number of hospitals to elucidate how NHS policy should inform changes 
to foundation training.  A key finding was that trainees (hereafter referred to as 
‘practitioners’) expressed the desire to develop an awareness of the competency clusters 
in the RPS Advanced Pharmacy Framework (1) such as quality, medicines safety, 
innovation and education, in order to secure jobs at the next grade in the hospital service. 
The author felt that this was appropriate (not least from a practice perspective) and they 
therefore led the development of learning outcome clusters entitled ‘quality and safety’, 
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‘individual & department performance’ and ‘leadership & innovation’, as a ‘bridge’ 
between foundation and advanced pharmacy practice.  A key area included by the author 
was a learning outcome around medication review and deprescribing which aligned with 
the increasing importance of these within NHS policy; and is outlined in Chapter 3.4.3. 
 
4.4 Key publication 7: The Acute Care Assessment Tool – Pharmacy ACAT (210) (see 
Appendix 12) 
4.4.1 Background 
Fundamental to the competency-based foundation programmes in medicine and 
pharmacy are the formative workplace based assessment (WPBA) tools, including the 
prospective mini clinical evaluation exercise (mini-CEX) and the retrospective case-based 
discussion (CbD) (see Appendix 19).  These were originally developed in medicine and are 
‘snapshot’ assessments that allow an assessor to observe performance in real time (mini-
CEX) or discuss a recent case into which the practitioner has had input (CbD).  
Assessments typically last 15-20 minutes with five minutes of feedback provided, 
recorded on a short checklist proforma, based on GLF competencies, and free-text 
comments, all of which are discussed with the practitioner.  A specified number of these 
WPBA are required throughout the foundation programme and are collected in a 
portfolio, which is subject to a summative portfolio review for the assessment 
requirements of the programme (see Chapter 4.4.3).  See Table 3 for examples of 
scenarios suitable for WPBA in the pharmacy foundation programme, with a list of the 
assessment tools. 
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Table 3: Example scenarios suitable for workplace-based assessments (WPBA) in 
pharmacy (tools reproduced in Appendix 19) 
Pharmacy WPBA type Practice example/s or description 
 
‘Mini-CEX’ (mini clinical 
evaluation exercise) 
 
 Observe medication history taking 
 Observe discharge medication ‘counselling’ 
 Observe interactions with other professionals 
‘CbD’ (case-based discussion) 
 
 Retrospectively discuss a case dealt with by the 
practitioner, e.g. 
o Prescription review 
o Identification of a medicines-related 
problem 
‘DOPS’ (direct observation of 
practical skills) 
 
 Like mini-CEX but observing practical skills, e.g. 
o Extemporaneous manufacture 
o Dispensing 
o Accuracy-checking complex items such as 
medication compliance aids 
‘mini-PAT’ (peer assessment) 
 
 360 degree feedback from colleagues and 
supervisors 
 See Chapter 4.6 
‘MRCF’ (medication-related 
consultation framework) 
 
 Like mini-CEX but used exclusively to assess 
consultation skills with patients 
‘Extended intervention’ 
 
 Written account of a care contribution for a 
specific clinical case 
 
The author regularly undertook summative portfolio reviews for practitioners as a 
member of the JPB core team, and became concerned that whilst the use of snapshot 
tools was invaluable, there was no method to explore performance over a period of time 
that was longer than a snapshot clinical encounter.  A tool, if it existed, would begin to 
support a judgement that medicines optimisation was being embedded in daily practice, 
with behaviours being observed and trends identified.  The author reasoned that a new 
type of assessment tool could explore skills such as time management and dealing with 
stress and prioritisation, for example on a ward pharmacy visit.  The author drew up a 
diagrammatic representation of the foundation pharmacy programme assessments using 
a ‘wagon wheel’ (210) (reproduced in Appendix 20), and used it to approach local hospital 
pharmacy Educational Programme Directors (EPDs) for comment.  They agreed that 
although snapshot assessments were useful, observations over a longer time (e.g. 30 
minutes) would be helpful, for example, where a practitioner was operating in a section 
such as the dispensary, or on a hospital ward.  The author asked their local hospital 
medical director for advice, who highlighted a published assessment tool in medicine 
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known as the Acute Care Assessment Tool (ACAT) (211).  This has been used by, for 
example, consultant anaesthetists to observe their registrars running an anaesthetic list, 
or by medical registrars to observe their juniors manage an acute medical ‘take’.  With 
this information, the author decided to develop a pharmacy equivalent and approached 
EPDs, some of whom agreed to collaborate with testing a pharmacy ACAT, the first known 
of its kind in the literature (shown in Appendix 19). 
 
4.4.2 Study outline 
With permission from the Joint Royal Colleges of Physicians, the author used the original 
ACAT and existing pharmacy WPBAs as templates for drafting a pharmacy ACAT.  The 
medical scoring system was replaced with pharmacy GLF competencies, some of which 
featured in existing snapshot assessments, along with others included that would be 
relevant for an observation over a longer time period.  Pharmacy ACAT was piloted in a 
small number of trainees employed by three London hospitals with a feedback form 
developed for practitioners and their supervisors to complete as part of the pilot.  A 
second version of pharmacy ACAT was developed for more senior pharmacists and was 
piloted in the author’s own hospital, as part of a local continuing professional 
development initiative. 
Feedback from trainees and their supervisors about appropriateness and utility suggested 
that pharmacy ACAT added value to the existing assessments by observing practitioners 
over a longer time period.  The developmental feedback provided by supervisors after 
each ACAT observation was reported as being applicable in practice by practitioners.  The 
pilot was also helpful for identifying an optimal observation period (15-20 minutes), 
which was helpful for managing the expectations of assessors who have their own clinical 
priorities to balance with their educational obligations. 
 
4.4.3 Impacts and associated outputs 
An unintended benefit of this article was the wider dissemination of the ‘wagon wheel’ of 
WPBA tools (Appendix 20), which was reported by supervisors to be helpful in clarifying 
the following: the differences between summative and formative assessment; that the 
subjectivity of formative assessment is acceptable if there is a range of assessors and a 
range of assessments; and how a complex assessment scheme such as the JPB 
programme, set across academia and the workplace, can fit together.  However, a 
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common question that the author consistently encountered, was how formative WPBA 
can be included in a summative portfolio of practice.  This tension was acknowledged 
elsewhere (203), where formative WPBA is described as having a ‘summative influence’.  
In a sense this might be perceived as an irreconcilable tension, but enquirers often 
reported being helped by the author’s explanation and wagon wheel, which sets each 
element of assessment in its place; and illustrated that the tools were formative but the 
portfolio review discussion was summative.  Importantly, the author always emphasised 
in tutor training that the core value of WPBA was the discussion between assessor and 
trainee about the clinical encounter discussed.  This agreed with other views, for example 
that “the value of directly observed student-patient interaction lies not in (the inherently 
flawed) scores but rather in the rich narrative feedback that stimulates a meaningful 
discussion between students and clinical supervisors” (212).  The author wholeheartedly 
agreed with this assertion and consistently taught this to supervisors and practitioners at 
every available opportunity. 
NHS Education Scotland is currently interested in adopting pharmacy ACAT, and although 
indirect, a recent American development of a prospective workplace-based assessment 
tool in medicine (the ‘e-CEX’) cites the pharmacy ACAT article as demonstrating the value 
of the mini-CEX tool within pharmacy (213).  The JPB itself now recommends Pharmacy 
ACAT as a WPBA tool for their entire foundation programme.  Hospital pharmacists have 
accepted it as an optional, rather than mandatory tool, which was disappointing for the 
author; although feedback suggested that it is still a well-used tool within pharmacy 
departments.   The lower-than-expected uptake suggested that whilst the tool is useful in 
theory to observe practice over time, in practice, such is the pressure on time for training 
in the health service, the workplace environment has perhaps reached its resource limits 
for training and assessment. 
 
4.5 Key publication 8: Developing a culture of self-directed learning in pharmacy (214) (see 
Appendix 13) 
 
4.5.1 Background 
During the author’s first year on secondment to the JPB, workplace supervisors in the 
local NHS became more vocal in their concerns about the philosophy of self-directed 
learning (SDL) that was promulgated as key to the pharmacy foundation programme.  In 
many conversations, the author was warned by supervisors that there is no assurance of 
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learning unless teaching from more experienced colleagues occurs and that the 
foundation programme was fundamentally flawed.  Negative sentiments like this began 
to filter down from trainers to practitioners, which risked undermining the integrity of the 
programme.  The author decided that a response was necessary by surveying the 
literature, exploring similar challenges faced by medicine, and publishing an article that 
could be used for reference that could also be used for tutor training.  The author 
reflected that with hindsight, the JPB may have been better served by identifying and 
acknowledging potential misconceptions about SDL from the outset of the programme. 
 
4.5.2 Prioritising the contents of this publication 
The author consulted medical colleagues at a medical foundation training conference 
who confirmed that similar concerns have been raised by trainers in that profession.  
Highlighting published work in the British Medical Journal (215), the author was 
encouraged by colleagues to remember the value of learning in the workplace and how 
SDL relates to that.  By drawing on Malcolm Knowles’ assumption that adult learners are 
independent and self-directed (215), the author initiated and chaired a small working 
group to discuss the relevant issues, with the aim of establishing a pharmacy-specific 
definition of SDL.  The group were able to review some of the literature around SDL and 
to challenge some existing definitions.  One description was that SDL is about the learner 
engaging in learning activities identified by themselves, requiring motivation and skilled 
behaviour (216), the latter of which foundation trainees have not yet developed due to 
inexperience.  It became clear to the author that a definition of SDL that can be used to 
train stakeholders in the foundation programme needed to relate to the ‘how’ learning 
should occur, rather than ‘what’ should be learned, the latter of which is set by the 
university in partnership with the NHS. ‘How’ learning can occur can take many forms, 
ranging from lectures and workshops, to work-shadowing, reading and peer review.  The 
author’s view supported other work which stated that the ‘what’ to learn should be non-
negotiable (217). Following this, the author then identified that JPB programme 
documentation did not make it clear that SDL was about the ‘how’.  Whilst this was 
unintentional, it became clear to the JPB team that earlier identification and 
communication of this distinction would have been helpful to stakeholders.  Feedback on 
the author’s tutor training incorporating this explanation was positive.  Many supervisors 
and practitioners have told the author that this has been a ‘eureka’ moment.  The 
author’s resulting article was then published in 2009. 
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4.5.3 Impacts and associated outputs 
The published article was immediately cited in a JPB update report to the Higher 
Education Funding Council for England (HEFCE) who had provided seeding funding for 
development of the foundation programme.  The author also incorporated a specific 40-
minute training session within a one-day tutor training programme, based on the article.  
This training was delivered in hospitals across the south-east of England between 2009-
2015, serving many hundreds of tutors.  Feedback forms were completed for this tutor 
training.  These consistently indicated that considering the ‘how’ rather than the ‘what’ is 
to be learned definition of SDL was helpful to them. The author’s peers were also 
reassured that self-directed learning required partnership with the hospital by providing a 
supporting infrastructure, the author’s notion being cited by Gammie (218).  The author 
was subsequently invited to contribute the SDL teaching and publication to a Master’s 
level programme in advanced pharmacy practice at University College London, where 
educational theories were included in a module on education, training and development.  
The author still assesses MSc assignments and this publication is regularly discussed and 
cited in candidates’ assignments.  Finally, a PhD student who was evaluating elements of 
the foundation programme approached the author for informal support and has been 
mentored by the author since 2018, with the agreement of the PhD supervisor (see 
Chapter 5.5 for further details).  Feedback from the student and their supervisor 
suggested that the author had been very helpful in providing the history around decision-
making in the foundation programme and in particular being able to explain many of the 
political and philosophical challenges. 
 
4.6 Key publication 9: Use of a multisource feedback tool to develop pharmacists in a 
postgraduate training programme (219) (see Appendix 14) 
4.6.1 Background  
Peer assessment was described as a process where participants of a similar status or 
experience evaluate the performance of their peers and give quantitative and/or 
qualitative feedback (220). Research has shown that it can help to improve clinical 
performance and has been widely used within medicine.  For example, peer assessment 
was originally used in medicine to assess practising physicians’ oral communication skills, 
teamwork, and problem-solving abilities from the perspective of others.  The use of peer 
assessment from multiple sources for junior doctors in the UK (defined here as ‘mini-PAT’ 
as it is an abbreviated version of an original tool (221)) was established through 
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Modernising Medical Careers.   Mini-PAT was evaluated (222) (223) with conclusions that 
in medicine, this approach can be practical, valid and reliable.  The author was familiar 
with the concepts having led their local pharmacy department’s response to the 
introduction of medical mini-PAT, by training pharmacists to contribute to the process for 
the doctors they work with, and publishing a national article to help other pharmacy 
departments (224).  The JPB programme adapted mini-PAT for use in pharmacy 
foundation training from the outset (see item 5, Appendix 19).  Practitioners nominated 
several assessors who confidentially complete a 10 minute online assessment, 
commenting on competencies that they should have met, as well as writing free text 
comments. A self-assessment was also included.  Following evaluations of the pharmacy 
mini-PAT (225) (226), the retrospective study outlined below was designed by the 
author’s colleagues to be the first to review use of the pharmacy mini-PAT on a larger 
scale in assessing performance over time.   
The author became aware of the study during a team meeting and suggested to their 
colleagues how the findings could be used to engage with hospital staff that complete 
these assessments.  At times, practitioners had reported difficulty in getting agreement 
from their tutors to complete them. The author was therefore invited to participate in the 
project group and assisted in the write up of this publication by drafting the context and 
background sections and interpreting the results and their application to practice.  
 
4.6.2 Article methodology and key findings 
Electronically-submitted mini-PAT data was collected during the time period 2007-2010.  
Data included assessors’ assessment ratings of practitioners, practitioners’ own self-
assessment ratings, professional details of assessors and dates of assessments.  The data 
was then analysed by the lead researchers. Particular note was made of the sequence of 
mini-PATs so that trends over time for each practitioner could be observed.  Coding of 
assessor roles in terms of profession and seniority allowed for analysis of trends between 
different professions and their grade.  The data was also categorised according to the 
different competency clusters used in the mini-PAT, in order to compare performance 
between them. 
The results yielded nearly 10,000 assessments and 146,000 ratings by assessors. There 
was an overall significant improvement in junior pharmacist performance over the length 
of the foundation programme as rated by both assessors and practitioners, whilst junior 
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pharmacists tended to rate their performance significantly lower than their assessors (see 
Figure 1 in Appendix 14). The strongest competency performance was in areas such as 
communication, professionalism, and teamwork, with lower scores for clinical knowledge 
and handling information.  Pharmacy assessors tended to rate practitioners significantly 
lower than other professionals did.  This matches the findings from an earlier cohort of 
pharmacy foundation trainees (226).  In discussion with supervisors, the author 
postulated that practitioners tended to rate themselves as just ‘meeting expectations’ for 
each competency, in order not to ‘lose face’ if an assessor score was lower.  Supervisors 
in conversation invariably agreed with the author, who incorporated these discussions 
into interactions with and teaching for practitioners, some of whom confirmed that they 
did not want to be seen to rate themselves higher than their assessors.  Research also 
suggested that self-assessment accuracy amongst junior doctors may be unreliable, with 
internal conflicts between wishing to understand how  their performance was rated by 
seniors, whilst wanting to portray themselves as knowledgeable and confident (227).  
Other work suggests that junior doctors rate themselves lower than their seniors (228).   
As such, self-assessment may be strategic and influenced by social contexts and 
interactions with the teacher (212). 
 
4.6.3 Impacts and associated outputs 
The author was able to use the results and this publication to update the tutor training 
provided by JPB, in order to assure workplace supervisors of the value of mini-PAT to both 
the employer and practitioner.  The author was empowered to encourage practitioners to 
avoid trying to manipulate their self-assessment in order not to ‘lose face’; and to develop 
tips to share on the interpretation and feedback provided by supervisors.  The tool 
remains central to the foundation programme.  This study was cited by others, including 
by the General Dental Council as they explored potential supporting evidence for 
assurance of practice in that profession (229). Little has been written about peer 
assessment (sometimes known as ‘multi-source feedback’ (MSF) within nursing, but one 
study suggested that there was value in the role of self-assessment as part of the 
professional development process (230).   
During the author’s secondment to the JPB, the Royal Pharmaceutical Society (RPS) 
assumed responsibility nationally for foundation training and mandated the use of mini-
PAT within foundation programmes.  The author acted in an advisory capacity to the RPS 
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as part of the decision-making for the structure of foundation training, and this key 
publication was submitted to them as part of the evidence for the use of mini-PAT and 
how it works.  Mini-PAT became a mandated part of foundation training accredited by the 
RPS (231). 
 
4.7 Summary 
The author’s seven-year secondment to the Joint Programmes Board allowed a significant 
contribution to be made to the culture of post-registration pharmacy foundation training 
in south-east England, with influences extending nationally and internationally.  The 
author played a leading role in changing the culture around WBL and WPBA, taking the 
lead in areas including SDL, educational infrastructure, tutor terminology and the 
understanding of workplace based assessment.  An example of international influence 
was the author’s tutor training being adapted for delivery in Iceland in a programme 
modelled on that developed by the JPB.  The author’s contributions around mini-PAT and 
acute care assessments continue to be used and ten years on from the start of the 
secondment, change has been embedded and taken forward nationally by the Royal 
Pharmaceutical Society, who used the author as a consultant, for example in media 
around the appropriate use of WPBA (232) (233) (234).  A Department of Health White 
Paper in 2008, two years after implementation of the JPB programme, stated that 
pharmacy training needed to change so that pharmacists are competent to develop their 
role.  The JPB model provided an opportunity for practitioners to make medicines 
optimisation part of routine practice through the demonstration and assessment of safe 
medicines use and understanding the patient experience.  In Chapters 2 and 3 of this 
thesis, the author outlined their contribution to some of the beneficial outcomes of 
medicines optimisation such as medication adherence and tackling polypharmacy.  Many 
of these contributions happened concurrently with the author’s educational roles, which 
allowed them to positively influence the JPB curriculum by ensuring that some of these 
outcomes were included. An example is the inclusion of a practice-based deprescribing 
learning outcome in the latter part of the JPB programme, which was popular with 
students and workplaces alike.  The author was encouraged that in some ways and in 
spite of political and philosophical challenges, the JPB approach was ahead of its time 
with respect to WBL, WPBA and the development of workplace supervisors.  
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PhD by Publication – Barry Jubraj 
Chapter 5: Medicines Optimisation: Supporting safe practice through 
professional and personal development of healthcare staff 
 
5.1. Introduction 
In Chapter 4 of this thesis, the author outlined background information to the developing 
requirement for health professionals to keep up-to-date in order to practise safely.  
Reference was made to the Kennedy report into the Bristol heart surgery scandal (187) 
and his emphasis on the need to maintain competence, engage with performance 
appraisal and continuing professional development (CPD) (188). This was part of the 
notion of ‘fitness to practise’ within an emerging patient safety and revalidation agenda.  
The author then outlined their own contribution to the competence and work-based 
learning imperatives in pharmacy arising from outputs such as the Kennedy report.   
Over time, ministries of Health, healthcare regulators, and professional bodies across the 
world have been advocating CPD as a strategy that leads to better health outcomes (235). 
Moreover, the ability to reflect effectively has been described as an important attribute 
of competent health care professionals (236), and over time this has become a 
requirement for CPD and revalidation within the health professions, including pharmacy. 
A consequence of this has been to encourage the use of reflective practice in health 
education.  Proponents of this suggest that reflective practice encourages learning from 
experiences and may support the integration of knowledge with the “ambiguities of 
practice” (237).  Mandatory CPD was made a requirement of pharmacy’s code of ethics in 
2009, with a subsequent statutory requirement made in 2010 (238).  This was broadly 
supported by the profession (239) and the author has acted as a CPD facilitator for 
pharmacy staff both locally and regionally over many years, as well as volunteering for 
national pilots for mandatory CPD recording.  Revalidation for pharmacists was 
implemented in 2018 (240). 
The author qualified as a pharmacist in 1991 as the move towards implementation of CPD 
recording gathered pace within pharmacy.  The author also trained as a teacher in the 
mid-1990s and was impacted positively by learning about the value of ‘significant 
incident’ analysis in teaching.  David Tripp’s well-known textbook on critical incidents in 
teaching (241), studied during the author’s Postgraduate Certificate in Education, 
prompted the author to extend this learning about reflection from education to their own 
Page 71
  
clinical practice and encouraging their trainees to do the same.  This led directly to the 
author becoming the first accredited clinical supervisor in their hospital who was a 
pharmacist (242).  This is a common practice in nursing where clinical staff can discuss 
and ‘unpack’ incidents in their practice as part of professional development and in order 
to restore and debrief.  The author, during their counselling training, also received 
frequent (clinical) supervision for their client base.  In this chapter, the author will outline 
their contribution to the CPD agenda within pharmacy, including publications around 
their work in developing healthcare staff in the areas of reflective practice, CPD training 
and developing senior pharmacy staff capable of educating and developing their juniors 
and students. 
 
5.2 Summary of the author’s work in reflective practice and continuing professional 
development 
5.2.1 Contribution between 1998-2007 
The author was working as a joint appointee between the NHS and academia in 1998 
when the regional body for pharmacy education and training in London at the time 
(London Pharmacy Education & Training – LPET; reference no longer available) invited 
lead pharmacists for education in London to train their staff locally in reflective practice 
and CPD.  The author developed reflective practice teaching and workshops in their own 
hospital and was subsequently invited to contribute this to LPET’s regional training.  The 
author’s expertise in CPD was then used by their hospital to support the implementation 
of the national ‘Knowledge and Skills Framework’ (KSF) (243).  This professional 
development framework was implemented for all NHS staff except doctors and senior 
managers across the NHS, and consisted of competency elements known as ‘core 
dimensions’ and ‘specific dimensions’, each of which contained a number of indicators.  
The KSF was intended to provide a facilitative framework for personal and professional 
development of NHS staff that could identify learning and development needs specific for 
a particular job role.  KSF was also intended to be used at appraisal to evaluate 
performance against the dimensions contained within the outline.  Producing KSF outlines 
required a detailed understanding of job roles by local leads for implementation across 
Great Britain.  The author produced KSF outlines for their local pharmacy department that 
pharmacy managers confirmed were accurate and demonstrated appropriate selection of 
dimensions for each job role.  This resulted in the author being invited to undertake a 
hospital-wide advisory role to other departments in writing their own outlines, which 
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involved discussions with departmental KSF leads in order to help them to identify which 
dimensions should be included in their KSF outlines.  This activity led to the author 
initiating and managing the publication of the local experience and advice for other NHS 
organisations using the KSF (244).  The KSF is now used less within the NHS but the author 
deems the experience invaluable because of the opportunity to critically evaluate job 
roles and the knowledge and skills required to undertake them. 
 
5.2.2 Contribution between 2006-2015 – The Joint Programmes Board 
In Chapter 4, the author outlined their role in making fundamental contributions to the 
structural development of the first postgraduate hospital pharmacy foundation 
programme in Great Britain.  The author’s core role included developing local educational 
infrastructures to support work-based learning and assessment in hospitals in south-east 
England.  This included championing the link between workplace development and CPD, 
since the author had experienced a perception that staff saw a dichotomy between the 
two. When being asked for advice on completing CPD records for the regulator, it often 
didn’t occur to staff to use their workplace development experience.  The author 
therefore co-wrote a publication about CPD, concluding that “CPD in the form of lifelong, 
self-directed, work-based learning, leading to a transparent demonstration of 
competence, is important for practitioners to embrace at an early stage of one’s career” 
(245). This reflects previous key government imperatives acknowledging in particular the 
role of work-based learning in CPD (246).  Following the publication of this article and the 
publication on self-directed learning (see Chapter 4), the author was invited to contribute 
to a discussion piece in a widely-read pharmacy journal encouraging pharmacists to make 
use of reflective practice (247).  This provided the opportunity to encourage senior 
pharmacists to model reflective practice to juniors, which was a key element of CPD 
within foundation pharmacy training.  The author’s substantial contribution to the 
development of foundation training led to invitations to collaborate on projects leading to 
the key publications and outputs in this chapter. 
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5.3 Key publication 10: Book chapter: Reflecting on Teaching and Learning in Healthcare 
(248) (see Appendix 15) 
5.3.1 Background 
An invitation in 2010 to co-produce a book chapter recognised the author’s increasing 
influence in the area of pharmacy workplace education, supervision and facilitation.  The 
Pharmaceutical Press contacted the JPB and commissioned an international group of 
leading pharmacy educators to write a book aimed at healthcare staff from non-teaching 
backgrounds who are expected to facilitate the learning process in healthcare disciplines. 
Chapters covering topics such as teaching and assessment strategies and designing course 
material were written to help readers understand common educational concepts, and to 
reflect and improve upon their own teaching practice. As well as supporting the editor in 
managing the development and review of chapters, the author was asked to co-write a 
chapter with Dr Sue Jones (SJ), a pharmacy colleague holding a PhD in CPD.  The chapter 
brief was to support new clinical educators, who may be experienced clinicians, in 
applying material from previous book chapters and also to reflect on their dual identity as 
clinicians and teachers.   
 
5.3.2 Chapter rationale and key elements 
It was recognised in the literature that hospital consultants who teach should strive to 
improve their teaching skills, acknowledging the importance of relevant training for 
hospital teachers (249).  The author and SJ agreed that this was imperative to help 
readers of our book to recognise the challenge of being an expert clinician whilst at the 
same time needing to develop as a novice teacher and gain relevant training.  It was also 
recognised that many clinicians who educate have never been taught to teach, supervise 
or assess students (250).  A particular emphasis in this book chapter was made on how 
clinician’s views of their own educational competence could impact their teaching.  The 
author and SJ shared their own experience of being new clinical educators and what it 
was like trying to train students and juniors to be competent clinicians, whist sometimes 
feeling insufficiently competent at teaching.  These reflections prompted the author to 
ensure that some basic concepts around reflection and reflective practice were included, 
and that practical tips and appropriate references were provided.  In order to support 
readers’ reflections, the author included the ‘confidence vs. competence’ model (original 
reference from book chapter no longer available), which suggested that there is a 
relationship between the two.  In addition, the author had previously sought to apply 
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Donald Winnicott’s notion of being a ‘good enough’ parent (251) (252) to being a ‘good 
enough’ practitioner (253), the point being to encourage novice clinical educators not to 
set an unrealistic self-standard of perfection in their teaching, but to allow themselves to 
learn and develop as teachers, just as they had previously done as clinicians. This principle 
was applied to clinical teaching in the book chapter.   
 
5.3.3 Impacts and associated outputs 
Soon after the release of the book, a national pharmacy journal unexpectedly published 
an abridged version of this book chapter in a journal article (254).  Dr Jones and the 
author were unaware of this until publication, and upon contacting the journal editor to 
thank them, the author was told that the driver for publication was to share more widely 
the need to avoid an ‘identity crisis’ when assuming the dual role of clinician and 
educator.  Subsequent reviews of the book itself were positive and feedback included 
commendations around the helpful use of self-disclosure in sharing personal reflections 
about our own journeys to becoming clinical educators. 
A significant output from this work was the author’s pioneering work with SJ and others 
in leading the development of a nationally accredited recognition programme for 
pharmacy educators.  The driver for this was an existing non-pharmacy ‘Statement of 
Teaching Proficiency’ (STP) at King’s College London (reference no longer available).  This 
was a programme offered to university teachers to develop their role through a 
combination of face-to-face teaching and the development of a portfolio. One of the 
author’s JPB managers was also a professor at King’s. Having recruited the author in 2008 
to the JPB in order to ensure that the development of a robust postgraduate foundation 
pharmacy programme was matched by appropriate tutor training (see Chapter 4.3), a 
tutor recognition scheme was seen as the next logical step.  In 2013 the author and SJ, 
based on their experience from a ‘Developing Educational and Practice Supervisors (DEPS) 
working group (see Chapter 5.4.1) and other work such as this book chapter, developed a 
pharmacy-specific STP programme.  This was under the auspices of King’s College London.  
With SJ, the author led an expert panel to develop the programme, which included face-
to-face training over one day and the development of a short portfolio based on 
competencies from the education competency cluster of the RPS Advanced Pharmacy 
Framework (1).  The one-day face-to-face event allowed an introduction to some key 
educational theories, work-based learning and assessment principles, role-modelling and 
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peer-observation of teaching.   The author led on the development of the aims of the 
programme, which were derived and adapted from a similar programme developed for 
doctors (255).  The STP team agreed with the author that time should be given to reflect 
on the importance of good quality tutoring and mentoring, which was influenced by the 
author’s counselling training and experience (see Chapter 2.2.3).   
The STP was launched by the author and colleagues in 2014 and became the first 
nationally accredited recognition programme of its kind by the Royal Pharmaceutical 
Society in 2016 (256). The JPB evolved into the ‘Joint Pharmacy Foundation School of 
King’s College and University College London’, accredited by the Royal Pharmaceutical 
Society; and the STP became an official offering of the joint foundation school.  To date 
the STP has supported several hundred pharmacy educators through the initial stages of 
the programme, mainly but not exclusively from London and the south-east of England.  
The potential impact of this programme is significant judging by the quality of written 
reflections that the author has seen during portfolio assessments.  These reflections 
commonly describe candidates thinking critically about their role modelling, and valuing 
peer observations of teaching as part of receiving feedback on their teaching and 
assessment.  The programme could reach many hundreds of pharmacy tutors in the 
future.  
 
5.4 Key publication 11: Development and piloting of a competency framework for 
pharmacy educational and practice supervisors  (257) (see Appendix 16) 
5.4.1 Background 
The author’s work in the field of foundation training came to the attention of one of the 
JPB partners, the Head of the NHS Pharmacy Deanery for Kent, Surrey and Sussex, Gail 
Fleming (GF).  The author and GF reflected that there was little in the literature 
concerning the ideal skills, attributes and knowledge for a pharmacy tutor.  This led the 
author and GF to establish a working group known as ‘Developing Educational and 
Practice Supervisors’ (DEPS) in 2009.  DEPS’ principal task was to design an accreditation 
and quality assurance framework for pharmacy trainers and tutors and seek to influence 
the Royal Pharmaceutical Society in its new leadership role in pharmacy foundation 
training.  The following sections outline the streams of work that emerged from the DEPS 
project.  DEPS was specifically cited in the landmark ‘Modernising Pharmacy Careers’ 
programme document of 2011 (see Chapter 4) as a practice example of focusing on the 
importance of workplace tutors. 
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Firstly, the author took the lead in an early project to standardise tutor terminology, with 
a migration towards the term ‘supervisor’ instead of ‘tutor’ (209).  The author recognised 
that pharmacy development programmes used different terms such as ‘tutor’ or 
‘facilitator’, without clear justification for the use of different terms.  Moreover, the 
author reasoned that aligning pharmacy workplace terminology with medicine, the JPB 
having emulated that profession’s use of workplace-based assessment tools, could 
support doctors and pharmacists assessing each other’s trainees, as suggested by the 
author’s earlier publication encouraging pharmacists to undertake mini-PAT assessments 
for junior doctors (224). See Chapter 4.6.2.  
This work stream on terminology facilitated the delineation of roles and responsibilities 
for different types of pharmacy supervisor.  This allowed the DEPS group to start work on 
developing a competency framework for the different types of pharmacy supervisors, 
which could be used alongside other existing pharmacy frameworks such as the Advanced 
Pharmacy Framework (1).   
 
5.4.2 Framework development 
Following the author publishing the DEPS pharmacy tutor terminology paper, roles and 
responsibilities were defined in consultation with DEPS stakeholders and with reference 
to published roles in other professions, including nursing and medicine.  Existing 
pharmacy frameworks were examined by the group for alignment and it became clear 
that none of them had the necessary level of detail to assess competence in specific tutor 
roles, including one emerging pharmacy educator framework (258).  This convinced DEPS 
of the merits of a dedicated tutor framework and the author was tasked with co-opting 
expertise to develop one.  The co-writer of the reflection book chapter described in 
Chapter 5.3 (SJ) joined DEPS and secured expert input from an academic with expertise in 
concept mapping, which was a tool that the author had no prior experience of.  A concept 
map is a diagram containing different concepts and the links connecting them represent 
the relationships between these concepts (259).  The author organised and collated DEPS 
members’ views on what they believed to be appropriate competencies for different 
aspects of pharmacy tutoring.  The external expert, with SJ, developed the framework for 
pharmacy supervisors.  The author then arranged the piloting of the framework and the 
collation of feedback.  Feedback was mixed, with some expressions of what the author 
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described as ‘framework fatigue’ with respondents expressing the sentiment ‘not another 
framework!’  However, the content was not disputed. 
 
5.4.3 Impacts and associated outputs from the author’s DEPS work 
The author’s suggested tutor terminology was adopted by the JPB and subsequently the 
UCL School of Pharmacy (260). Health Education England (HEE) for London and the south-
east of England have also followed suit (261).  As a result of this work, the term 
‘supervisor’ was acknowledged as an alternative term to ‘tutor’ in the Royal 
Pharmaceutical Society (RPS) draft standards for tutors (262).  This led to the author 
being invited to provide advice on behalf of the DEPS group and JPB to advise the RPS for 
their national establishment of pharmacy foundation schools, as part of their advisory 
role described at the end of Chapter 4.6.3.  The author advised on the development of 
accreditation standards for foundation schools and guidance on training for 
tutors/supervisors.  The influential ‘Modernising Pharmacy Careers’ programme was 
mentioned in Chapter 4.1 (191) and the DEPS work was specifically outlined with mention 
made of the efforts made to support and further develop the pharmacy tutor workforce.  
It also reproduced the tutor terminology outlined in the publication described in Chapter 
5.4.1 that was led by the author.  
Below is a testimonial from spring 2019 by a leading pharmacy educator who has been 
working with XXXX: 
“Currently HEE (London & South-East - LaSE) is working on revising both the Practice 
Supervisor and Education Supervisor (ES) frameworks and I have been tasked to map our 
KHP STP with the DEPS and HEE multi-professional framework (MPF).  My observations 
about the HEE DEPS in particular is that it was filling a gap in the educational 
infrastructure where we, as a profession, had nothing in place to ensure a standardised 
approach to the development of pharmacy education supervisors.  HEE KSS always 
required their ES's to be trained according to the DEPS and HEE LaSE commissioned a 
company to deliver online training based on the DEPS framework as they had nothing else 
to go on.  The feedback from the profession in London in particular was the training was 
too detailed and took too long to complete (up to 6 months) and HEE are now revising the 
framework. 
My personal view is that the content of the framework is really good although the 
language needs to be reviewed to make it in line with other professions' frameworks (such 
as the HEE MPF and the Association of Medical Educators - AoME) so that it is less 
pharmacy-centred.  There are some clusters which have too many competencies which 
could be moved into a curriculum section so that the framework itself remains high level 
with the detail elsewhere. 
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There is an opportunity here to line up Educational Supervisor frameworks into one 
framework which could be taken up by both HEE and the RPS which is where our 
Statement of Teaching Proficiency [see Chapter 5.3.3] comes in.  Our ultimate goal should 
be to use the DEPS, STP , MPF and others to have one framework which is recognised by 
HEE, RPS and all of the pharmacy schools for when we have 'learning in practice' 
supervisors, as part of the revised process for registering pharmacists (GPhC initial 
education standards for Pharmacists) which are recognised by all.  Your initial work laid 
the foundations for this by developing the DEPS framework”.   
(XXXX personal communication.  Reproduced with permission) 
 
The author also participated in a mapping exercise of the DEPS competency framework to 
the pharmacy Advanced Level Pharmacy Framework, which was subsequently published 
(263).  This exercise demonstrated transferability to different geographies and sectors of 
pharmacy, and led to the framework being used to accredit both pharmacists and 
pharmacy technicians in a wide range of specialist roles within the Kent, Surrey and 
Sussex region. 
Finally, in 2015 the author was asked to co-supervise a Masters-level student project 
exploring the necessary qualities of a pharmacy workplace tutor.  The author contributed 
the history of workplace pharmacy tutoring over the last ten years to inform the project 
and potential experts to contribute to a Delphi-style exercise (264) to elucidate the 
qualities.  Sixteen national experts agreed on 20 important qualities, which support the 
literature from other professions.  Examples of coherence include good communication 
and also knowledge (medicine) (265); character, competence and communication 
(dentistry) (266); and communication and role-modelling (nursing) (267).  This work has 
been presented at a 2019 pharmacy education conference (268). 
5.5 Mentoring and PhD supervision 
Over the course of the author’s educational practice, many requests for mentoring have 
been received, typically at study days where the author has been a speaker.  Due to 
workload the author has been unable to proactively offer themselves as a mentor but 
typically endeavoured to follow up requests with at least one telephone conversation.  
Requesters typically affirm the author’s reputation in this area. The author has also 
benefitted from a long-term peer-mentoring relationship with Professor Nina Barnett 
(NB), which led to the publication of their key experiences in 2011 (269).  This in turn led 
to an invitation from the Royal Pharmaceutical Society (RPS) in 2012 to perform a 
conference ‘live play’ of a typical peer mentoring session (270).  Feedback received 
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focused on the openness, authenticity and honesty that was displayed by the peer-
mentors, along with modelling what the audience felt were helpful mentoring 
behaviours, such as reflecting back, asking questions; and largely being non-directive 
(271).  The RPS were not aware of any previous ‘live’ work similar to the author/NB’s 
having been presented in such detail before.  Subsequently, the RPS asked to film further 
peer-mentoring sessions that are now hosted on their website as examples of good 
practice (272). The author had ideal experience to teach pharmacy educators about 
mentoring in the ‘Statement of Teaching Proficiency’ programme (Chapter 5.3.3), linking 
the importance of mentoring with recognition through the Royal Pharmaceutical Society 
using the Advanced Pharmacy Framework (273). 
Finally, the author was asked in 2017 by their immediate superior, a Professor of Clinical 
Pharmacy, to be a lead supervisor for a PhD in the area of clinical decision-making, an 
under-researched area within the pharmacy profession.  The PhD student was also a 
colleague and clinical lecturer at King’s College London.  At the time of the request, the 
author reminded the professor that they did not currently hold a PhD.  The author was 
reassured that, in the opinion of King’s College London, the author’s credentials were 
sufficient and the author had previously stated an ambition to be a PhD supervisor.  The 
PhD in 2019 reached the transfer viva stage, and at the time of writing remains in 
progress.  The author was also approached in 2017 to support a PhD candidate exploring 
the results of assessments in the JPB foundation programme (assessments are outlined in 
Chapter 4.5.3).  This support was instrumental in ensuring that the context of foundation 
training and the history of assessment is included in the write up.  The lead PhD 
supervisor was keen for the author to assume a formal co-supervisor role.   
 
5.6 Summary 
The author’s passion for developing people in the workplace and the classroom over 25 
years has provided the opportunity to suggest and share good practice through 
publications in the areas of CPD, reflective practice, mentoring, tutoring/supervision and 
professional recognition.  Key outputs were adopted by the Royal Pharmaceutical Society 
and the Joint Programmes Board, and continue to be used nationally.  For example, the 
resources section of the current RPS tutor guidance (274) contains seven of the author’s 
publications as additional reading.   
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The responsibility and privilege of developing professionals included the author’s work 
outlined in Chapters 2, 3 and 4.  A common theme was the author’s desire to change 
culture by educating ‘bottom up’ and to equip students and trainees to gain experience of 
future imperatives in medicines optimisation, such as medication review and adherence 
support.  In the exemplar case described in Chapter 1.9, the author outlined how they 
would explain the relevant decision-making to the junior doctors and medical students on 
the ward round. On one occasion, two junior doctors expressed their motivation to the 
author to explore this further, culminating in them contributing to and co-presenting a 
poster presentation about the junior doctor survey described in Chapter 3.4 at a national 
conference (275).  The RPS national ‘excellence in education’ award nomination in 2013 
specifically mentioned the author’s desire to develop others.  The author believes that 
their training as a teacher and counsellor and their life experience have contributed to 
their skills, qualities and ethos that have led to local and national recognition.  It was 
encouraging to be recognised for educating directly, and influencing indirectly, the 
education of many healthcare staff to care well for their patients and to develop 
themselves at the same time. 
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PhD by Publication – Barry Jubraj 
Chapter 6: Summary of research methods; evaluation of thesis aims; and 
conclusion 
 
The title of this thesis is ‘Medicines optimisation: a pharmacist’s contribution to delivery 
and education’.  The author’s original working title of “Equipping stakeholders to deliver 
Medicines Optimisation using a collaborative approach” (see Appendix 5) was a helpful 
starting point, but the themes of delivery and education have become more prominent 
this process.  Therefore, this thesis describes in detail key publications as well as other 
published outputs, resulting from a professional journey of delivery and education in 
areas of pharmacy practice that are now located within the concept of medicines 
optimisation. 
 
6.1 Summary of research methods represented within the key publications in this thesis. 
A range of research methods have been applied to the key publications in this thesis. For 
each research study the method was selected to align with the circumstances of the 
relevant work.  For example, observational quantitative research was undertaken in key 
publication 1 (39), whilst the author used dialogic and collaborative methods to produce 
key publications 8 (214) and 10 (248).  Some publications were developed in collaboration 
with academic partners and leaders in the field, which allowed the author to engage in 
deeper learning about the principles of research and publication. 
It is important to note that the key publications in this thesis were not undertaken 
sequentially.  This sometimes limited the opportunity for the learning from some 
publications to be applied to subsequent outputs, particularly where the genre was 
different. However the author has focused on building expertise in multiple 
methodologies and is now confident in using a range of tools.   
Table 4 outlines the methods used for the key publications contained in this thesis. 
Barriers and/or limitations, with suggestions for improvement, are indicated in the final 
column (italicised) and discussed further in Chapter 6.1.1.  The author’s contribution to 
each publication is summarised in the author verification descriptions in Appendix 3.   
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Table 4: Methods, rationale and comments for key publications in this thesis 
Key Publication Summary of methods used Outputs obtained Rationale and barriers or limitations 
 
Horne R., Sumner S., Jubraj B., Weinman 
J., Frost S. 2001. Haemodialysis patients' 
beliefs about treatment: implications for 
adherence to medication and fluid‐diet 
restrictions. International Journal of 
Pharmacy Practice, 9 (3), pp.169-175 
(Appendix 6) (39) 
Observational quantitative 
research. Consecutive 
sampling. Beliefs about 
Medicines Questionnaire 
(BMQ) (4 and 5-point scales)  
Questions about adherence on 
consecutive sample (5-point 
Likert scale), 
Tabulated scores with standard 
deviation, comparison using 
Spearman’s rank correlation 
Appropriate for identifying data 
without affecting outcome. Patients 
could complete the questionnaires 
during treatment a session. BMQ is a 
validated tool. Limitations: self-
report is a limited measure of 
adherence;  this was a small sample 
size 
Jubraj B., Barnett N.L., Grimes L., Varia 
S., Chater A. and Auyeung V. 2016. Why 
we should understand the patient 
experience: clinical empathy and 
medicines optimisation. International 
Journal of Pharmacy Practice, 24(5), 
pp.367-370 (Appendix 7) (57) 
Dialogic and collaborative 
Document analysis 
Narrative from conversations 
between colleagues combined with 
literature review to create a thought 
paper 
Method of documenting the synergy 
between health professionals’ 
conversations as concepts develop 
in their application to pharmacy. 
Limitation: Could be developed and 
expanded through a survey of 
patients and professionals 
Jubraj B., Deakin A., Mills S., Grimes L., 
January 2016. Pharmacy consultations 
with patients with learning 
disabilities. The Pharmaceutical 
Journal, 296, No 7885 (Appendix 8) (78) 
Document analysis; focus 
groups; brief literature review; 
collaborative qualitative 
research  
Narrative combining dialogue 
between peers and insights from 
focus group 
Utilising existing Down’s Syndrome 
Association resources to identify key 
issues for families in pharmacy 
consultations. Brief literature review 
used to develop collaborative 
research piece.  Limitation: A larger 
focus group would strengthen the 
reliability of the initial findings 
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Key Publication Summary of methods used Outputs obtained Rationale and barriers or limitations 
 
Saheb M.A., Jubraj B., Bovill I., Kuo S. and 
Marvin V. 2014. Intermediate 
Care. Geriatric Medicine, 44, pp.13-17 
(Appendix 9) (126) 
Mixed-methods 
observational and quantitative 
research using consecutive 
sampling over 5 months.  
Rehabilitation facility- based 
 
Numbers of medicines stopped and 
number of times STOPIT medication 
review tool used in medication 
reviews in this cohort 
Exploration of utility of STOPIT tool 
in practice.  Limitations: The small 
sample precluded more detailed 
data collection or analysis.  
Qualitative analysis of free text 
comments could have been 
undertaken using coding to establish 
themes for a larger dataset 
Jubraj B., Marvin V., Poots A.J., Patel S., 
Bovill I., Barnett N., Issen L. and Bell D. 
2015. A pilot survey of junior doctors’ 
attitudes and awareness around 
medication review: time to change our 
educational approach? European Journal 
of Hospital Pharmacy, 22(4), pp.243-248 
(Appendix 10) (154) 
Observational quantitative 
survey research using online 
tool. Questions created from 
focus group themes 
Descriptive statistics, Ordinal data 
(responses to questions) presented 
graphically 
Allowed collation of views from a 
variety of health professionals in a 
short space of time. Limitations: 
Qualitative analysis of free text 
comments could have been 
undertaken using coding to establish 
themes if more time had been 
available (student project) 
Jubraj B., Barnett N.L. (guest eds). 2017 
Themed issue on Deprescribing. 
European Journal of Hospital Pharmacy. 
January 2017, Volume 24 Issue 1 
(Appendix 11) (170) 
Case studies, literature 
reviews, observational 
quantitative studies and 
dialogic collaborative narrative 
texts from a number of 
worldwide researchers in the 
issue 
A themed issue presenting literature 
and data to develop the readers 
understanding of the deprescribing 
agenda 
To share current practice and 
thinking internationally between 
communities involved in aspects of 
medicines optimisation. Limitations: 
Selections of topics and authors 
based on known contacts rather 
than inviting interest or randomly 
selecting 
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Key Publication Summary of methods used Outputs obtained Rationale and barriers or limitations 
 
Jubraj B., Patel S., Naseem I., Copp S. and 
Karagkounis D. 2017. The acute care 
assessment tool: ‘Pharmacy ACAT’. The 
Clinical Teacher, 14(3), pp.184-188 
(Appendix 12) (210) 
Descriptive quantitative 
method, Qualitative data 
collected not interpreted.  
 
Number of respondents agreeing to 
statements, examples of free text 
response statements 
To discover whether the ACAT tool 
could be used in practice. 
Limitations: Further analysis could 
have included qualitative analysis of 
free text comments interpreted 
using coding to establish themes. 
Gaining consent from other 
participants would have increased 
the sample size for analysis 
Jubraj B. 2009. Developing a culture of 
self-directed workplace learning in 
pharmacy. The Pharmaceutical Journal, 
283:47-48 
(Appendix 13) (214) 
Dialogic and collaborative; 
brief literature review; 
document analysis 
Narrative from conversations 
between colleagues combined with 
literature review to create a thought 
paper 
Method of documenting the synergy 
between health professionals’ 
conversations as concepts develop 
in their application to pharmacy.  
Limitations: for a similar publication 
in future could widen the pool of 
expertise 
Davies J.G., Ciantar J., Jubraj B. and Bates 
I.P. 2013. Use of a multisource feedback 
tool to develop pharmacists in a post-
graduate training program. American 
Journal of Pharmaceutical Education, 77 
(3), Article 52 
(Appendix 14) (219) 
Retrospective quantitative 
observational cohort research, 
using descriptive statistics  
Comparison of pharmacist 
performance over time; assessor and 
pharmacist scores; inter-professional 
ratings 
Data used to identify statistically 
significant differences in 
performance over time and 
assessments between professional 
groups. Limitations: A repeat study 
could help to overcome risks of bias 
in student mis-selection of raters and 
misinterpretation of competency 
statements 
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Key Publication Summary of methods used Outputs obtained Rationale and barriers or limitations 
 
Jones S.C., Jubraj B. Reflecting on 
teaching and learning. 2012 (book 
chapter (see references for details) 
(Appendix 15) (248) 
Dialogic collaborative research 
leading to narrative which 
includes extracts from 
qualitative interviews 
Book chapter with examples and 
reflection questions 
To educate readers on the benefits 
of reflection, using short explanatory 
narrative and examples from nurses 
and pharmacists in practice.  
Limitation: Could widen the use of 
experts and supporting literature  
Jones S.C., Fleming G., Hay D., Ibrahim 
M., Pettit M., Wright E. and Jubraj B., 
2012. Development and piloting of a 
competency framework for pharmacy 
educational and practice 
supervisors. Pharmacy Education, 12 
(1):14-19 
(Appendix 16) (257) 
Action research: Qualitative 
analysis of output from focus 
group using concept mapping 
and thematic analysis. 
Quantitative analysis of 
questionnaire developed from 
concepts. 
Concept maps and resulting themes 
with illustrative quotations. 
Descriptive statistics from 
questionnaire 
Mixed methods approach allowed 
use of qualitative data to inform 
development of questionnaire with 
quantitative output.  Limitation:  
Should validate the framework, 
preferably with national cohorts of 
supervisors 
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6.1.1 Reflections on methods, barriers and limitations outlined in Table 4 
Table 4 allowed the author to reflect on the methods, barriers and limitations in their key 
publications over the course of their professional and personal journey throughout nearly 
30 years of pharmacy practice. For example, key publication 1 (39) enabled the author to 
learn how to develop and deliver questionnaire studies, which was invaluable experience 
deployed in, for example, key publication 5 (154) and other research examples (177) 
(268).  A powerful example of how the author’s research and career journey culminated 
in a particular output is key publication 6, an international themed journal issue on 
deprescribing (170).  In the author’s role as joint editor, they used the knowledge and 
experience of research methods gained throughout their career to appropriately evaluate 
the worldwide submissions for inclusion, which included providing feedback on the 
limitations and areas for development.  Indeed, Table 4 contains examples of the author’s 
research experience which match the different types of submissions for the themed 
journal issue. 
Table 4 also allowed the author to reflect on some of the limitations of their publications 
and barriers to making further progress with individual pieces of work.  For example, key 
publications 1 and 5, with associated outputs (177) (257) involved undergraduate or 
postgraduate projects where students were available for a finite time period, limiting, for 
example the amount of data that could be collected.  This barrier has taught the author 
that student projects, whilst invaluable, will frequently act as pilot studies that should be 
explored further and on a larger scale with more time and greater data collection.  
Moreover, key publication 4 (126) illustrated the challenge of data collection in 
environments where there is low patient turnover, which limits the potential for data 
collection.  Key publication 3 (78) showed that undertaking research with vulnerable 
individuals, in this case learning disability, may involve communication barriers that need 
to be accounted for when designing data collection tools.  The author has developed their 
skills to overcome these challenges to produce their key publications that continue to be 
cited by others in the wider literature. 
 
6.1.2 Plans for personal development related to Table 4 
The author’s personal development with respect to Table 4 relates to their ambition to 
implement their learning in future research and other publications.  For example, an 
undergraduate student study was supervised by the author with nursing students as 
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subjects.  The aim was to follow up the author’s survey with medical and pharmacy 
students about their knowledge and awareness of medication review and polypharmacy 
(177).  The author’s project supervision for the nursing project demonstrated improved 
direction provided to the student and team in a number of areas: 
 
 Improving the standard of questionnaire items, including coding (see limitations in 
Table 4, key publication 5) 
 Anticipating issues around consent (see limitations in Table 4, key publication 7) 
 Greater awareness of bias in self-report type responses (see limitations in Table 4, key 
publications 1 and 9) 
 
Chapter 6.1.3 outlines the next work streams that the author is planning for.  With 
respect to shared decision-making (SDM), a recent essay outlined some barriers that have 
slowed the progress of embedding this in doctors’ practice (276).  The author has 
informally surveyed pharmacists about this at a national network event.  A substantial 
follow-up piece of research to explore whether the barriers are similar for pharmacists 
would be an invaluable addition to the primary literature; and an opportunity for the 
author to lead and develop this work which would be their most substantial yet.  It will be 
able to draw on all the learning outlined in Table 4. 
 
6.1.3 Plans for future work  
The World Health Organisation’s ‘medication without harm challenge’ (119) will remain 
an important driver for improvements in medication safety into the 2020s.  NHS England’s 
Specialist Pharmacy Services (SPS) (52) are hosting some of this work in that country and 
the author’s work in medication adherence, medication review, polypharmacy and 
deprescribing continues to attract attention within SPS and its partners.  As discussed in 
Chapter 2.2.3, the author has discovered an opportunity to link non-adherence with 
medicines-related risk, and will shortly be leading the writing of a paper on this link.  This 
will require the use of literature review skills and the development of robust survey 
instruments.   
The Secretary of State for Health’s mission, initiated in 2019, to reduce overprescribing 
(Chapter 3.4.3) demonstrates the government’s commitment to tackling polypharmacy, 
with NICE and CPPE beginning national work streams in the area of SDM.  The links are 
becoming clearer between SDM, medicines-related risk and the responsibility of 
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pharmacists to actively engage with these person-centred principles.  The author is 
beginning to support primary care network pharmacists nationally in their NHS work and 
is emphasising that pharmacists are largely not used to SDM and need to see it in 
medicines-related consultations as their responsibility and not leave it to someone else.  
A lack of SDM can lead to the risk of patient dissatisfaction which can, for example, 
increase the risk of intentional medication non-adherence.  This thesis will provide key 
reflections to inform the author’s future work in these areas. 
 
With respect to education, the pharmacy regulator, the General Pharmaceutical Council, 
has been consulting on revising their standards for the initial education and training for 
pharmacists.  Their proposals include greater integration of academic study and 
workplace experience, and the need to improve communication skills (277).  This thesis 
demonstrates that the author has been engaged in all of these topics and has the 
opportunity to use their work to further influence change, for example through their 
teaching, speaking and writing. 
 
6.2 Aims of the thesis revisited 
The aims of this thesis, outlined in Chapter 1.10, will now be revisited.  The author’s 
contribution to the medicines optimisation agenda over their career will be summarised, 
and a published case vignette written about the author will conclude this thesis as it 
summarises their philosophy and approach to the delivery of care, associated education, 
and expressing this through publication. 
 
Aim 1: Demonstrate that the author’s body of published work: 
a. Coheres with, and in some cases predates the definitions and goals of 
medicines optimisation found in Chapter 1.3 and 1.4 
b. Broadly aligns to the Royal Pharmaceutical Society principles of medicines 
optimisations 1 and 3 (see Figure 1) 
Table 5 summarises how Chapter 2 of this thesis describes the author’s publications that 
predate and particularly match RPS medicines optimisation in principle 1. It also 
summarises how the author’s work in Chapter 3 aligns with RPS principle 3.  
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Table 5: Some of the publications and publication themes in this thesis mapped with the goals, challenges and principles of medicines 
optimisation described in Chapter 1 
Medicines optimisation: 
 Goals (Chapter 1.4) 
 Challenges (Chapter 1.9)  
 Principles (Figure 1)  
 
Publications or themes 
 Goal: 
o Avoid taking unnecessary medicines 
 
 Challenges: 
o Non-adherence 
o Polypharmacy 
o Need for patient involvement in decisions 
 
 Medicines optimisation principle: 
o No 1: Understand the patient experience 
 
In Chapter 2, the author’s published work on medication adherence and 
clinical empathy highlighted the importance of acknowledging patients’ 
beliefs about medicines and the need to build relationships with them in 
order to have better consultations. Some of this work predates the term 
‘medicines optimisation’.  Factors that can lead to non-adherence 
include polypharmacy, which the author outlined in Chapter 3.  
Vulnerable patients, such as those with a learning disability, and older 
patients can be helped through a tailored approach to consultations and 
tools like ‘My Medication Passport’. The written articles, blogs and 
videos demonstrated the author’s vision for all pharmacists to recognise 
these imperatives. 
 
 Goals: 
o Avoid taking unnecessary medicines 
o Improve medicines safety 
 Challenges: 
o More older people living with >1 long term condition 
o Polypharmacy 
o Deficiencies in the safety of medicines 
 Medicines optimisation principle: 
o No 3: Ensure medicines use is as safe as possible 
 
In Chapter 3, the author described their published work in identifying 
and supporting particularly older people at risk of problematic 
polypharmacy and falls.  The use of medication review tools was 
described and other publications highlighted that these risks can be 
increased during transitions of care between settings, such as on 
admission to hospital. 
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Much of the author’s work outlined in Table 5 is seen in their approach to managing cases 
such as the exemplar patient outlined in Chapter 1.9, where the author mapped the 
thesis chapters to the medicines-related challenges described in the relevant NICE 
guidance (5).  The NICE challenges overlap with the goals and principles of medicines 
optimisation and the author consistently sought to resolve these types of medicines-
related problem with their patients.  It was not uncommon, following the author’s 
person-centred consultations, for patients to disclose that they were feeling much 
happier, pleased to be taking fewer medicines, “seeing the point” of taking those that 
remained; and feeling much more in control.  In the National Patient Safety Award 
presentation described in Chapter 1.9, the judging panel were also interested in the fact 
that we had reduced the relevant patient’s pill burden by almost 3000 tablets per year at 
an annual cost of £100.  If extrapolated to many thousands of patients, this is likely to 
have a significant economic impact; and the author used this example to illustrate the 
importance of cost-benefit aspects of medication review in their teaching. 
The author has reflected through this thesis that their thinking around adherence and the 
need for pharmacists to develop their consultation skills predated the published 
descriptions of medicines optimisation.  This was in common with other writers, who 
believed that RPS medicines optimisation principle one (understand the patient 
experience) is arguably the most important for the pharmacy profession at this time.  This 
encouraged the author primarily because it demonstrated that medicines optimisation 
was an evolving concept and that it was possible to develop it further, as outlined in the 
author’s proposed definition outlined in aim 4 below. 
Finally, through the author’s research into the views of juniors and students about 
medication review and deprescribing (see Chapter 3), they were able to suggest 
educational approaches to support these aspects of medication safety. 
 
Aim 2: Develop the scope of principle 4, to demonstrate that making ‘medicines 
optimisation part of routine practice’ should include appropriate education and training 
approaches, which the author has championed through their publications 
 
In Chapter 1.4, the author stated reservations about the RPS explanation of medicines 
optimisation principle 4 (8). No direct mention was made of the need for educating staff, 
students or patients as part of making medicines optimisation part of routine practice.  
The author’s ‘bottom up approach to education around medication review and 
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deprescribing’ (see Chapter 3.4.2) was an example of how the author initiated an 
educational change intended to influence the delivery of a key aspect of medicines 
optimisation.  This was achieved by key publication 5 (154) which led to a number of 
other publication outputs including papers, posters and conference abstracts (158) 
(163)(167)(177). 
 
Aim 3: Demonstrate that their body of published work has positively impacted clinical and 
educational practice that relates to principles of medicines optimisation 
As well as the ‘bottom up approach’ outlined above, the author described their approach 
to caring for patients like the exemplar case in Chapter 1. The rehabilitation unit 
consultant ward round typically included the author, nursing staff, junior doctors and 
medical students.  The author, as with all of their clinical activity, routinely made a point 
of explaining their rationale and decision-making to these stakeholders, highlighting the 
need for them to consider the NICE challenges (5) when dealing with similar patients in 
the future.  In Chapters 4 and 5 of this thesis, the author described their work in 
developing staff and students with the intention of equipping them to deliver the goals, 
principles and challenges related to medicines optimisation in their future practice.  For 
example, the author used their educational influence to include relevant learning 
outcomes on medication review in foundation training for pharmacists, described in two 
publications (163) (167) (Chapter 4.3).  Chapter 4.7 also described how workplace-based 
assessment (WPBA) allowed practitioners to demonstrate safe practice, in real time, with 
their patients. The author’s publication describing the importance of WPBA (201) led to 
their involvement in the development of key Royal Pharmaceutical Society resources. 
 
Chapter 5 outlines how the author worked to support more established practitioners with 
their own professional growth, for example in a publication describing key aspects of 
continuing professional development (245).  Additional publications were aimed at senior 
staff who develop others, for example tutors (214) (209) (224) (248).  It has been said that 
“the education of junior doctors is vital to ensure the safe management of our patients in 
the future” (249), and that “a poor surgeon hurts one person at a time but a poor teacher 
hurts 130” (265).  The author’s contribution in this area is summarised by their belief that 
education and development underpins the fitness-to-practice and competence agendas, 
as described in their publication that took the form of an opinion piece (207).  As such, in 
order to understand the patient experience (see medicines optimisation principle 1 and 
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Chapter 2 of this thesis) and to make medicines use as safe as possible (see principle 3 
and elements of Chapter 3), the education of students and juniors (see Chapter 4) 
together with equipping of their seniors and tutors (see Chapter 5), is essential in the 
author’s view.  
 
Aim 4: Reflect on whether a more unifying definition of medicines optimisation can be 
recommended (see Appendix 5 where the author stated this as an intention) 
At the outset of this thesis, the author aimed to explore the possibility of developing a 
more unifying definition of medicines optimisation, to address concerns about RPS 
principle 4, whilst maintaining an awareness of existing descriptions in Chapter 1.3.  The 
concept has generally been described rather than being tightly defined, and the 
descriptions vary according to different writers.  Through the writing of this thesis, the 
author has concluded that a modified version of the definition offered by NICE (5) could 
be offered as follows [modifications in brackets]: 
“Medicines optimisation is defined as a person-centred approach to safe and effective 
medicines use, [supported by appropriate education of all stakeholders], to ensure people 
obtain the best possible outcomes from their medicines”. 
Aims 2 and 3 above are key to the author’s rationale, because of their belief that principle 
4 should be more clearly defined and include educational imperatives.  These views have 
been published and delivered at conferences (154) (158) (163) (167) . 
Educational imperatives should then be added to an existing clear and concise definition 
that includes the essential elements of person-centeredness, safety, effectiveness and 
best outcomes.  In discussion with a pharmacy Professor XXXX, the author received the 
following feedback on this recommendation:  
“..frame it as a recommendation though, rather than being ‘proved’ [for what it's  
worth it has massive face validity with me and I can't imagine anyone disagreeing!]”.   
 
(XXXX, personal communication. Reproduced with permission) 
The author agrees with this view, based on some representative examples from this 
thesis describing the need to underpin improvements in practice with education: 
1. The professional development implications of the Bristol heart surgery scandal as 
part of clinicians maintaining their competence (Chapters 1 and 4) 
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2. The educational responses to the Francis enquiry into poor standards of care at 
mid-Staffordshire hospitals (Chapter 2) 
3. Junior clinicians not being aware of medication review tools that can support 
deprescribing decisions until they were taught about them (Chapter 3) 
  
6.3 Conclusion 
The author’s principle career focus has been to provide direct patient care and educate 
the workforce in order to care well for their patients and to develop themselves.  
Although the author’s focus towards the start of their career was not originally education, 
research or publication, they began to publish their work in the 2000s in order to share 
good practice and out of personal interest.  Such was the feedback received and the 
author’s motivation, they increased and accelerated their publication outputs according 
to their roles and secondments at different stages of their career journey (see timelines in 
Figure 5).   
The author has achieved over 150 citations of their work (not including self-citations) and 
many of these are for small-scale research projects or practice-based publications.  This 
encourages the author to share the message with the pharmacy profession that 
publication of smaller projects can achieve a positive impact on students, colleagues and 
ultimately patients, at a time when pharmacists struggle to engage with this important 
research role that they should have as clinicians, as mandated by the existence of the 
research cluster of the RPS Advanced Pharmacy Framework (1). 
Finally, the following vignette from a recent publication (85) was an example of how 
others perceive the author’s approach to identifying, communicating and disseminating 
ideas to improve care.  The vignette is written by the author’s colleagues at CLAHRC NWL 
(see Chapter 2.4.1) and relates to the use of ‘My Medication Passport’ (which was 
described below as ‘the innovation’) that was outlined in Chapter 2.4.  These colleagues 
have observed at first-hand how the author has sought to build working relationships and 
actively identify ideas that may improve the delivery of medicines optimisation.  The 
author was said to have identified “at least” two different sorts of peer community.  
Another community influenced by the author is undoubtedly educational stakeholders.  
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Vignette: Advocates for patients who live with learning disabilities 
This vignette is based on publications highlighting the role and 
experiences that one person who described himself as “carer, parent, 
patient and health‐care professional (pharmacist)” and the influence 
he had on others. He was an advocate for the use of the innovation and 
he published a case study about his own use of MMP to support the care 
of his son who has multiple disabilities including a learning disability. 
By publishing the case study and outlining the context in which the 
innovation was useful and through the publication of an additional article 
written for a broader audience with learning disabilities, at least two 
different sorts of peer community were influenced via peer and third 
sector networks. 
First, professional networking between the author of the publication and 
colleagues within his own workplace influenced pharmacists and 
paediatric staff.  Second, peer‐peer influence engaged paediatric 
services for patients with learning disabilities in a London hospital where 
MMP was extensively used. A poster about that service's use of the 
innovation was shown at a conference attended by peers in 2016. 
Third, through personal experience of a third sector advocacy and support 
network, the author of the papers referred to above communicated 
effectively with the wider learning disability community. This was, 
demonstrated by a nationally recognized organization which endorsed the 
use of the innovation and made it available via their website to its users. 
 
Reproduced with permission: 1. XXXX, and 2. The publisher: 
© 2016 John Wiley & Sons Ltd 
 
This vignette, the sentiments of which could be applied to many of the key publications in 
this thesis, epitomises the author’s core career philosophy, which has been to identify 
and publish opportunities for improving patient care, the education that underpins it, 
professional development for those who deliver it, and to do this in a way that is 
supportive, encouraging, compassionate and empathic.   
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Curriculum Vitae: 
Barry Jubraj, BPharm (Hons), MSc, DipHe, PGCEA, MCPP, FHEA, FFRPS, FRPharmS 
 
1. Personal details 
 Date of birth: 19th December 1967 
 Contact details: 78 Norbiton Avenue, Kingston-Upon-Thames, Surrey, KT1 3QP 
 Home telephone: 020 3673 2881.  Mobile: 07968 786052 
 Next of kin: Rosemary Jubraj (wife) 
 
2. Career summary 
In a career spanning 29 years, I am uniquely trained as a pharmacist, teacher and counsellor.  I am 
a highly experienced clinician and clinical educator who is well-respected and recognised as a 
leader in pharmacy education. My achievements have been recognised and rewarded through 
Fellowship of the Royal Pharmaceutical Society, the RPS Faculty and the Higher Education 
Academy. I have won awards and published widely in the fields of pharmacy practice, education 
and practice-based research. 
 
3. Clinical experience 
 Mastery (Consultant) level expert professional practice (RPS Advanced Pharmacy Framework, 
APF) in elderly care rehabilitation pharmacy and patient consultation 
 Specialist clinical experience: Adult intensive care/renal pharmacy 
 General clinical experience: General medicine, general surgery, day surgery, care of the 
elderly, HIV/GUM, liver disease 
 Clinical services manager, leading a team of ward pharmacists 
 
4. Educational experience 
 Mastery level in cluster 5 (education) of the APF 
 Undergraduate pharmacy education as a lecturer, tutor, facilitator and MPharm programme 
director 
 Postgraduate pharmacy education: co-developer of foundation training, tutor accreditation, 
tutor development and MSc teaching 
 A highly experienced mentor, facilitator and provider of pastoral care 
 Wide ranging experience of educating other health professionals at undergraduate and 
postgraduate levels 
 Leading an education and training pharmacy team 
 
5. Research and publication experience (see below for publication list) 
 Mastery level in cluster 6 (research) of the APF 
 Adherence and health beliefs 
 Medication review, medicines optimisation and ‘deprescribing’ 
 Educational supervision 
 Work-based learning and workplace-based assessment in the clinical setting 
 Consultation skills and empathy 
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6. My ‘firsts’ 
 
 Co-developer of the first known competency framework for pharmacy supervisors 
 First to co-author a definition of ‘self-directed learning’ in the pharmacy context 
 One of the first wave of RPS Faculty Fellows 
 Co-developer of the first RPS-accredited accreditation/recognition scheme for pharmacy 
tutors 
 First to articulate and publish a strategy to educate undergraduate and foundation doctors 
and pharmacists about medication review and de-prescribing 
 First to co-edit an entire journal themed issue on deprescribing 
 
7. Professional Qualifications  
 
1990: B Pharm (Hons), King’s College, University of London 
1992: Certificate in Pharmacy Practice, School of Pharmacy, University of London 
1994: MSc Clinical Pharmacy, School of Pharmacy, University of London 
1995: Teaching & Learning Module, University of London 
1997: City & Guilds Further & Adult Education Teachers’ Certificate, City Literary Institute 
1997: City & Guilds NVQ D32 Award, City Literary Institute 
1998: Postgraduate Certificate in Education (Adults), University of Greenwich 
2008: Dip HE in Theology & Counselling, London School of Theology, Middlesex University 
 
8. Registration, accreditations, memberships, and fellowships  
 
1991: Member of the Royal Pharmaceutical Society of Great Britain (Membership no: 85271) 
1994: Member of the Renal Pharmacy Group (until 2007) 
1997: Accreditation by the Staff and Educational Development Association  
2000: Member by Practice, College of Pharmacy Practice 
2000: Fellow of the Higher Education Academy 
2001: Honorary Lecturer, King’s College London 
2010: Member of the Royal Pharmaceutical Society (post RPSGB) 
2010: Registered with the General Pharmaceutical Council (Registration no: 2038921 – post-
RPSGB) 
2012: Honorary Associate Professor, School of Pharmacy, University of London 
2012: Fellowship of the Royal Pharmaceutical Society 
2013: Fellow of the Faculty of the Royal Pharmaceutical Society 
2015: Visiting Senior Lecturer, King’s College London 
2016: Visiting Senior Lecturer, University College London 
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2018: Visiting Fellow, Kingston University 
 
9. Awards and shortlistings 
 
2012: Inaugural winner of Chelsea & Westminster Hospital ‘Educator/Mentor of the year’ award  
2013: Royal Pharmaceutical Society ‘Excellence in Education’ Award winner 
2013: Chelsea & Westminster Hospital Council of Governors Quality Award winner 
2014: Developing a medication STOPIT tool, with a focus on the elderly rehabilitation setting  
           (Jubraj B, Bovill I, Abdul-Saheb S, Kuo S, Marvin V. Patient Safety and Care Awards:  
           Preventing Avoidable Harm. Finalist www.patientsafetyandcareawards.com) 
 
10. Current Posts  
 
From December 2018: 
 
1. Associate Director, Medicines Use & Safety Division, Specialist Pharmacy Services 
(www.sps.nhs.uk) (0.4 WTE) 
Key responsibilities include: 
 Responsible for network events (face-to-face and webinars), particularly related to the 
WHO medication without harm challenge, see: 
https://www.who.int/patientsafety/medication-safety/en/  
 Strategic vision and leadership to deliver service improvements, wide dissemination of 
innovation, implementation support, and the development of indicators which support 
the monitoring of performance improvement   
 Facilitate and encourage collaboration on medicines optimisation and pharmacy services 
across England. 
 
2. Clinical Senior Lecturer (Medicines Optimisation), King’s College London (0.3WTE) until end 
July 2019 
Key responsibilities: 
 Professional lead for MPharm (Master of Pharmacy) year 1 
 Module lead for ‘Principles of Clinical Care’ module 
 Undergraduate and postgraduate teaching, including MPharm and independent 
prescribing 
 Assessment for all programmes 
 Personal tutor 
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11. Previous posts 
 
November 2015 – December 2018: Clinical Senior Lecturer in Medicines Optimisation, King’s 
College London (0.8WTE), and Honorary Pharmacist for Medicines Optimisation, NIHR CLAHRC 
NW London 
Key responsibilities (King’s College London) – as above as well as the following: 
 MPharm programme director 
 Marketing and outreach 
 Admissions tutor 
 Acting senior tutor 
 Module lead for MPharm 2 nervous system module 
 
2003-2015: Chelsea & Westminster Hospital NHS Foundation Trust, with secondments: 
Primary employer: Chelsea & Westminster Hospital NHS Foundation Trust  
 
Core role Secondment 1 Secondment 2 
 
Lead Pharmacist for 
Academic studies  
(0.2 WTE) 
 
Lead for Work-based Learning support, 
UCL School of Pharmacy 
(0.4WTE) 
 
NIHR CLAHRC for NW 
London Pharmacist for 
Education and Research 
(0.2WTE) 
 
 Educational 
Programme director 
(diploma)  
 Learning disability 
group 
 Weekly consultant 
ward round 
(supporting 
discharge) 
 Provision of training and other 
resources to develop supervisors 
and educational infrastructure 
associated with postgraduate 
foundation training 
 Development of accreditation of 
postgraduate pharmacy supervisors 
 Associate Director for a number of 
hospital Training Centres 
 Programme contribution: 
assessment, support of hospitals, 
curriculum and assessment design 
 Publication of good practice relating 
to work-based learning (WBL), 
workplace-based assessment 
(WPBA) and the development of 
WBL supervisors 
 External representation and 
publication  
 
 Focus on medicines 
optimisation 
 Research into 
stopping potentially 
inappropriate 
medicines in elderly 
patients 
 Development of 
educational strategies 
around medication 
review and de-
prescribing for novice 
practitioners 
 Engaging universities, 
NHS bodies and Royal 
Colleges around 
education in 
medication review 
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2001-2003: Principal Pharmacist for Education & Training, Chelsea & Westminster Hospital 
(0.8WTE): 
 Clinical commitment, elderly care 
 Management of Certificate/Diploma/International MSc  courses 
 Co-ordination of medicines-related training to Trust staff, including doctors, nurses, allied 
health professionals and patients 
 Management of rotational pharmacist training scheme 
 CPD facilitation  
 
1998-2001: Teacher/Practitioner, King’s College London/Chelsea & Westminster Hospital 
Key responsibilities – King’s College (0.5 WTE):  
 Undergraduate module leadership  
 Lecturing and formative/summative assessment provision 
 Personal tutoring 
 Clinical group placement tutor 
 Postgraduate teaching at diploma/MSc level 
 
Key responsibilities – Chelsea & Westminster Hospital (0.5 WTE):  
 Certificate/Diploma course management 
 Rotational pharmacist training scheme innovation and management 
 Pre-registration tutor and manager 
 Strategic planning of educational activities  
 
1994-1998: Deputy Clinical Services Manager/Clinical Specialist (Grade C), St Mary’s Hospital 
1991-1993: Basic Grade Pharmacist (rotational), St Mary’s Hospital 
1990-1991: Pre-registration Graduate, St Mary’s Hospital 
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12. National profile, collaborations, achievements and advocacy 
 
Organisation 
 
Role/s Date/s 
Royal 
Pharmaceutical 
Society (RPS): 
 
 Advocacy and supporting the development of 
assessment methodology for RPS Faculty 
 Faculty Assessor 
 Faculty Champion 
 Foundation Champion 
 Advocacy, publicity and publication to develop 
RPS mentoring 
 Key role in development of national RPS 
Foundation Training programme 
 See 
http://blog.rpharms.com/blog/2015/02/02/
rps-fellowship-valuable-career-milestone/ 
 
2010 onwards 
School of 
Pharmacy/ 
University College 
London 
 Hospital supervision of undergraduate 
pharmacy students 
 Contribution to the pharmacy degree curriculum 
 Teaching on home and international MSc 
programmes 
2013 onwards 
 
2014 onwards 
2000 onwards 
Centre for 
Pharmacy 
Postgraduate 
Education (CPPE) 
 Review of Consultation Skills package 
 Contribution to Learning disability package 
2014-2015 
2016-17 
Department of 
Health/Modernising 
Pharmacy Careers  
 
 Consultation skills work stream and training 
package development 
 
2013 onwards 
Kent, Surrey, Sussex 
Deanery Pharmacy  
 
 Co-development of the first pharmacy 
competency framework for supervisors 
 Mapping competencies to the Advanced Level 
Framework 
 Redesign of terminology for pharmacy tutors 
 
2010-2013 
Peer-reviewed 
journals 
 Peer reviewer for research papers and other 
publications 
2011 onwards 
National Clinical 
Assessment Service 
(2011) 
 
 Hospital Pharmacy working Group and 
development of pharmacy assessment strategy  
 
2011 
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13. Outside pharmacy 
 
 I am married to Rosemary and together we care for our disabled son Alexander: 
o We love swimming, fast rides at theme parks and spending time lounging on the 
bean bag together 
o I have worked hard to learn Makaton sign language to communicate with 
Alexander 
o I have used my parent and carer experience professionally as a clinician and a 
teacher 
 Alexander attends a special school and I have been a trustee of the school charity, the 
‘Friends of Dysart School’ 
 I continue to use my counselling skills training in pastoral care in a church setting 
 I co-lead a ministry to families with special needs at our church 
 I watch sport when I can particularly, rugby, cricket and football 
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Appendix 2: Full publication list updated to June 2019 
 
With key publications for this thesis discussed in chapters 2-5 
highlighted 
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Journal articles 
1. Jubraj B., Marvin V., Ward E. Developing a doctor–pharmacist consensus on medicine-
related problems in older adults. Clinical Pharmacist.  April 2019  Volume 11 No 4: 99-
100 
 
2. Marvin V., Jubraj B. Polypharmacy and Older People in the Hospital Environment. 
Public Policy & Aging Report. Volume 28, Issue 4, 8 November 2018, 150–155, 
https://doi.org/10.1093/ppar/pry029 
 
 
3. Waghorn J., Jubraj B. Undergraduate Education for Medicines Optimisation Principle 
1: The ‘Socialisation Internship’ and views from Mosaic Clubhouse, one of the partner 
organisations. Journal of Medicines Optimisation. September 2018 Volume 4 No 2: 
54-77 
 
 
4. Marvin V., Ward E., Jubraj B., Bower M., Bovill I. Improving Pharmacists’ Targeting of 
Patients for Medication Review and Deprescription. Pharmacy. April 2018: 6: 32 
doi:10.3390/pharmacy6020032 
 
 
5. Barber S., Jubraj B. Medicines Optimisation and Patient Safety NIHR CLAHRC Learning 
Event, held 16th January 2017. Journal of Medicines Optimisation. June 2017; Volume 
3 No 2: 30-33 
 
 
6. Jubraj B. Going to the Chemist. Down’s Syndrome Association Journal Spring/Summer 
2017; 135: 26 
 
 
7. Barnett N., Jubraj B. A themed journal issue on ‘Deprescribing’. European Journal of 
Hospital Pharmacy. January 2017; Volume 24 No 1: 1-2 
 
 
8. Poots AJ., Jubraj B., Barnett N. Education around deprescribing: ‘spread and embed’ 
the story so far. European Journal of Hospital Pharmacy January 2017 Volume 24 No 
1: 7-9 
 
 
9. Marvin V., Ward E., Poots AJ., Heard K., Rajagopalan A., Jubraj B. Deprescribing 
medicines in the acute setting to reduce the risk of falls.  European Journal of Hospital 
Pharmacy 2017; 24:10-15. Doi:10.1136/ejhpharm-2016-001003. 
 
 
10. Jubraj B., Barnett N., Grimes L., Varia S., Chater A., Auyeung V. Why we should 
understand the patient experience? Clinical empathy and Medicines Optimisation.  
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International Journal of Pharmacy Practice 2016 Volume 24 Issue 5: 367-370.   Doi: 
10.1111/ijpp.12268 
 
 
11. Picton C., Jubraj B. Royal Pharmaceutical Society Principles of Medicines Optimisation 
– Interview with Catherine Picton. Journal of Medicines Optimisation June 2016 
Volume 2 No 2: 25-27 
 
 
12. Jubraj B. A carer’s perspective on medicines optimisation.  Journal of Medicines 
Optimisation March 2016 Volume 2 No 1: 3-4 
 
13. Jubraj B., Deakin A., Mills S., Grimes L.. Pharmacy Consultations with people with 
learning disabilities. The Pharmaceutical Journal. Vol 296, No 7885, online | DOI: 
10.1211/PJ.2016.20200330 
 
14. Jubraj B., Patel S., Naseem I., Copp S., Karagkounis D. The Acute Care Assessment 
Tool: ’Pharmacy ACAT’. The Clinical Teacher 2016; 13:1-5 
 
 
15. Jubraj B., Barber S., Ward E., Husson F., Turley M.. Patient perspectives on the use of 
‘My Medication Passport’. Geriatric Medicine. August 2016; Volume 12 no 8: 25-28 
 
 
16. Jubraj B., Thakkar K., My Medication Passport. Down’s Syndrome Association Journal 
Autumn/Winter 2015; 132: 23 
 
 
17. Jubraj B., Marvin V., Poots AJ., Patel S., Bovill I., Barnett N., Issen L., Bell D. A pilot 
survey of junior doctors’ attitudes and awareness around medication review: time to 
change our educational approach? European Journal of Hospital Pharmacy 22: 243-
248. Doi:10.1136/ejhpharm-2015-000664 
 
 
18. Duraisingham S., Jubraj B., Marvin V., Kuo S., Bovill I., Poots AJ. Stopping 
Inappropriate Medicines in the Outpatient Setting. Geriatric Medicine 2015; May: 37-
41 
 
 
19. Jubraj B., Blair M. Use of a medication passport in a disabled child seen across many 
care settings. BMJ Case Reports 2015. Doi:10.1136/bcr-2014-208033 
 
 
20. Jubraj B. ‘Dragon’s Den’: an entrepreneurial method to develop innovation among 
junior pharmacists. European Journal of Hospital Pharmacy 2015; 22: 64-65. 
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21. Duraisingham S., Jubraj B. Time to stop. Clinical Pharmacist 2014; 6: 162 
 
 
22. Saheb MA., Jubraj B., Bovill I., Kuo S., Marvin V, Intermediate Care. [An optimal 
setting for review of inappropriate medication in elderly patients]. Geriatric Medicine 
February 2014. 13-17 
 
 
23. Barnett N., Jubraj B. How peer-mentoring helps pharmacists prepare for RPS Faculty 
admission The Pharmaceutical Journal 2013; 291: 500 
 
 
24. Barnett N., Varia S., Jubraj B. Adherence: are you asking the right questions and 
taking the best approach? The Pharmaceutical Journal 2013; 291: 153 
 
 
25. Fleming G., Jubraj B., Wright E., Pettit M., Jones S.C. Mapping education 
competencies to demonstrate advanced level practice. The Pharmaceutical Journal 
2013; 290: 648 
 
 
26. Davies JG., Ciantar J., Jubraj B., Bates I.P. Use of a Multisource Feedback Tool to 
Develop Pharmacists in a Postgraduate Training Program. American Journal of 
Pharmaceutical Education 2013; 77 Issue 3, Article 52. 
 
 
27. Jones S.C, Fleming G., Hay D., Ibrahim M., Pettit M., Wright E., Jubraj B. Development 
and piloting of a competency framework for pharmacy educational and practice 
supervisors. Pharmacy Education, 2012; 12 (1): 14 – 19 
 
 
28. Jones S.C., Jubraj B. Ways to avoid an identity crisis when you take on a teaching role. 
Clinical Pharmacist 2012; 4: 30–1. 
 
 
29. Jubraj B. Back to basics – medicines expertise is vital but is not always complicated. 
The Pharmaceutical Journal 2011; 287: 548  
 
 
30. Jubraj B., Barnett N. Keys to peer mentoring: similar experience, trust, honesty and a 
willingness to change. The Pharmaceutical Journal 2011; 287: 500-501  
 
 
31. Jubraj B., Innes I., Kavanagh R. Dispel the myths and see the benefits of workplace-
based assessments. The Pharmaceutical Journal 2011; 287: 467-468  
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32. Morris K., Safdar A., Jones S.C., Jubraj B. Make reflection part of your daily practice. 
Clinical Pharmacist 2010; 2: 397-399  
 
 
33. Chung C., Jubraj B. Training junior doctors to prepare and administer injectable 
drugs. British Journal of Clinical Pharmacy 2010; 2 (10): 309-311  
 
 
34. Jubraj B., Henry D., Hardy I., McCall-Peat N. Training doctors to use electronic 
prescribing information sources. British Journal of Clinical Pharmacy 2010; 2 (1): 21-
22  
 
 
35. Jubraj B., Fleming G., Wright E., Jones S., Cook S., Morris K. Say goodbye to clinical 
tutors: standardising the terminology in education. The Pharmaceutical Journal 2010; 
285: 191-192  
 
 
36. Jones S., Safdar A., Jubraj B. Educational Infrastructure: teach a man to fish and you 
feed him for life. The Pharmaceutical Journal 2010; 284: 45  
 
 
37. Jubraj B. Developing a culture of self-directed workplace learning in pharmacy. The 
Pharmaceutical Journal 2009; 283:47–8.  
 
 
38. Bruno A., Jones S.C., Jubraj B. Continuing Professional Development (CPD) in 
Pharmacy Practice: Is it really about learning to learn or legislating learning? 
International Pharmacy Journal 2009; 25 (2): 20-25  
 
 
39. Jubraj B., Karemo K., Morris K., Pullinger W., Safdar A., Hatton K. Make the most of 
the time you spend tutoring diploma students. Clinical Pharmacist 2009; 1: 141-143  
 
 
40. Jubraj B. A new diploma. Tomorrow’s Pharmacist 2008; 20  
 
 
41. Safdar A., Pullinger W., Karemo K., Jubraj B. Workforce development – rising to 
current challenges. Hospital Pharmacist 2007; 14: 267 
 
 
 
42. Jubraj B. Patient counselling and medication adherence: What can we learn from 
mainstream counselling. Pharmacy in Practice 2007; 17 (1): 8  
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43. Tisley T., Jubraj B. Evolution of Rotational Pharmacy Technician Training at Chelsea & 
Westminster following the implementation of Agenda for Change and the Knowledge 
& Skills Framework. Pharmacy Technician Journal Winter edition. 2006 
 
 
44. Jubraj B., Karemo K., Pullinger W., Safdar A. Have you considered a career as an 
education and training pharmacist? Hospital Pharmacist 2006; 13: 403  
 
 
45. Jubraj B. Assessing Junior Doctors – How Pharmacists can be Prepared. Hospital 
Pharmacist 2006;13: 291  
 
 
46. Hewitt K, Jubraj B, Cox D, Ankrah S. KSF implementation – producing outlines for 
pharmacy staff. Hospital Pharmacist 2006; 13:169  
 
 
47. Jubraj B., Chantler., S., Mycroft, J., Wilkins, K. Do pre-registration trainees benefit 
from cross-sector training? Pharmaceutical Journal 2002; 269: 682  
 
 
48. Horne R., Sumner S., Jubraj B., Weinman J., Frost S. Haemodialysis patients’ beliefs 
about treatment: implications for adherence to medication and fluid-diet restrictions. 
International Journal of Pharmacy Practice 2001; 9:169  
 
 
49. Farrington P., Buddell K., Jubraj B. Recruitment and retention initiatives and 
competence-based training for junior pharmacists. The Pharmaceutical Journal 2001; 
267: 55  
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Books/e-books (Pharmacy and Counselling related)/Journal editor activity 
1. Barnett N., Jubraj B. Themed guest editors (2017) Themed issue on ‘Deprescribing’. 
European Journal of Hospital Pharmacy  https://ejhp.bmj.com/content/24/1 (accessed 
7.6.19) 
 
2. Kuo S., Jubraj B, Bovill I., Marvin V. Case Studies of innovation in Medicines Optimisation 
during Admission, Discharge and Medication Review, at the Chelsea & Westminster 
Hospital. 2eqipp  Chichester: Kingsham Press December 2014. ISBN : 1-904235-978 
 
 
3. Jones S.C., Jubraj B. Reflecting on teaching and learning. In Carter S., Editor. Facilitating 
Learning in Healthcare. London: Pharmaceutical Press, 2012  
 
 
4. Jubraj, R., Jubraj, B. Infertility – The Silent and Unseen Issue. Horsham: RoperPenberthy, 
2007 
 
 
 
Conference abstracts/posters; and learning event/webinar presentations 
1. Olayide A., Davies JG., Jubraj B.  The qualities of an effective work-based pharmacist tutor  
Abstract, poster and oral presentation at the Pharmacy Education Symposium ‘Ancora 
Imparo – I am still learning’.  Monash University, Prato July 2019 
 
2. Crook J., Patel D., Marvin V., Jubraj B., Abbadi I., Ward, E. An evaluation of the views of 
adolescent patients with a learning disability and their carers on a Medicines Information 
Leaflet. Poster presentation at the 24th Neonatal & Paediatric Pharmacists’ Group (NPPG) 
Annual Professional Conference and Exhibition, Bristol November 2019 (see 
https://adc.bmj.com/content/103/2/e1.35; (accessed 14.7.19) [NB, author omitted from 
co-authorship in error] 
 
3. Lumb R., Jubraj B., Barber S. The use of ‘My Medication Passport’ in Special Schools – A 
proof of principle study. Poster and oral assessment at the MPharm 4 poster day, King’s 
College London March 2019 
 
 
4. Williams H., Jubraj B., Shaw M., Anderson E. Learning Disability: User perspectives and the 
CPPE learning disabilities training package. Poster presentation at the 7th Clinical 
Pharmacy Congress, London April 2018 
 
 
5. Waghorn J., Jubraj B. Socialisation Internship: A Novel Placement for Pharmacy Students. 
Abstract, poster and oral presentation at the Pharmacy Education Symposium ‘Pharmacy 
education and collaboration for global practice’.  Monash University, Prato July 2017 
 
 
Page 131
  
6. Jubraj B., Adams D. Issues for patients with a learning disability and their carers – top tips 
on how pharmacy teams from all sectors can provide medicines optimisation support.  
NHS Specialist Pharmacy Services Medicines Use & Safety Network webinar July 2017 
 
 
7. Jubraj B. A carer’s perspective on medicines optimisation. NHS Specialist Pharmacy 
Services Medicines Use & Safety Network webinar March 2017  
 
 
8. Patel D., Ward E., Jubraj B., Marvin V., Smith E., Abbadi I. An evaluation of the views of 
adolescent patients with a learning disability and their carers on a Medicines Information 
Leaflet and the My Medication Passport. Abstract and Poster presentation at the NWL 
Research Symposium on 21 Sept 2016. Also presented at the CLAHRC Medicines 
Optimisation and Patient Safety learning event Jan 2017 
 
9. Szymanski T., Marvin V., Ward E., Jubraj B. Deprescribing following medication review in 
acute care: the ReMAC project. Abstract and presentation at the Pharmaceutical Care 
Network Europe, Hillerød, Denmark February 2016. Conference abstract also published in 
International Journal of Clinical Pharmacy p17. DOI 10.1007/s11096-016-0283-8. Also 
presented at the CLAHRC Medicines Optimisation and Patient Safety learning event 
January 2017 
 
 
10. Jubraj B. Supporting patients with a learning disability and their carers. NHS Specialist 
Pharmacy Services (SE England) learning event presentation September 2016 
 
 
11. Marvin V., Dinesen L., Ward E., Jubraj B., Gilbert M., Poots AJ. Frailty and polypharmacy. 
(Abstract and Poster) International Forum on Quality and Safety in Healthcare, 
Gothenburg, Sweden April 2016 
 
 
12. Marvin V., Ward E., Jubraj B., Rajagopalan A., Poots AJ. Reducing falls risk in elderly falls 
patients through pharmacist medicines review.  Abstract and poster presented at the 
NWL Research Symposium for Health Professions,  London November 2015 
 
 
13. Marvin V., Patel S., Kuo S., Ward E., Jubraj B., Reed J. Evaluating the accuracy of 
medicines reconciliation in acute admissions. (Poster presentation) International Forum 
on Quality and Safety in Healthcare. London, April 2015 and at the NWL Research 
Symposium for Health Professions, London November 2015 
 
 
14. Jubraj B., Marvin V. (2015) Influencing undergraduate education on medication review 
and deprescribing NIHR CLAHRC NW London Summer Collaborative Learning Event 
presentation. London 17th July 2015 
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15. Sathyamoorthy G., Jubraj B. NIHR CLAHRC NWL – Introduction to medicines optimisation 
project in the ‘frailty’ area of work Imperial College Health Partners Medicines 
Optimisation Roadshow Plenary session 5. London 3rd March 2015 
 
 
16. Patel S., Jubraj B., Marvin V., Bovill I., Umer M., Trehane S.J., Poots A.J. A survey 
exploring junior doctors attitudes to medication review. (Poster presentation) 26th Annual 
Scientific Meeting, PRIMM (Prescribing and Research In Medicines Management) “One 
for All and All for One – Different Perspectives in Medicines Optimisation”: London, 
January 2015. Also published in Pharmacoepidemiology and Drug Safety Prescribing and 
Research in Medicines Management (UK & Ireland) Published Online First: 15/6/15 doi: 
10.1002/pds.3812 
 
 
17. Jubraj B. Developing a sustainable workplace-based learning infrastructure.  Royal 
Pharmaceutical Society conference: Preparing pharmacy for the challenges of workplace-
based learning. London May 2011 
 
 
18. Barnett N., Jubraj B. Peer mentoring live play. Royal Pharmaceutical Society Mentoring 
Training Event. London April 2011 
 
 
19. Jubraj B. Clinical pharmacy and the new practice models/The heart of the system: new 
learning environments and workforce development Tempus PQPharm Networking event 
for Serbian Pharmacists. London November 2011 
 
Professional blogs 
Barnett N., Grimes L.,  Jubraj B. (2015) Making our Patients Feel Cared for 
http://www.pharmaceutical-journal.com/opinion/blogs/making-our-patients-feel-cared-
for/20067874.blog  
 
Jubraj B., Patel S., King E. Pharmacists of the future need to prompt doctors to review and 
stop unnecessary medicines 2014. http://www.pharmaceutical-
journal.com/opinion/blogs/pharmacists-of-the-future-need-to-prompt-doctors-to-review-
and-stop-unnecessary-medicines/20066189.blog 
 
 
Other media 
1. Jubraj B. Promotional video for the Centre for Pharmacy Postgraduate Education (CPPE) 
Learning disabilities distance learning programme. March 2017 (and subsequent 
Facebook panel event April 2017).  https://vimeo.com/208110072 (accessed 7.6.19) 
 
2. Barnett N., Jubraj B. Deprescribing: a special issue from the European Journal of Hospital 
Pharmacy.   Podcast March 17: https://soundcloud.com/bmjpodcasts/deprescribing-a-
special-issue-from-ejhp (accessed 7.6.19) 
 
Page 133
  
 
3. Jubraj B., Adams D., Foreword for the Centre for Pharmacy Postgraduate Education 
(CPPE) Learning disabilities distance learning programme. February 2017 
 
 
4. Jubraj B. Speaking on various aspects of medication adherence. Medication Adherence 
MOOC.  King’s College London January 2017.  https://app.frame.io/reviews/4df0208d-d90a-
4341-8c23-403b265f62af/4e53a7b6-ce31-40be-b619-ed4071f993cf (accessed 14.6.19) 
 
 
5. Jubraj B., Crilly P. Support for Carers Interview.  Kingston University School of Pharmacy 
November 2016.  https://vimeo.com/192330461 (accessed 7.6.19) 
 
 
6. Jubraj B. The bottom up approach to education around medication review and 
deprescribing. NIHR CLAHRC NWL Collaborative Learning Event July 2015  
https://www.youtube.com/watch?v=QqO1VooHlHY (accessed 7.6.19) 
 
 
7. Jubraj B. From counselling to consulting. Video tutorial for the national Consultation Skills 
for Pharmacy Practice pathway 2014 
http://www.consultationskillsforpharmacy.com/share3.asp?P=7# (accessed 7.6.19) 
 
 
 
8. Barnett N., Jubraj B. Two videos for the Centre for Pharmacy Postgraduate Education 
(CPPE) Consultation Skills initiative 2014. ‘Making a difference in a short consultation’.   
https://vimeo.com/150664602 and ‘Making a difference in a short consultation; the 
experts debrief’. https://vimeo.com/150664603 (both accessed 7.6.19) 
 
 
Articles in preparation or submitted for publication  
1. Jubraj B., Grant D., Reddy B., Barnett N., Stevenson J. Education around Medication 
Review and Deprescribing: Results of a pilot scoping exercise. Submitted June 2019 to 
https://www.mdpi.com/journal/pharmacy  
 
2. Poots A., Jubraj B., Ward E., Wycoco A., Barnett N. Education around medication review 
and deprescribing: a survey of medical and pharmacy students’ perspectives. Resubmitted 
June 2019 following peer review to Therapeutic Advances in Drug Safety 
https://journals.sagepub.com/home/taw at June 2019 
 
 
3. Barber S., Jubraj B. Pharmacy staff use of My Medication Passport to support 
conversations with patients in medication review settings. In preparation for submission 
to The Pharmaceutical Journal (anticipated August 2019) 
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Appendix 3: Co-authored journal article verifications 
THE AUTHORSHOP STATEMENTS HAVE BEEN REMOVED FROM 
THIS ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY 
TEXT REMAINS BELOW: 
 
This appendix contains verification emails from colleagues who co-authored journal 
articles or other key publications with the author of this PhD thesis. 
Listed publications are followed by a short email trail that includes: 
 The author’s (Barry Jubraj): 
o Request for verification 
o Statement of their contribution to each article 
 
 The response from one co-author (who is representative if there is more than one) 
Please note: 
 Each reference is numbered according to the order in appendix 2, the full 
publication list. 
 
 Articles are not listed in this appendix if the author (Barry Jubraj) is the sole author 
 
 Only journal articles or other key publications are included in this table, since 
these are the largest contributor to this PhD by publication.  Videos, abstracts and 
conferences are not included 
 
 Where the author and a co-author have collaborated on more than one article: 
 
o These articles are grouped together in the table 
o The email trail contains the author’s statement of their contribution to 
each article 
 
 Where there are multiple authors on an article, only one co-author has been 
approached to verify the author’s contribution.  This will typically be the main co-
author 
 
 Key publications for this thesis are highlighted 
 
 There are a very small number of unverified articles, because the author has been 
unable to contact the co-author.  These are clearly marked and the author is 
satisfied that these publications make little if any direct impact on this PhD thesis
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Appendix 4: Fellowship of the Faculty of the Royal Pharmaceutical Society 
2013 - Summary and personal development plan 
 
Note: 
This personal development plan is based on mapping the author’s achievements to the 
Royal Pharmaceutical Society’s Advanced Pharmacy Framework, which can be found 
here: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Fram
eworks/RPS%20Advanced%20Pharmacy%20Framework.pdf (accessed 9.6.19) 
 
Reproduced with permission: 
 
The Royal Pharmaceutical Society 
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Feedback Summary  
 
The feedback summary (below) is based on the outcomes of the assessment of your 
Advanced Practice Portfolio and evidence against the Advanced Practice Framework. The 
comments are from the two Faculty assessors assigned to you and intended to help you to 
reflect on your practice and support your ongoing professional development and create an 
action plan.   
  
The feedback is broken down into the six clusters  
  
 Expert Professional Practice EPP  
 Collaborative Working Relationships CWR  
 Leadership L  
 Management M  
 Education, Training & Development ET&D  
 Research & Evaluation R&E. 
 
Cluster 
Competencies Cluster 
outcome Stage I Stage II Mastery   
Expert Professional Practice (EPP) 0 0 4 out of 4 3 
Collaborative Working 
Relationships (CWR) 
0 0 2 out of 2 3 
Leadership (L) 0 0 5 out of 6 3 
Management (M) 0 3 6 out of 9 3 
Education, Training & 
Development (ET&D) 
0 0 6 out of 6 3 
Research & Evaluation (R&E) 0 1 6 out of 7 3 
      
 
Assessment 
outcome 
(algorithm) 
3 
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Appendix 5: Kingston University PhD by Publication Prima Facie Statement 
 
 
Minus: 
 
Appendix 1: 
Curriculum vitae and publication list (updated for this thesis – see appendix 2) 
 
Appendix 2:  
Publication themes diagram (see introduction of this thesis where it is reproduced) 
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Prima facie stage of application for PhD by prior publication/portfolio 
Barry Jubraj - November 2017 
 
 
1. The name of the proposed supervisor and the School/research area within which the 
PhD is to be located:  
 
 
 
2. A full CV including all publications and research outputs. See appendix 1 
 
 
3. A brief summary of the relevant publications and/or portfolio materials to be included 
in the final PhD submission See appendix 2 
 
 
4. A statement of intent/outline of the introductory section (approximately 500-700 
words). This should include the proposed title of the work and seek to contextualise 
the selected publications, demonstrate their coherence, and identify the contribution 
to the advancement of knowledge in the chosen area of research. See appendix 3 
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Personal Statement 
Summary 
My application for PhD by publication is a culmination of nearly three decades of service 
to the NHS and clinical education.  As I have developed my expertise, my publication 
profile reflects the contribution that I have made on a local, national and international 
level. 
Upon qualifying as a pharmacist in 1991, I gained a thorough grounding in NHS hospital 
pharmacy and working as a mid-grade pharmacist in the first 7 years of my career.  Over 
the next ten years, I trained as a teacher and a counsellor; and subsequently combined 
these three areas in order to practice pharmacy, act as a role model, and educate 
students and practitioners, to a standard that has been recognised through professional 
fellowships and awards.  My current roles as a Clinical Senior Lecturer and Honorary 
Pharmacist for ‘Medicines Optimisation’ give me the opportunity to utilise my training 
and experience to focus on clinical education, research supervision and quality 
improvement in the NHS. 
 
Early publications (2001 – 2008):  
My research for an MSc in Clinical Pharmacy in 1994 was around health beliefs and 
medication adherence. My findings demonstrated that haemodialysis patients 
intentionally do not adhere to treatment recommendations.  Our work was published in 
2001 and to this day is still cited in the literature.  At the time of publication, I was 
working as a pharmacy ‘teacher-practitioner’ for the Chelsea & Westminster Hospital and 
King’s College London.  At that time, I decided to publish our hospital’s work on retaining 
and developing resident pharmacists, which led to the realisation that I enjoy writing and 
publishing.  This became a powerful driver as I sought opportunities to complete key 
projects with a publication.   Early examples included my co-creation of a pre-registration 
pharmacy programme with placements both in hospital and the community.  I also 
developed a methodology of writing job outlines for a health service framework that was 
published and used by a number of colleagues around London. 
 
Workplace education and assessment publications (2009 onwards) 
A secondment to the UCL School of Pharmacy gave me the opportunity to contribute to 
the development of the first competency-based post-registration foundation programme 
for pharmacists in Great Britain.  Our approach was debated nationally because of 
philosophical views around the merit of competency-based training, and other drivers 
that included the need to develop the pharmacy workforce cost-effectively.  This inspired 
me to regularly publish, speak publically and develop other media as I was expected to 
comment and provide answers to some of the challenges of developing the workforce in 
times of change, particularly given the impact of economic austerity.  I led the 
development of workplace supervisor training and developed substantial expertise in 
workplace-based assessment, leading to educational infrastructures that are still in place 
across London and south-east England.  With colleagues I published the first known 
pharmacy-specific definition of self-directed learning. This was an important influence on 
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the way that foundation trainees and their supervisors perceived workplace education in 
terms of their roles and responsibilities for clinical development.  I also co-developed a 
competency framework for pharmacy workplace supervisors which was adopted for use 
by the Kent, Surrey and Sussex pharmacy deanery for its initial training strategy for 
supervisors in that locality.  This led directly to published work on redefining the 
terminology around pharmacy workplace supervisors. 
 
Quality improvement publications (2014 onwards) 
 
I was seconded from my hospital role in 2014 to the National Institute for Health 
Research (NIHR) Collaboration for Leadership in Applied Health Research and Care 
(CLAHRC) for northwest London. NHS drivers such as delivering ‘more for less’, translating 
research into care more rapidly, and delivering quality improvement more systematically, 
gave me opportunities to critically evaluate pharmacy services and pilot improvements, 
all of which I have published and presented.  Examples include piloting a ‘Medication 
Passport’ in my disabled son, and demonstrating the utility of a medication review tool in 
novel settings such as elderly care rehabilitation and outpatients.  My work has been 
recognised through awards and shortlisting, for example being a finalist at the National 
Patient Safety Awards for a case study on ‘deprescribing’.   
 
It is during this secondment that I grasped the opportunity to combine my educational 
expertise with quality improvement.  As a clinician and educator, I began to reflect about 
the need for education to underpin the development of clinical care, quality improvement 
and service development, by ensuring that curricula for undergraduates and foundation 
trainees included these concepts.   My work with CLAHRC northwest London led to a 
published ‘bottom up approach to education around medication review and 
deprescribing’, which is the first known strategy to be published worldwide, and outlines 
the impact of our work in securing a presence of this teaching area in teaching for 
undergraduate and postgraduates in pharmacy. 
 
Caring, consultation and learning disability publications (2015 onwards) 
Becoming a parent to a disabled child with a learning disability in 2006, and a becoming a 
patient myself have led to many personal experiences of receiving healthcare, some of 
which have been negative, and sometimes have involved pharmacists.  These have led me 
to reflect powerfully on my professional identity as a pharmacist and galvanised me into 
engaging with national drivers for pharmacists to provide person-centred care as 
clinicians. My publication outputs, both written and spoken, have been driven by 
identifying the need for pharmacists to consult more effectively with patients with a 
learning disability and their carers, to engage with the notion of ‘clinical empathy’ and to 
consider their pastoral, mentoring and developmental role for trainees and colleagues so 
that they can contribute to this agenda. I also care about the development of individual 
students and practitioners in terms of their personal and professional growth, which is 
evidenced by my outputs on mentoring and feedback.   
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PhD theme: Equipping stakeholders to deliver Medicines Optimisation using a 
collaborative approach 
 
No single definition of ‘Medicines optimisation’ exists, but key stakeholders generally 
support the different published explanations of the term, and agree with the Royal 
Pharmaceutical Society’s ‘four principles of medicines optimisation’ that were published 
in 2013.  Medicines optimisation has become a defining concept for the pharmacy 
profession, and is endorsed by other health professions. It has been incorporated by the 
National Institute of Clinical Excellence (NICE) into national policy, including the 
development of a quality standard. The Chief Pharmaceutical Officer for England 
representing the Department of Health, Professor Keith Ridge is a regular speaker on 
medicines optimisation.  NHS England has also been establishing ‘Regional Medicines 
Optimisation Committees’ (RMOCs) to drive forward the necessary changes to optimise 
medicines use.  Two published descriptions of medicines optimisation summarise the 
concept of medicines optimisation.  Firstly, medicines optimisation has been described by 
NICE as “an approach that seeks to maximise the beneficial clinical outcomes for patients 
who take medicines, with an emphasis on safety, governance, professional collaboration 
and patient engagement”. Beneficial clinical outcomes that I have been particularly active 
in include improved adherence, partnership in clinical decision-making, and tackling 
polypharmacy.  Secondly and more succinctly, medicines optimisation has been defined 
by NICE as “a person-centred approach to safe and effective medicines use, to ensure 
people obtain the best possible outcomes from their medicines.”  My full PhD submission 
will seek to demonstrate that my publication outputs relate to beneficial clinical 
outcomes that are closely associated with my work; and have equipped a number of 
defined stakeholders (including students and other professionals) to advance their 
mission to deliver them.  For example, one outcome is a better patient experience which 
requires clinicians to understand their patients’ experience.  I advocate strongly that this 
is where the pharmacy profession urgently needs to improve in order to meet the 
expectations of patients, public, the wider health system and national government. Many 
of my publications are deliberately targeted at practitioners in professional publications, 
rather than academic journals, in order to target and influence those ‘at the coalface’. 
 
Impact examples from my publication outputs 
 
My impact on a range of individuals over 25 years has included helping them get to where 
they want to go professionally, achieving the dual outcomes of personal growth and an 
ability to care well for patients.  A number of my students and trainees have become chief 
pharmacists, consultant pharmacists, academics and respected clinicians.  Another impact 
that I am pleased with relates to work in establishing ‘educational infrastructures’ in 
hospital pharmacy departments to support workplace assessment, supervision and 
tutoring across London and south east England.  This is still embedded as part of the 
original ‘Joint Programmes Board’ foundation programme.  More recently, my 
recommendations around adding learning outcomes and competency statements relating 
to medication review and deprescribing have been taken up by four Schools of Pharmacy 
in south-east England, the Royal Pharmaceutical Society, and are captured in one of the 
first international journal themed issues on deprescribing, which I co-edited.   
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Summary 
 
My career journey has given me many rich opportunities, ranging from undertaking 
teacher and counselling training, to making a contribution to pharmacy education, quality 
improvement and the carer/learning disability agenda.  My contribution has been 
recognised through three fellowships, honorary academic positions and conference 
speaking and publication invitations.  I continue to be a carer at home and I use these 
experiences in my teaching, speaking and writing.  My publications range from journal 
articles, to conference presentations and audio-visual media.  This work has had a direct 
impact on pharmacy education and patient care.  For example, my published work has led 
directly to changes in undergraduate and postgraduate education (for example around 
work-based learning and assessment), and influenced pharmacy students and clinicians to 
think differently about managing patients who take lots of medicines. 
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Appendix 2: Summary of relevant journal publications and portfolio materials to be 
included in the final PhD submission 
 
1. Publication themes diagram  
 
As outlined in my personal statement, the theme of my PhD by publication is intended to 
be ‘medicines optimisation’.   I have chosen to relate my publication outputs for my PhD 
submission to the beneficial clinical outcomes that I have defined in the following 
publication themes diagram.  I have taken an accepted definition of medicines 
optimisation and related it to four of my publication themes.  In turn, I have drawn out 
some beneficial clinical outcomes that relate to the publication themes, and identified 
example publication outputs that link some of them together. 
 
My publication themes of medication review, polypharmacy and deprescribing; as well as 
health beliefs, medication adherence, consultation skills, patient empowerment and 
clinical empathy have clear links to the medicines optimisation agenda that I will unpack 
in the full thesis.  I believe that the uniqueness of my thesis will be my equipping of the 
following stakeholders to begin delivering beneficial outcomes: 
 
1. Patients, carers and service-users 
2. Undergraduate pharmacy students 
3. Foundation pharmacists 
4. University Schools of Pharmacy 
5. The wider pharmacy workforce 
6. Other healthcare professionals 
7. Opinion-formers in medicines optimisation 
 
I posit that in order to provide the desired outcomes of medicines optimisation, 
stakeholders need to be appropriately educated, trained, empowered and motivated.  My 
publications reflect my contribution in seeking to achieve that. 
 
  
Summary of key publications within each theme in the publication themes diagram 
At a national policy level, medicines optimisation has been driven and embraced by NHS 
England.  The concept is widely referred to in discussions around how society can get the 
best out of medicines and tackle medicines-related challenges such as non-adherence.  
The wider body of literature continues to articulate what it means and how it is to be 
practised.  I have contributed to this literature and my publication themes relate to the 
beneficial clinical outcomes required by medicines optimisation. Moreover, I believe that 
my publications contribute to the natural development of the concept as well as a deeper 
understanding of what it means in practice for professionals and patients. 
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2.1 Medication review, polypharmacy and deprescribing publications 
Research and other publications have demonstrated that an ageing population is leading 
to patients living longer, often with multiple long-term medical conditions.  Medicines are 
often prescribed for these conditions and can lead to large numbers of medicines being 
taken by individual patients (‘polypharmacy’).  Polypharmacy may be defined as 
‘appropriate’ or ‘problematic’, and the following publications and portfolio materials 
reflect my contribution to this agenda, particularly in the areas of education, medication 
review and the use of appropriate review tools.  This quality improvement work has been 
undertaken on secondment with NIHR CLAHRC NW London  
(http://clahrc-northwestlondon.nihr.ac.uk/home), who seek to combine the expertise of 
different types of professionals to undertake research to find new ways of improving 
patient care.  A strong philosophy is to ‘spread and embed’ work of demonstrable value, 
in order to maximise impact.  CLAHRC NW London has, since 2009, had an active 
medicines optimisation work-stream that has focused on tackling polypharmacy, 
particularly in elderly patients.  My contribution, in partnership with CLAHRC and others, 
has been to draw out and emphasise the need to actively stop medicines (i.e. 
‘deprescribe’), which has led to a number of educational impacts as well as invitations to 
present at conference and to co-edit the first known themed issue on ‘deprescribing’ 
internationally. 
1. Barber S., Jubraj B. Medicines Optimisation and Patient Safety NIHR CLAHRC Learning 
Event, held 16th January 2017. Journal of Medicines Optimisation. June 2017; Vol 3 
No 2: 30-33 
 
2. Barnett N., Jubraj B. A themed journal issue on ‘Deprescribing’. European Journal of 
Hospital Pharmacy. January 2017; Vol 24 no 1: 1-2 
 
3. Marvin V., Ward E., Poots AJ., Heard K., Rajagopalan A., Jubraj B. Deprescribing 
medicines in the acute setting to reduce the risk of falls.  European Journal of Hospital 
Pharmacy 2017; 24:10-15. doi:10.1136/ejhpharm-2016-001003 
 
4. Duraisingham S., Jubraj B., Marvin V., Kuo S., Bovill I., Poots AJ. Stopping 
Inappropriate Medicines in the Outpatient Setting. Geriatric Medicine 2015; May: 37-
41 
 
5. Saheb MA., Jubraj B., Bovill I., Kuo S., Marvin V, Intermediate Care. [An optimal 
setting for review of inappropriate medication in elderly patients]. Geriatric Medicine 
February 2014. 13-17 
 
6. Kuo S., Jubraj B, Bovill I., Marvin V. Case Studies of innovation in Medicines 
Optimisation during Admission, Discharge and Medication Review, at the Chelsea & 
Westminster Hospital. 2Eqipp  Chichester: Kingsham Press, December 2014. ISBN : 1-
904235-978 
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2.1.1 Portfolio materials 
 
1. Szymanski T., Marvin V., Ward E., Jubraj B. Deprescribing following medication 
review in acute care: the ReMAC project. Abstract and presentation at the 
Pharmaceutical Care Network Europe, Hillerød, Denmark February 2016. 
Conference abstract also published in International Journal of Clinical Pharmacy 
p17. DOI 10.1007/s11096-016-0283-8. Also presented at the CLAHRC Medicines 
Optimisation and Patient Safety learning event January 2017 
 
2. Marvin V., Dinesen L., Ward E., Jubraj B., Gilbert M., Poots AJ. Frailty and 
polypharmacy. (Abstract and Poster) International Forum on Quality and Safety in 
Healthcare, Gothenburg, Sweden April 2016 
 
3. Marvin V., Ward E., Jubraj B., Rajagopalan A., Poots AJ. Reducing falls risk in 
elderly falls patients through pharmacist medicines review.  Abstract and poster 
presented at the NWL Research Symposium for Health Professions,  London 
November 2015 
 
4. Sathyamoorthy G., Jubraj B. NIHR CLAHRC NWL – Introduction to medicines 
optimisation project in the ‘frailty’ area of work Imperial College Health Partners 
Medicines Optimisation Roadshow Plenary session 5. London 3rd March 2015 
 
2.2 Health beliefs, medication adherence, consultation skills, patient empowerment 
and clinical empathy publications 
There is clear evidence that patients do not always take the medicines prescribed for 
them as intended.  ‘Non-adherence’ is an accepted term for this phenomenon and may 
be defined as ‘intentional’ or ‘unintentional’.  Research shows that the quality of the 
patient/clinician relationship, particularly listening to their perspectives and experience, 
has an important impact on adherence and this is an area that I took seriously in my years 
of clinical practice.  ‘Understanding the patient experience’ is a key principle of medicines 
optimisation that the following publications explore.  For example, a CLAHRC NW London 
initiative was the development of ‘My Medication Passport’ (MMP), a patient held record 
of medicines developed by patients.  The MMP publications below, as with the others, 
reflect my joint work in exploring what it is like for patients to manage their medicines 
whilst coping with advancing age, illness or disability.  The portfolio materials within this 
theme reflect ongoing work to equip students and practitioners to consult better with 
patients and develop appropriate empathy to imagine what their patients contend with.  
This work has led directly to my involvement in supporting national and local initiatives to 
improve pharmacist engagement with patients, including the development of a learning 
disability training package, a published definition of ‘clinical empathy’, and the promotion 
of MMP by the Down’s Syndrome Association. 
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1. Jubraj B. Going to the Chemist. Down’s Syndrome Association Journal 
Spring/Summer 2017; 135: 26 
 
2. Jubraj B., et al. Why we should understand the patient experience? Clinical 
empathy and Medicines Optimisation.  International Journal of Pharmacy Practice 
2016: doi: 10.1111/ijpp.12268 
 
3. Jubraj B. A carer’s perspective on medicines optimisation.  Journal of Medicines 
Optimisation March 2016 Vol 2 No 1: 3-4 
 
4. Jubraj B., et al. Pharmacy Consultations with people with learning disabilities. The 
Pharmaceutical Journal. Vol 296, No 7885, online | DOI: 
10.1211/PJ.2016.20200330 
 
5. Jubraj B., et al. Patient perspectives on the use of ‘My Medication Passport’. 
Geriatric Medicine. August 2016; Vol 12 no 8: 25-28 
 
6. Jubraj B., Thakkar K., My Medication Passport. Down’s Syndrome Association 
Journal Autumn/Winter 2015; 132: 23 
 
7. Jubraj B., Blair M. Use of a medication passport in a disabled child seen across 
many care settings. BMJ Case Reports 2015. doi:10.1136/bcr-2014-208033 
 
8. Jubraj B. Patient counselling and medication adherence: What can we learn from 
mainstream counselling? Pharmacy in Practice 2007; 17 (1): 8  
 
9. Horne R., Sumner S., Jubraj B., Weinman J., Frost S. Haemodialysis patients’ 
beliefs about treatment: implications for adherence to medication and fluid-diet 
restrictions. International Journal of Pharmacy Practice 2001; 9:169  
2.2.1 Portfolio materials 
 
1. Barnett N., Jubraj B. Deprescribing: a special issue from the European Journal of 
Hospital Pharmacy.   Podcast, March 17: https://tinyurl.com/m8srm4w (accessed 
5.7.17) 
 
2. Waghorn J., Jubraj B. Socialisation Internship: A Novel Placement for Pharmacy 
Students. Abstract, poster and oral presentation at the Pharmacy Education 
Symposium ‘Pharmacy education and collaboration for global practice’.  Monash 
University, Prato July 2017 
 
3. Jubraj B., Adams D. Issues for patients with a learning disability and their carers - 
top tips on how pharmacy teams from all sectors can provide medicines 
optimisation support.  NHS Specialist Pharmacy Services (SE England) webinar July 
2017 
 
4. Jubraj B. A carer’s perspective on medicines optimisation. National Medication 
Safety Network webinar March 2017  
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5. Barnett N., Grimes L.,  Jubraj B. (2015) Making our Patients Feel Cared for 
http://www.pharmaceutical-journal.com/opinion/blogs/making-our-patients-
feel-cared-for/20067874.blog  
 
6. Patel D., Ward E., Jubraj B., Marvin V., Smith E., Abbadi I. An evaluation of the 
views of adolescent patients with a learning disability and their carers on a 
Medicines Information Leaflet and the My Medication Passport. Abstract and 
Poster presentation at the NWL Research Symposium on 21 Sept 2016. Also 
presented at the CLAHRC Medicines Optimisation and Patient Safety learning 
event Jan 2017 
 
7. Jubraj B. Promotional video for the Centre for Pharmacy Postgraduate Education 
(CPPE) Learning disabilities distance learning programme. March 2017 (and 
subsequent Facebook panel event April 2017 
 
8. Jubraj B., Adams D., Foreword for the Centre for Pharmacy Postgraduate 
Education (CPPE) Learning disabilities distance learning programme. February 
2017 
 
9. Jubraj B., Crilly P. Support for Carers Interview.  Kingston University School of 
Pharmacy November 2016.  https://vimeo.com/192330461 (accessed 4.7.17) 
 
10. Jubraj B. Speaking on various aspects of medication adherence. Medication 
Adherence MOOC.  King’s College London January 2017.  
https://vimeo.com/204204844/e79d7d1082 (accessed 4.7.17) 
 
11. Barnett N., Jubraj B. Two videos for the Centre for Pharmacy Postgraduate 
Education (CPPE) Consultation Skills initiative – ‘Making a difference in a short 
consultation’.  Available through Journal of Medicines Optimisation 2016; 2 Issue 1 
(accessed 4.7.17) 
 
2.3 Clinical education and training publications 
In Great Britain, postgraduate pharmacy education until the 2000s was typically 
classroom based, with some application in the workplace.  Medical education literature 
suggests that learning in a professional context, work-based learning and workplace-
based assessment can deliver a greater assurance of performance and competence in 
practice.  It also suggests that a deeper level of reflective learning occurs, compared with 
classroom-based learning.  The south-east England initiative by the Joint Programmes 
Board (JPB) to emulate this model of work-based learning was intended to ‘build a 
collaborative exemplar for a formal postgraduate educational infrastructure that can 
address policy developments in health care’, for example the Foster review, fitness to 
practice and patient safety agendas.  The term ‘medicines optimisation’ is relatively 
recent, but I believe that the underlying concepts have their roots in the need to address 
medicines-related policy developments, and have been articulated in different ways and 
practised long before the definition.  In other words, I contend that the concept of 
medicines optimisation predates the term itself. My secondment to the JPB allowed me 
to profoundly influence the education and development of a generation of newly-
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qualified pharmacists in this geography, so that they may deliver the benefits of 
medicines optimisation.  As such, the publications and portfolio materials below 
represent my mission as a clinical educator to improve the training and assessment of 
clinicians, as well as establishing appropriate educational systems and infrastructure.  The 
educational initiatives published below aim to develop competent and capable 
practitioners who can practise safely and effectively. 
1 Jubraj B., et al. The Acute Care Assessment Tool: ’Pharmacy ACAT’. The Clinical 
Teacher 2016; 13:1-5 
 
2 Fleming G., Jubraj B., Wright E., Pettit M., Jones S.C. Mapping education 
competencies to demonstrate advanced level practice. The Pharmaceutical Journal 
2013; 290: 648 
 
3 Davies JG., Ciantar J., Jubraj B., Bates I.P. Use of a Multisource Feedback Tool to 
Develop Pharmacists in a Postgraduate Training Program. American Journal of 
Pharmaceutical Education 2013; 77 Issue 3, Article 52. 
 
4 Jones S.C, Fleming G., Hay D., Ibrahim M., Pettit M., Wright E., Jubraj B. 
Development and piloting of a competency framework for pharmacy educational 
and practice supervisors. Pharmacy Education, 2012; 12 (1): 14 – 19 
 
5 Jubraj B., Innes I., Kavanagh R. Dispel the myths and see the benefits of workplace-
based assessments. The Pharmaceutical Journal 2011; 287: 467-468  
 
6 Chung C., Jubraj B. Training junior doctors to prepare and administer injectable 
drugs. British Journal of Clinical Pharmacy 2010; 2 (10): 309-311  
 
7 Jubraj B., Henry D., Hardy I., McCall-Peat N. Training doctors to use electronic 
prescribing information sources. British Journal of Clinical Pharmacy2010; 2 (1): 21-
22  
 
2.3.1 Portfolio materials 
 
1 Jubraj B., Poots A. Planning for sustainability through clinical education: Medication 
review and deprescribing. Presentation at the NIHR CLAHRC NW London Winter 
Collaborative Event.  February 2017 
 
2 Jubraj B. Developing a sustainable workplace-based learning infrastructure.  Royal 
Pharmaceutical Society conference: Preparing pharmacy for the challenges of 
workplace-based learning. London May 2011 
 
2.4 Developing and empowering the workforce publications 
Key NHS bodies agree that better training delivers better care.  Sir John Temple’s key 
document, ‘Time for Training,’ was an important milestone in shifting the culture away 
from education being an ‘add on’ to day-to-day clinical work.  A key focus in my 
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publication list is the personal and professional development of staff, echoing my long-
held belief that education should be at the core of clinical practice.  For example, I have 
written about the importance of mentoring, facilitating self-development, inculcating 
habits of reflective practice and influencing the development of role identity at an early 
career stage.  The work I have led on education around medication review and 
deprescribing is based on my belief that in order to change practice across a health 
system, culture change is needed, which involve exposing novice practitioners to the 
concepts and empowered to contribute to service improvement.  The first-known 
pharmacy-specific definition of ‘self-directed learning’ changed the mind set of trainees 
and their tutors as I began to spread this definition in my teaching of foundation trainees 
and training of tutors across south east England. 
 
1. Poots AJ., Jubraj B., Barnett N. Education around deprescribing: ‘spread and 
embed’ the story so far. European Journal of Hospital Pharmacy January 2017 Vol 
24 No 1: 7-9 
 
2. Picton C., Jubraj B. Royal Pharmaceutical Society Principles of Medicines 
Optimisation – Interview with Catherine Picton. Journal of Medicines Optimisation 
June 2016 Volume 2 No 2: 25-27 
 
3. Jubraj B., Marvin V., Poots AJ., Patel S., Bovill I., Barnett N., Issen L., Bell D. A pilot 
survey of junior doctors’ attitudes and awareness around medication review: time 
to change our educational approach? European Journal of Hospital Pharmacy 2015 
doi:10.1136/ejhpharm-2015-000664 
 
4. Duraisingham S., Jubraj B. Time to stop. Clinical Pharmacist 2014; 6: 162 
 
5. Barnett N., Jubraj B. How peer-mentoring helps pharmacists prepare for RPS 
Faculty admission The Pharmaceutical Journal 2013; 291: 500 
 
6. Jubraj B., Barnett N. Keys to peer mentoring: similar experience, trust, honesty 
and a willingness to change. The Pharmaceutical Journal 2011; 287: 500-501  
 
7. Morris K., Safdar A., Jones S.C., Jubraj B. Make reflection part of your daily 
practice. Clinical Pharmacist 2010; 2: 397-399  
 
8. Jubraj B. Developing a culture of self-directed workplace learning in pharmacy. 
The Pharmaceutical Journal 2009; 283:47–8.  
 
9. Bruno A., Jones S.C., Jubraj B. Continuing Professional Development (CPD) in 
Pharmacy Practice: Is it really about learning to learn or legislating learning? 
International Pharmacy Journal 2009; 25 (2): 20-25  
 
10. Safdar A., Pullinger W., Karemo K., Jubraj B. Workforce development – rising to 
current challenges. Hospital Pharmacist 2007; 14: 267 
 
11. Jubraj B. Assessing Junior Doctors – How Pharmacists can be Prepared. Hospital 
Pharmacist 2006;13: 291  
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12. Hewitt K, Jubraj B, Cox D, Ankrah S. KSF implementation – producing outlines for 
pharmacy staff. Hospital Pharmacist 2006; 13:169  
 
13. Farrington P., Buddell K., Jubraj B. Recruitment and retention initiatives and 
competence-based training for junior pharmacists. Pharmaceutical Journal 2001; 
267: 55  
2.4.1 Portfolio materials 
1 Jubraj B., Marvin V. (2015) Influencing undergraduate education on medication 
review and deprescribing NIHR CLAHRC NW London Summer Collaborative Learning 
Event presentation. London 17th July 2015 
 
2 Patel S., Jubraj B., Marvin V., Bovill I., Umer U., Trehane S.J., Poots A.J. A survey 
exploring junior doctors attitudes to medication review. (Poster presentation) 26th 
Annual Scientific Meeting, PRIMM (Prescribing and Research In Medicines 
Management) “One for All and All for One - Different Perspectives in Medicines 
Optimisation”: London, January 2015. Also published in Pharmacoepidemiology and 
Drug Safety Prescribing and Research in Medicines Management (UK & Ireland) 
Published Online First: 15/6/15 doi: 10.1002/pds.3812 
 
3 Jubraj B., Patel S., King E. Pharmacists of the future need to prompt doctors to 
review and stop unnecessary medicines 2014. http://www.pharmaceutical-
journal.com/opinion/blogs/pharmacists-of-the-future-need-to-prompt-doctors-to-
review-and-stop-unnecessary-medicines/20066189.blog 
 
 
A statement of intent/outline of the introductory section (approximately 500-700 words). 
This should include the proposed title of the work and seek to contextualise the selected 
publications, demonstrate their coherence, and identify the contribution to the advancement 
of knowledge in the chosen area of research 
 
Appendix 3: Statement of intent/outline of the introductory section 
Proposed title of the work: Equipping stakeholders to deliver Medicines Optimisation 
using a collaborative approach 
 
I believe that my submission for PhD by publication will present a body of work that 
coheres with the concept of ‘medicines optimisation’.  It is well-known that patients 
experience problems with their medicines, but little research exists around how patients 
actually use their medicines in practice. NHS England drove the development of 
medicines optimisation (MO) as a term and a concept, seeking to improve practice in 
areas such as patient engagement/empowerment and medication safety.  MO also seeks 
to embed itself as part of routine practice. 
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The four publication themes in my PhD submission cohere with the concept of MO and 
have had an impact as follows: 
 
Medication review, polypharmacy and deprescribing: Medication review has become an 
accepted element of MO, in order to ensure that patients are on the right medicines for 
the right length of time.  ‘Deprescribing’ or stopping inappropriate medicines, is a logical 
outworking of this.  My published co-developed quality improvement projects have 
supported the embedding of medication review in hospitals across north-west London, 
and the publication of an international themed issue on deprescribing which I jointly 
edited.  A patient case identified through one of my joint projects involving the use of a 
medication review tool in the elderly rehabilitation setting, was a finalist at the National 
Patient Safety Awards 2014.  Our use of the tool in the hospital outpatient setting then 
suggested utility in spite of reservations that it would impede the working of doctors in 
this busy and time-pressured setting. 
 
Health beliefs, medication adherence, consultation skills, patient empowerment and 
clinical empathy publications 
 
My earliest published work in this section was as a researcher investigating the health 
beliefs of haemodialysis patients. The findings from my 1993 study that these patients 
expressed concerns about their medicines which may impact adherence to them, inspired 
me to begin a journey of exploration of health beliefs, adherence and patient views about 
treatment that are represented in all the publications in this section.  The haemodialysis 
study has been widely cited, including by the former ‘Medicines Partnership’ which was a 
national authority at the time. 
 
Since then, I have jointly articulated a definition of ‘clinical empathy’ and for the first 
time, linked it to one of the key principles of MO.  I mapped in a novel fashion, my 
experience as a carer to the principles of MO which has led to some of the portfolio 
activities listed in this prima facie statement, which have been used at face-to-face and 
online at pharmacy meetings and formal teaching around south-east England.  My case 
study on the use of ‘My Medication Passport’ (MMP) in a disabled child was the first use 
of this tool in this type of patient.  My publications on learning disability, partly borne out 
of my experience as a parent and carer, led to an invitation to review and co-write the 
foreword for a national learning disabilities training package that was published in 2017. 
 
Clinical education and training 
 
Predating the term ‘MO’ but coherent with the concept, my publications in this section 
relate to medication safety and the need to train staff on students to provide safe and 
effective care.  My publications include the development of training programmes for 
newly-qualified doctors that are now embedded in a major teaching hospital in London.   
This type of work prepared me for future work in implementing competency-based 
training for newly-qualified pharmacists in south-east England (known as ‘Foundation 
Training’).  My publications reflect the ongoing impacts; including providing guidance for 
an educational infrastructure for hospital pharmacies to support work-based learning and 
assessment.  This and other published work around workplace-based assessment and 
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feedback, were key elements of the mission in south-east England to develop trainee 
performance in the workplace.  Foundation training is now embedded in London and 
beyond, with international interest in the programme philosophy.  I have also advised the 
Royal Pharmaceutical Society in its quest to develop and accredit national ‘Foundation 
Schools’. 
 
Developing and empowering the workforce 
 
I have written and spoken widely on professional development topics including 
mentoring, and reflective practice.  I have been regularly invited to speak on these topics, 
including by the Royal Pharmaceutical Society (RPS), and jointly wrote and spoke about 
the benefits of peer mentoring for candidates to join the RPS Faculty.  Later on, I jointly 
published the first pharmacy-specific definition of self-directed learning which has been a 
key element of training hospital Foundation pharmacy tutors in south-east England for a 
decade.  I also led the publication of the ‘bottom up approach to education around 
medication review and deprescribing’, being amongst the first to articulate strategies to 
change the culture of medication review by targeting education and training to 
undergraduate and novice practitioners.  This has led to the development of 
deprescribing teaching for undergraduates and postgraduates, with the stated aim of 
empowering them to take the initiative in starting conversations with patients and 
colleagues, in a collaborative way, that lead to appropriate medication review.  Our work 
was also successfully submitted to the Royal Pharmaceutical Society in order to advocate, 
with others, for ‘deprescribing’ to be mentioned in the recently published single 
competency framework for prescribers.  Finally, I seek to empower through exhortation, 
as my short editorials and blogs about medication review demonstrate.  These 
publications have proved to be useful in the educational setting as short discussion pieces 
to stimulate group reflection.  A new example of this is the embedding of a workshop on 
MO into the undergraduate pharmacy degree at King’s College London. 
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Appendix 6: Key Publication 1 (See Chapter 2.2) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Horne R., Sumner S., Jubraj B., Weinman J., Frost S. Haemodialysis patients’ 
beliefs about treatment: implications for adherence to medication and fluid-diet 
restrictions. International Journal of Pharmacy Practice 2001; 9:169  
 
 
 
Reproduced with permission: 
 
© 2001 Royal Pharmaceutical Society of Great Britain 
 
 
NB: Quality of the reproduction: 
 
This version was downloaded from the publisher’s website and is the best image 
available from them. 
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Appendix 7: Key Publication 2 (See Chapter 2.3) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Jubraj B., Barnett N., Grimes L., Varia S., Chater A., Auyeung V. Why we should 
understand the patient experience? Clinical empathy and Medicines Optimisation.  
International Journal of Pharmacy Practice 2016 Volume 24 Issue 5: 367-370.   doi: 
10.1111/ijpp.12268 
 
 
 
Reproduced with permission: 
 
© 2016 Royal Pharmaceutical Society 
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Appendix 8: Key Publication 3 (See Chapter 2.4) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Jubraj B., Deakin A., Mills S., Grimes L. Pharmacy Consultations with people with 
learning disabilities. The Pharmaceutical Journal. Vol 296, No 7885, online | DOI: 
10.1211/PJ.2016.20200330 
 
 
Reproduced with permission: 
 
© 2016 Royal Pharmaceutical Society 
Available from: http://www.pharmaceutical-journal.com 
 
 
NB: Type of reproduction: 
 
Formatting of the original online article into a Word version was done as 
requested by the Executive Editor – Research & Learning, of the Pharmaceutical 
Journal 
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Appendix 9: Key Publication 4 (See Chapter 3.3) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Saheb MA., Jubraj B., Bovill I., Kuo S., Marvin V, Intermediate Care. [An optimal 
setting for review of inappropriate medication in elderly patients]. Geriatric 
Medicine February 2014. 13-17 
 
 
Freely available at: 
 
https://www.gmjournal.co.uk/intermediate-care   
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Appendix 10: Key Publication 5 (See Chapter 3.4) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Jubraj B., Marvin V., Poots AJ., Patel S., Bovill I., Barnett N., Issen L., Bell D. A pilot survey 
of junior doctors’ attitudes and awareness around medication review: time to change our 
educational approach? European Journal of Hospital Pharmacy 22: 243-248. 
doi:10.1136/ejhpharm-2015-000664 
 
 
 
BMJ permissions confirm that permission is not required to reproduce this article 
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Appendix 11: Key Publication 6 (See Chapter 3.5) 
 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
 
 
Barnett N., Jubraj B. Themed guest editors (2017) Themed issue on ‘Deprescribing’. 
European Journal of Hospital Pharmacy  https://ejhp.bmj.com/content/24/1 
(contents page accessed 19.6.19) 
 
 
 
BMJ permissions confirm that permission is not required to reproduce this contents page 
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Appendix 12: Key Publication 7 (See Chapter 4.4) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
 
Jubraj B., Patel S., Naseem I., Copp S., Karagkounis D. The Acute Care Assessment 
Tool: ’Pharmacy ACAT’. The Clinical Teacher 2016; 13:1-5 
 
 
 
Reproduced with permission: 
 
© 2016 John Wiley & Sons Ltd and The Association for the Study of Medical 
Education 
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Appendix 13: Key Publication 8 (See Chapter 4.5) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Jubraj B. Developing a culture of self-directed workplace learning in pharmacy. 
The Pharmaceutical Journal 2009; 283:47–8.  
 
 
Reproduced with permission: 
 
© 2009 Royal Pharmaceutical Society of Great Britain 
Available from: http://www.pharmaceutical-journal.com 
 
 
NB: Type of reproduction: 
 
Formatting of the original online article into a Word version was done as 
requested by the Executive Editor – Research & Learning, of the Pharmaceutical 
Journal 
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Appendix 14: Key Publication 9 (See Chapter 4.6) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
 
Davies JG., Ciantar J., Jubraj B., Bates I.P. Use of a Multisource Feedback Tool to 
Develop Pharmacists in a Postgraduate Training Program. American Journal of 
Pharmaceutical Education 2013; 77 Issue 3, Article 52. 
 
 
 
Reproduced with permission: 
 
Copyright © 2013 American Association of Colleges of Pharmacy 
 
Available at: http://europepmc.org/articles/PMC3631727  
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Appendix 15: Key Publication 10 (See Chapter 5.3) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
Jones S.C., Jubraj B. Reflecting on teaching and learning. In Carter S., Editor. 
Facilitating Learning in Healthcare. London: Pharmaceutical Press, 2012  
 
 
 
Reproduced with permission: 
 
© 2011 Royal Pharmaceutical Society  
Available at: https://www.pharmpress.com 
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Appendix 16: Key Publication 11 (See Chapter 5.4) 
 
THE KEY PUBLICATIONS HAVE BEEN REMOVED FROM THIS 
ELECTRONIC COPY OF THE THESIS.  THE INTRODUCTORY TEXT 
REMAINS BELOW: 
 
 
Jones S.C, Fleming G., Hay D., Ibrahim M., Pettit M., Wright E., Jubraj B. 
Development and piloting of a competency framework for pharmacy educational 
and practice supervisors. Pharmacy Education, 2012; 12 (1): 14 – 19 
 
 
 
Permissions: 
 
Freely available at: 
http://pharmacyeducation.fip.org/pharmacyeducation/article/view/286/258  
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Appendix 17: NIHR CLAHRC for north-west London - Medication review 
tool: The ‘STOPIT’ tool (See Chapter 3.2) 
 
THIS HAS BEEN REMOVED FROM THIS ELECTRONIC COPY OF THE 
THESIS.  THE INTRODUCTORY TEXT REMAINS BELOW: 
 
 
Available from: https://www.sps.nhs.uk/wp-content/uploads/2017/07/STOPIT-review-
form-clahrc-NWL-GENERIC-pdf.pdf (accessed 9.7.19) 
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Appendix 18: Nomination for the Royal Pharmaceutical Society 2013 
‘Excellence in Education’ award; and other student feedback 
 
Please see the start of chapter 4 
 
NB: Quality of the reproduction: 
Material for this appendix has been copied from emails and this is the best reproduction 
achievable. 
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ROYAL PHARMACEUTICAL SOCIETY EXCELLENCE IN EDUCATION AWARD:  
NOMINATION ONLY 
 
Name of nominee: Mr Barry Jubraj 
   
Contact Phone Number (incl. area code): 020 8746 8000 x58845 
Email Address: Barry.Jubraj@chelwest.nhs.uk  
 
Postal Address (incl. post code): Pharmacy Department, Chelsea and Westminster Hospital, 369 
Fulham Road, London, SW10 9NH 
 
Place of work and job title: Chelsea and Westminster NHS Foundation Trust, London.  
Lead Pharmacist for Academic Studies & Professional Development. 
 
The award will be made to a person who has made an outstanding contribution to pharmacy 
education and development, which would be recognised throughout the UK.  The nomination will 
be expected to demonstrate one or more of the following criteria: - 
 excellence in pharmacy education and development;  
 leadership in pharmacy education and development; 
 working effectively across organisational and departmental boundaries to deliver pharmacy 
education and development; 
  innovation that has markedly improved pharmacy education and development 
Please describe in no more than 500 words why you feel you or your nominee meets the above 
criteria. 
Please highlight text and start here (500 words max) 
Barry is a truly inspirational educator and mentor, and is so humble that he would never say this 
himself or mention his more recent honorary professorship or RPS fellowship, and undoubtedly 
there are many more acolades to his name than those of which I am aware.  
He continues to work tirelessly for the good of those around him – not just those whom he is 
officially responsible for and to, but to all within his immediate pharmacy team. He has a 
compassionate and a holistic approach to the education and development of all those he meets, 
interested in helping them to develop as people - not just as pharmacists. This has perhaps been 
most clearly seen in his role with training the often newly qualified (and young!) resident hospital 
pharmacists that start each year. Without his guidance and, more importantly, I suspect many of 
these new professionals would have “sunk” and not “swum” as they began at the deep end of their 
new careers in that hospitals' busy and demanding environment.  
Furthermore Barry frequently caring and enquiring after staff many years after they have left his 
immediate team (to which I can testify personally, despite never having had a role that worked 
closely with his).   
He is widely published on the topic of education, both within pharmacy and beyond, as well as in 
other areas outside of pharmacy (again there are likely to be many more papers than those of 
which I am aware, so please do ask for his publication list).  
Despite having worked at C&W hospital for in excess of 15 years (I don't know how long exactly) 
his experience and view of pharmacy is not narrow or hospital centric, nor London centric. He has 
worked in extensively collaboration with the School of Pharmacy (University of London) as part of 
the Joint Programme  Board and was instrumental in the set up and validation of the General Level 
Framework competency assessment, followed by the Advanced to Consultant Level Framework 
which is the tool forming the basis for the RPS's Faculty competency assessment.  
He is truly empathetic and supportive to those he works with and always has a calm considered 
and rational approach to the crises in which many staff find themselves and so turn to him for 
support. 
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From: Neagle, Ann < > On Behalf Of McFadzean, Ian 
Sent: 07 June 2019 14:44 
To: Jubraj, Barry < > 
Subject: King's Education Award 
Dear Barry 
I am writing to let you know that your students nominated you recently for a King’s Education 
Award; many congratulations.   I would also like add my personal thanks for going that extra mile 
to ensure that our students gain the most from their time at university. 
I have appended any citations that came with your nominations below so that you can see how 
appreciative the students are of your efforts. 
Barry has supported me throughout the MPharm programme. He is willing to share his past 
experience to us fellow students. He also provides great teaching with his up to date and 
comprehensive knowledge in clinical pharmacy. He is one of the lecturers that is willing to go the 
extra mile to help and support his students.  
All the lecturers and academic staff are very professional and helpful when required however I feel 
that Barry deserves recognition as an exceptional form tutor.     He has helped me immensely in 
my first 2 years of education which have been quite difficult due to personal circumstances 
however Barry has been a figure I could largely trust with sensitive information and he too shares 
his personal struggles and how he manages them which I have always appreciated and 
admired.     He has always been supportive and offered personalised support to my general 
challenges which I feel is partially responsible for my progression in the course. Furthermore, he 
has never judged me when I have faulted in my course however, he always motivated me to be the 
best individual I can be. Finally he always reassures me and has spoken to ease my anxieties at 
times where it has been a problem for me which I appreciate.    For these reasons I feel that Barry 
deserves recognition for the work that he does as he goes the extra mile to get the best out of his 
students/tutees.  
Made me feel comfortable when first starting university   Makes learning engaging and he’s 
relatable   Increased my confidence and made me feel at ease even when times were stressful . 
Always encouraging students 
With very best wishes 
Ian 
Professor Ian McFadzean FRSB, FBPhS 
Dean of Bioscience Education  
Faculty of Life Sciences & Medicine 
Room 1.2N, Hodgkin Building 
King's College London  
Guy's Campus 
LONDON SE1 1UL 
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Appendix 19: Workplace-based Assessment (WPBA) Tools mentioned in 
Chapter 4 
 
THESE HAVE BEEN REMOVED FROM THIS ELECTRONIC COPY OF 
THE THESIS.  THE INTRODUCTORY TEXT REMAINS BELOW: 
 
 
Tools included are as follows (NB – some tools reproduced in part to illustrate the 
principles): 
 
1. Mini-clinical evaluation exercise (mini-CEX) – includes page 2 of guidance  
a. A prospectively snapshot tool 
 
2. Direct observation of practical skills (DOPS): 
a. As above, focusing on practical skills 
 
3. Medication-Related Consultation Framework (MRCF): 
a. As above, focusing on practical skills 
 
4. Case-based discussion (CbD): 
a. A retrospective snapshot tool 
 
5. Mini-Peer assessment tool (mini-PAT): 
a. A type of 360 degree feedback tool  
b. See chapter 4.6 and key publication 9 
 
6. The Pharmacy Acute Care Assessment Tool (Pharmacy ACAT): 
a. See chapter 4.4 and key publication 7 
 
Reproduced with permission: Professor Ian Bates, UCL School of Pharmacy, June 2019 
(The versions included were used at the time of the author’s activity.  They have since 
been superseded by updates from the Royal Pharmaceutical Society, based on the Joint 
Programme Board’s original work) 
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Appendix 20: Author’s ‘wagon wheel’ to illustrate Workplace-based 
Assessment (WPBA) and summative assessment tools used in the London 
pharmacy foundation programme 
 
 
 
See: 
Section 4.4 
Key publication 7 (appendix 12) 
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Mini-Peer  
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Figure 1: 'Wagon wheel' of WPBA & summative assessment in pharmacy foundation training 
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Page 173
